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Abstract 
Understanding the mechanisms of limbic epileptogenesis in cellular and 
molecular terms may provide novel therapeutic targets for its prevention. The 
neurotrophin receptor tropomyosin-related kinase B (TrkB) is thought to be critical for 
limbic epileptogenesis. Enhanced activation of TrkB, revealed by immunodetection of 
enhanced phosphorylated TrkB (pTrkB), a surrogate measure of its activation, has been 
identified within the hippocampus in multiple animal models. Knowledge of the cellular 
locale of activated TrkB is necessary to elucidate its functional consequences. Using an 
antibody selective to pTrkB in conjunction with confocal microscopy and cellular 
markers, we determined the cellular and subcellular locale of enhanced pTrkB induced by 
status epilepticus (SE) evoked by infusion of kainic acid into the amygdala of adult mice. 
SE induced enhanced pTrkB immunoreactivity in two distinct populations of principal 
neurons within the hippocampus—the dentate granule cells and CA1 pyramidal cells. 
Enhanced immunoreactivity within granule cells was found within mossy fiber axons and 
giant synaptic boutons. By contrast, enhanced immunoreactivity was found within apical 
dendritic shafts and spines of CA1 pyramidal cells. A common feature of this enhanced 
pTrkB at these cellular locales is its localization to excitatory synapses between 
excitatory neurons, presynaptically in the granule cells and postsynaptically in CA1 
pyramidal cells. Long-term potentiation (LTP) is one cellular consequence of TrkB 
activation at these excitatory synapses that may promote epileptogenesis. 
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The importance of TrkB in diverse neuronal processes, as well as its involvement 
in various disorders of the nervous system, underscores the importance of understanding 
how it is activated.  The canonical neurotrophin ligand which activates TrkB is brain 
derived neurotrophic factor (BDNF).  Zinc, however, has also been demonstrated to 
activate this receptor through a mechanism whereby it does not directly interact with it, 
known as transactivation.  Presynaptic vesicles of mossy fiber boutons of stratum 
lucidum are particularly enriched in zinc, where it is co-released with glutamate in an 
activity dependent fashion, and incorporated into these vesicles by the zinc transporter, 
ZnT3.  Given the presence of large quantities of zinc within stratum lucidum, we 
hypothesized that this metal may contribute to TrkB transactivation at this locale.  To this 
end, we examined the contributions of both BDNF and synaptic vesicular zinc to TrkB 
activation in stratum lucidum of mouse hippocampus under physiological conditions.  
Utilization of mice which are genetic knockouts for BDNF and/or ZnT3 allowed us to 
examine TrkB activation in the absence of one or both of these ligands.  This was done 
using an antibody for pTrkB in conjunction with confocal microscopy, assaying 
immunoreactivity at the cellular and synaptic locales within stratum lucidum where 
pTrkB was previously found to be enriched.  Our results suggest that BDNF contributes 
to TrkB activation within stratum lucidum.  Interestingly, ZnT3 mice displayed an 
increase in BDNF protein and TrkB activation, demonstrating that synaptic zinc regulates 
BDNF and TrkB signaling at this locale. 
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1. Introduction 
1.1 Overview 
Epileptogenesis is defined as the process by which a normal brain becomes 
epileptic.  Understanding the cellular and molecular mechanisms by which 
epileptogenesis occurs will lead to a better understanding of the pathophysiology of this 
serious disease, and may reveal novel targets that can be the subjects of pharmacologic 
therapy.  A central concept in the pathogenesis of epilepsy, introduced by the British 
neurologist Sir William Gowers who described the observation that “seizures beget 
seizures”, is that seizures themselves actually lead to permanent changes in brain 
plasticity that facilitate the development of epilepsy (Gowers, 1881).  Though the 
underlying mechanisms by which these changes occur are not fully understood, multiple 
lines of evidence implicate the neurotrophin receptor, tropomyosin-related kinase B 
(TrkB), as being central to this phenomenon (Binder et al., 1999b; He et al., 2004; He et 
al., 2010; Liu, submitted).  Such findings underscore the importance of understanding the 
specific neuroanatomical locales within the brain where TrkB signaling occurs, as well as 
what ligands mediate activation of this receptor at these locations.  This is because 
elucidating where TrkB signaling occurs during epileptogenesis is likely to implicate 
specific cell populations, as well as subcellular locations within them, that contribute to 
neuronal excitability culminating in epilepsy.  Understanding the ligands involved in 
TrkB receptor activation at these locales will further clarify molecules that may be central 
to this phenomenon.  Such insights will better refine specific cellular and molecular 
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targets for study in epilepsy research, which are likely to be helpful in development of 
therapies against this disease.  The objective of the investigations undertaken within this 
dissertation, therefore, was to better elucidate both of these aspects of TrkB signaling. 
Numerous studies have demonstrated that TrkB is activated within hippocampus 
in models of temporal lobe epilepsy (TLE), suggesting the importance of its activation 
within this structure for the process of limbic epileptogenesis (Binder et al., 1999a; 
Danzer et al., 2004; He et al., 2004; He et al., 2002; He et al., 2010).  For this reason, I set 
out to better define the cellular and synaptic locales where activated TrkB was enriched 
within hippocampus during epileptogenesis using a mouse model of limbic epilepsy.  
This was done by employing an antibody specific for a phosphorylated tyrosine residue 
(pY816) on the receptor, a surrogate marker for activated TrkB (Segal et al., 1996), using 
immunohistochemistry coupled with confocal microscopy. 
Previous work from our laboratory has demonstrated that the transition metal, 
zinc, can cause activation of TrkB in vitro through a mechanism whereby it does not 
directly interact with the receptor (Huang et al., 2008).  Zinc is particularly enriched 
within synaptic vesicles of dentate granule cells in a region of hippocampus known as 
stratum lucidum, and released from these vesicles during neuronal activity (Choi and 
Koh, 1998; Frederickson and Danscher, 1990; Frederickson et al., 2005).  Interestingly, 
activated TrkB has also been found to be particularly enriched at this location during the 
development of limbic epilepsy (Binder et al., 1999a; Danzer et al., 2004; He et al., 2004; 
He et al., 2002; He et al., 2010).  Because of both the temporal and spatial concordance of 
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this ligand and its activated receptor within stratum lucidum, I hypothesized that synaptic 
zinc may contribute to TrkB activation within this region.  Therefore, I set out to test the 
relative contributions of both synaptic zinc and the canonical TrkB ligand, brain derived 
neurotrophic factor (BDNF), to TrkB activation within stratum lucidum of mouse 
hippocampus under physiological conditions.  This line of investigation employed the 
same immunohistochemical techniques as for the activated TrkB localization studies, and 
also utilized mice that were deficient in synaptic zinc and/or BDNF (Cole et al., 1999; He 
et al., 2004).  Completion of these studies yielded valuable information on both the 
anatomic locales of TrkB activation within hippocampus and the ligands contributing to 
its activation, and provided new insights into the understanding of TrkB signaling that are 
likely to be pertinent to the understanding of limbic epileptogenesis. 
1.2 Epilepsy 
  Epilepsy is a serious neurological disease which is also very common, defined 
most simply by the occurrence of repeated and unprovoked seizures (Engel and Pedley, 
2008).  The disorder is estimated to have a prevalence of approximately 4-10 per 
100,000, and though it may develop at any age, arises more often in young and elderly 
individuals (Forsgren et al., 2005; Sander, 2003).  Lifetime prevalence rates of epilepsy 
are higher, as most that develop the disease go into remission within five years of 
diagnosis (Sander, 2003).  However, up to one third of those who are initially diagnosed, 
even in developed countries where antiepileptic drugs are readily available, will 
eventually go on to develop medically refractory epilepsy (Kwan and Sander, 2004).   
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Epilepsy has a devastating impact on the life of the afflicted individual.  In those 
with the most severe refractory epilepsy, the only viable treatment option may be surgical 
resection of significant portions of brain tissue in an attempt to remove the epileptic foci 
(Engel and Pedley, 2008), the magnitude of such an operation demonstrating the sheer 
severity of the disease these patients are experiencing.  In addition to significant lifestyle 
impairments, those with symptomatic epilepsy have an increased risk of sudden death, 
with a shortened life expectancy of as much as 18 years (Gaitatzis et al., 2004; Lhatoo et 
al., 2001).  Even in patients who are able to control their disease with the use of 
antiepileptic drugs, side effects from these medications can be significant, having a 
substantial impact on adherence to medication regimes and representing a major source 
of morbidity, disability, and even mortality related to epilepsy (Perucca and Gilliam, 
2012).  Furthermore, all antiepileptic drugs in use provide only symptomatic treatment, 
acting generally to reduce neuronal excitability, such as drugs which block sodium or 
calcium channels, or augment neuronal inhibition, such as drugs which enhance the 
activity of GABA receptors.  These nonspecific mechanisms of action contribute to the 
severity of the side effects experienced, and the inability of these drugs to treat the 
underlying abnormality contributes to a significant risk of relapse in patients who decide 
to discontinue pharmacologic therapy (Engel and Pedley, 2008).  Patients may therefore 
need to stay on these therapies for life, and also endure their difficult to tolerate side 
effects.  All of these issues exemplify the need for new and effective treatments for this 
horrible disease.  Basic science research into the molecular and cellular mechanisms of 
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epileptogenesis is a crucial first step in identifying new potential therapeutic targets that 
may more effectively treat or even cure epilepsy.  
1.2.1 Clinical Aspects of Epilepsy 
Epilepsy is the occurrence of repeated seizures, which are themselves defined as 
paroxysmal episodes of aberrant neuronal activity accompanied by stereotypical changes 
in behavior (Engel and Pedley, 2008).  Such behavioral changes can range from 
momentary losses of consciousness to episodes of generalized myoclonic convulsions 
involving the entire body, and the accompanying aberrant, synchronous neuronal activity 
can be recorded with the use of an electroencephalogram (EEG).  Epilepsy is not actually 
one disease, but rather represents a broad constellation of symptoms that arise from a 
variety of underlying causes, which in many cases may not be known.  To this end, the 
epilepsies can be broadly classified into those arising from structural/metabolic, genetic, 
and unknown causes (Berg et al., 2010).  Structural/metabolic epilepsies are those in 
which seizures arise as a consequence of specific etiologies such as a brain lesion, for 
example after traumatic brain injury.  Genetic epilepsies, as the name implies, arise from 
an underlying genetic syndrome.  Those with an unknown etiology likely fall into one of 
the two former categories, but the cause cannot be identified. 
 Specific types of seizures are classified clinically based on a system devised by 
the International League Against Epilepsy (2010), with the two major classifications 
being focal and generalized seizures.  Generalized seizures are those where aberrant 
neuronal activity engages both brain hemispheres, and can involve both cortical and 
 6 
 
subcortical structures.  These seizures are further classified into tonic-clonic, absence, 
myoclonic, clonic, tonic, and atonic based on their specific behavioral and EEG features.  
Focal seizures, as their name suggests, originate from a specific epileptogenic focus 
within the brain and are limited to only one hemisphere, though they have the potential to 
secondarily generalize.  Note that a previous version of this classification system further 
categorized seizures into simple, where the sufferer remains conscious during the event, 
and complex, where a loss of consciousness was involved (1989).  A particularly severe 
form of seizures is known as status epilepticus (SE), defined clinically as uninterrupted 
seizures lasting more than five minutes or the occurrence of two or more seizures in 
which the patient does not return to baseline conditions, and it can potentially last for 
days (Nair et al., 2011).  It is one of the most common neurological emergencies, requires 
immediate treatment to end the episode, and mortality in those with SE may be up to 20% 
(Trinka et al., 2012). 
The most common epilepsies are focal, with the most common source of seizure 
activity being the temporal lobe (Engel and Pedley, 2008).  TLE also represents the 
largest single class of epilepsy in patients who are  refractory to medical treatment 
(Shukla and Prasad, 2012), making it particularly important to study.  At present, those 
with medically intractable TLE may face surgical resection as the only treatment option, 
which can make the disease respond to pharmacologic therapy (Engel and Pedley, 2008).  
TLE is characterized by a seizure foci that is located within the limbic system 
(Bartolomei et al., 2005), and commonly begins in childhood or early adulthood.  There 
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is a strong association between developing TLE and having experienced an “initial 
precipitating event”, such as febrile SE or trauma during the early years of life, followed 
by a latent period of as long as years before epilepsy actually develops (Mathern et al., 
2002; Shukla and Prasad, 2012).  Patients with TLE also very commonly have 
hippocampal sclerosis, first recognized in postmortem specimens over 180 years ago 
(Bouchet, 1826) and readily detectable using modern radiologic techniques.  The 
pathological findings are hippocampal atrophy, neuronal loss, and gliosis, which is most 
profound in area CA1.  Damage can be either unilateral or bilateral, and can also effect 
adjacent regions such as the parahippocampal gyrus and amygdala (Engel and Pedley, 
2008; Malmgren and Thom, 2012).  Whether this neuropathological finding actually is 
causative of the epilepsy, however, has been debated.  Another common finding in 
hippocampal sclerosis, seen in humans with temporal lobe epilepsy as well as in animal 
models of this disease, is mossy fiber sprouting (Nadler et al., 1980).  This phenomenon 
involves axons of dentate granule cells forming recurrent excitatory connections onto 
themselves, and has been hypothesized as a mechanism by which neuronal excitability is 
enhanced.  Its causal contribution to the pathogenesis of temporal lobe epilepsy, however, 
has not been definitively established (Malmgren and Thom, 2012).  As temporal lobe 
epilepsy is so common, and also commonly resistant to pharmacological treatment, this 
form of epilepsy has been a focus of study in our lab, and the hypotheses studied in 
Chapter 2 of this dissertation and (Helgager et al., 2013) are examined within the context 
of temporal lobe epilepsy. 
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1.2.2 Models of Epilepsy for Research Purposes 
 The study of epilepsy would be best conducted in humans who actually have the 
condition, and clinical trials are obviously an integral last stage in the development of any 
drug which may be used to treat epilepsy.  However, use of animal models of epilepsy 
which reflect the human condition are invaluable research tools.  Ethical concerns would 
preclude the study in humans of novel, experimental drugs which could potentially have 
safety issues, as could using invasive techniques to obtain specimens for examination of 
the molecular and cellular changes that take place in this disease.  Furthermore, using 
animal models are in many cases much more efficient to study epileptic phenomena.  
Mice and rats, the most commonly used experimental animals, can be obtained in large 
numbers, and electrical or chemical convulsive stimuli can be administered in a 
controlled fashion.  This results in the development of epilepsy in a predictable manner 
which is amenable to studying the natural progression of this disease, as well as for 
examining potential therapies.  Finally, development of genetic knockout and transgenic 
technology, particularly in mice, allows for the controlled study of genetic modifications 
and how they may influence epilepsy and/or epileptogenesis. 
 An important factor in any animal model employed for the study of epilepsy is 
how accurately it emulates the human condition and, for the development of clinical 
therapies, how predictive it is of a drug being efficacious in humans.  Interestingly, many 
antiepileptic drugs were initially validated through testing their efficacy in suppressing 
seizures directly induced by convulsant stimuli, such as using electroshock or 
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pentylenetetrazole (a chemoconvulsant), in normal animals (Loscher, 2002).  Such 
models may accurately model seizures, but fail to emulate epileptogenesis.  Efficacy of 
drugs in these models reflects their anticonvulsant actions, but does not address their 
ability to intervene in the process of epileptogenesis.  Therefore, more accurate animal 
models of epilepsy are those which model the chronic aspects of this disease, and are also 
much more optimal for studying the molecular and cellular mechanisms by which this 
disorder develops (Loscher, 2002).  Such models involve the process of actually making 
an animal epileptic, so that it would ultimately experience spontaneous recurrent seizures 
(SRSs) which are unprovoked.  Furthermore, these models also replicate some of the 
neuropathology seen in humans with epilepsy, such as hippocampal sclerosis in those 
models which are thought to emulate TLE. 
1.2.2.1 The Pilocarpine Model 
 The pilocarpine model was first developed and described as in (Turski et al., 
1983a; Turski et al., 1983b).  In this model, animals are made epileptic through prolonged 
SE, which features uninterrupted tonic-clonic seizures induced by intraperitoneal 
injection of pilocarpine.  It was first developed in rats, though has subsequently been 
adapted to mice (Curia et al., 2008).  The mechanism by which pilocarpine causes SE 
appears to be through activation of M1 muscarinic cholinergic receptors, as mice which 
are genetic knockouts of this receptor fail to develop seizures when injected with 
pilocarpine (Hamilton et al., 1997).  However, after the initial occurrence of SE, seizures 
seem to be self-sustaining as they are unable to be terminated with atropine, a blocker of 
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muscarinic receptors (Clifford et al., 1987).  Depending on the specific protocol, SE is 
allowed to spontaneously terminate after several hours, or is stopped using an 
anticonvulsant, generally a benzodiazepine (Curia et al., 2008).  The pilocarpine model is 
considered to be one of TLE as it emulates many features of the disease.  Namely, 
animals are subjected to an initial precipitating event, SE, and seizures during this 
episode have been documented to spread to the hippocampus (Turski et al., 1983a).  
Following termination of SE, there is a latent period which lasts from one to six weeks, 
after which animals enter a chronic period where they experience SRSs which are usually 
limbic in nature (Cavalheiro et al., 1991), demonstrating that these animals have 
developed epilepsy.  Animals made epileptic in this model exhibit characteristic 
pathological findings of hippocampal sclerosis and mossy fiber sprouting (Curia et al., 
2008).  However, it should be noted that SRSs may be extra-limbic, a possible caveat in 
using it as a model of TLE (Harvey and Sloviter, 2005).  Probably the biggest drawback 
of using this model is the high mortality encountered during the initial SE event, which 
has been reported to be around 30-40%, though some have reported even worse outcomes 
(Curia et al., 2008).  This is a particular consideration when using lines of genetically 
modified mice, which may be in limited supply and difficult to readily generate. 
1.2.2.2 The Kainic Acid Model and Kainic Acid Microinfusion Models 
Kainic acid was first isolated from Digenea simplex, a species of seaweed, and is 
an agonist of kainic acid receptors (Raol and Brooks-Kayal, 2012).  As with the 
pilocarpine model, it can be administered systemically through intraperitoneal injection 
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in rats and mice, and results in the development of generalized SE.  Animals enter into a 
latent period following termination of SE, and develop SRSs after approximately a week 
(Williams et al., 2009).  SRSs are generally limbic in nature, the same pathology as found 
in the pilocarpine model can be found in the hippocampi of animals treated with kainic 
acid, and for this reason the model is generally considered to be a model of TLE (Nadler 
et al., 1978; Raol and Brooks-Kayal, 2012; Tauck and Nadler, 1985).  However, use of 
systemic kainic acid as a model of epileptogenesis has been limited by an excessively 
high mortality rate, as well the fact that a high percentage of animals treated with kainic 
acid induced SE do not go on to develop SRSs (Leite et al., 2002). 
Alternative methods of kainic acid administration involve intraventricular or 
intrahippocampal infusions, and our lab has successfully adopted a method where kainic 
acid is infused into the basolateral amygdala through a surgically placed cannula, referred 
to as the kainic acid microinfusion model (Mouri et al., 2008).  This model offers the 
advantage of directly activating limbic structures, unlike with systemic administration, 
ensuring that the epileptogenic focus is within the limbic system.  Furthermore, mortality 
in this model is only around 10%, and mice reliably develop SRSs within a week of 
kainic acid induced SE.  This lower mortality during SE and faster progression to 
developing epilepsy is much shorter and more practical than what is found in the 
pilocarpine model.  Pathology consistent with hippocampal sclerosis, such as neuronal 
loss, gliosis, and mossy fiber sprouting, are also observed in this model, but this occurs 
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only on the side where kainic acid is infused.  This unilateral hippocampal pathology is 
also commonly found in patients with temporal lobe epilepsy (Engel and Pedley, 2008). 
1.2.2.3 The Kindling Model 
 The kindling model was discovered by Graham Goddard and colleagues 
(Goddard, 1967; Goddard et al., 1969) in the late 1960s.  It differs from the pilocarpine 
and kainic acid models described above in that it does not involve giving an animal SE, 
but rather involves the controlled, chronic elicitation of focal seizures as a means of 
promoting epileptogenesis.  In this model, initially subconvulsive focal electrical 
stimulations, when applied repeatedly, result in intense focal seizures which eventually 
generalize (Goddard et al., 1969).  In order for kindling to occur, the electrical 
stimulation must initially elicit a small synchronous firing of neurons, known as an 
“afterdischarge” (Racine, 1972a).  Kindling can be performed from a variety of locations 
in the brain, but the evolution of activity from brief to prolonged seizures is much more 
evident when they occur within limbic structures (Engel and Pedley, 2008).  Kindling is 
commonly performed by electrical stimulation from the amygdala, and repeated 
stimulations evoke progressively more severe seizures which progress through the 
following behavioral classes (Racine, 1972b): Class 1, facial clonus; Class 2, head 
nodding; Class 3, unilateral forelimb clonus; Class 4, bilateral forelimb clonus with 
rearing; Class 5, rearing and falling with loss of postural control.  These behaviors are 
accompanied by progressively longer and more generalized electrographic seizures.  An 
animal is deemed “kindled” after it has progressed to developing Class 5 seizures; this 
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enhanced response to any further electrical stimuli will persist for the lifetime of that 
animal, demonstrating that it has undergone epileptogenesis (Engel and Pedley, 2008).  In 
further support of this notion, animals that continue to receive electrical stimulation after 
developing Class 5 seizures will eventually display SRSs.  Particularly later in the 
kindling process, neuropathological changes reminiscent of hippocampal sclerosis do 
become observable, such as neuronal death and gliosis, paralleling the condition of TLE 
(Cavazos et al., 1994; Cavazos et al., 1991). 
1.3 Overview of Hippocampal Circuitry 
 As this dissertation extensively employs histology and microscopy to examine 
cellular and subcellular structures of hippocampus, a discussion of basic hippocampal 
circuitry is warranted.  The unidirectional glutamatergic, excitatory pathways that 
underlie the major connections of the hippocampus was first coined the trisynaptic circuit 
by (Andersen et al., 1971).  The major inputs to the hippocampus arise from the 
entorhinal cortex (Shepherd, 2004).  The perforant path, which mostly innervates 
dendrites of dentate granule cells located in the molecular layer of the dentate gyrus, 
arises from layer II of the entorhinal cortex.  Dentate granule cells project axons, known 
as mossy fibers, to the proximal dendrites of CA3 pyramidal neurons within stratum 
lucidum.  Mossy fibers possess specialized giant boutons, which also synapse onto 
particularly enlarged, clustered spines on CA3 neurons known as thorny excrescences.  
The CA3 pyramidal cells send axons both ipsilaterally and contralaterally to other CA3 
neurons, termed associational-commissural projections.  They also make numerous  
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Figure 1: Confocal micrographs of hippocampus in a Thy1-GFP expressing mouse. 
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A) Low power image of hippocampus.  Dentate granule cells (DGCs, arrows 
point to soma) project their dendrites into the molecular layer (ML) of the dentate 
gyrus.  At this site the dentate granule cells receive input into the hippocampus from 
axons of entorhinal cortex (not visible).  Axons of DGCs, known as mossy fibers, 
project to stratum lucidum (SL) where synapses are made onto dendrites of CA3 
pyramidal cells (CA3).  CA3 pyramidal cells in turn project their axons to CA1 
pyramidal cells (CA1), which project back to entorhinal cortex.  B&C) Close up 
views of stratum lucidum (SL) showing axons of dentate granule cells (A, arrow) 
which terminate in giant synaptic boutons (B, arrows).  D) Image of a CA3 
pyramidal cell (arrow points to soma), highlighting the entire dendritic tree of this 
neuron.  E) The portion of CA3 dendrite within stratum lucidum has multiple 
thorny excrescences (arrows), large spines onto which giant mossy fiber boutons 
synapse.  Images are pseudocolored projections of z-series acquired through 
confocal microscopy. 
projections, known as Schaffer collaterals, onto CA1 pyramidal neurons.  CA1 neurons 
either project directly back to entorhinal cortex, or project to neurons within subiculum 
which themselves send connections back to entorhinal cortex.  Other projections 
originating from layer III of entorhinal cortex, termed the temporoammonic pathway, 
bypass dentate granule cells and CA3 neurons to project mostly onto CA1 pyramidal cell 
dendrites located within stratum lacunosum moleculare of CA1.  It should be noted that 
this simplified description of excitatory hippocampal projections neglects to discuss 
myriad connections with multiple different types of interneurons located throughout 
hippocampus.  Furthermore, the hippocampus also receives projections from other brain 
regions besides entorhinal cortex, such as the amygdala.  Confocal micrographs of some 
of the basic hippocampal regions, cells, and their structures are shown in Figure 1.  These 
micrographs were taken in a Thy1-GFP expressing mouse, in which GFP labels a subset 
of hippocampal neurons in this animal. 
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1.4 The Neurotrophin Receptors, TrkB, and Synaptic Plasticity 
As the subject of this dissertation focuses on activation of the TrkB receptor, particularly 
as it relates to increased neuronal excitability facilitating epileptogenesis, the following 
discussion of the neurotrophin receptors will largely center on TrkB activation and 
evidence that it contributes to enhanced neuronal excitability. 
1.4.1 Overview of the Neurotrophin Receptors and Their Molecular 
Biology 
The tropomyosin-related kinase (Trk) family of neurotrophin receptors are named 
for the oncogene that resulted in their discovery, a gene which contained a translocation 
of a portion of non-muscle tropomyosin with a piece of a novel tyrosine kinase (Barbacid 
et al., 1991).  This novel tyrosine kinase was subsequently named the TrkA receptor, and 
the other two tyrosine kinase receptors in this family, TrkB and TrkC, were identified 
shortly thereafter.  The prototypical ligands for these receptors are the neurotrophins, 
homodimeric proteins of about 14 kDa which are synthesized and thought to be released 
by neurons and some non-neuronal tissues, particularly in response to neuronal activity 
(Huang and Reichardt, 2001; Lessmann and Brigadski, 2009). Interestingly, the 
neurotrophin ligand for TrkA, nerve growth factor (NGF), predated identification of its 
receptor by several decades.  In the mid-20th century, this ligand had been demonstrated 
to be critical to survival of sympathetic neurons (Cowan, 2001).  It was shown to be 
internalized in a receptor-dependent fashion and transported down axons using an 
energy-dependent process, having both local effects on nerve growth cones as well as 
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nuclear-dependent actions which influenced gene expression (Huang and Reichardt, 
2001).  It was not until 1991, however, that definitive evidence was provided showing 
that NGF acted through binding to the TrkA receptor (Kaplan et al., 1991; Klein et al., 
1991).  Brain-derived neurotrophic factor (BDNF) was originally isolated from pig brain 
by (Barde et al., 1982), and demonstrated to be the major ligand for TrkB, though 
neurotrophin-4 (NT-4) may also activate this receptor.  Neurotrophin-3 (NT-3) is the 
major ligand for TrkC, though it can also bind and activate TrkA and TrkB (Barbacid, 
1995).  The neurotrophins have also been demonstrated to bind to the low affinity 
neurotrophin receptor p75NTR, a member of the tumor necrosis factor (TNF) family 
(Huang and Reichardt, 2003).  This receptor reduces the ability of NT-3 to activate TrkA 
and TrkB, and NT-4 to activate TrkB, making the three neurotrophin receptors more 
selective for NGF, BDNF, and NT-3 (Huang and Reichardt, 2003).  Additionally, p75NTR 
can have both prosurvival and apoptotic actions depending on the cell.  However, a 
consistent finding is that p75NTR leads to cell death in the absence of Trk receptors 
(Dechant and Barde, 1997). 
Neurotrophins and their receptors were originally identified as being necessary for 
the survival of developing neurons.  For example, NGF was identified using in vitro 
studies as necessary for the survival and differentiation of sympathetic and some dorsal 
root ganglion neurons in the peripheral nervous system, and mice that are genetic 
knockouts for NGF were born severely deficient in both of these neuronal populations 
(Lindsay, 1996).  TrkC appeared to be particularly important for the survival and 
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development of large fiber proprioceptive neurons in the peripheral nervous system, with 
TrkC knockout mice also being deficient in these cell populations (Lindsay, 1996).  
Signaling through all of these receptors, however, has subsequently been shown to be 
critical for diverse neuronal processes including survival and proliferation, remodeling 
and growth of axons and dendrites, and synaptic plasticity (Huang and Reichardt, 2001).  
In support of the critical role for these receptors in the nervous system, in situ 
hybridization as well as northern analysis has demonstrated virtually ubiquitous 
expression throughout both the central and peripheral nervous systems (Lindsay, 1996).  
More than one receptor type is usually expressed in a single neuron, and there are some 
general developmental and regional expression patterns.  TrkB and TrkC are expressed 
by almost all neurons in the central nervous system, whereas TrkA expression is confined 
to cholinergic neurons in the striatum and basal forebrain (Lindsay, 1996).  In the 
peripheral nervous system, neurotrophin receptors are expressed in all neurons with the 
notable exception of the parasympathetic neurons of the ciliary ganglia (Lindsay, 1996).  
Expression of the neurotrophins largely parallels that of their receptors. 
Neurotrophin receptors are activated in a manner typical of tyrosine kinase 
receptors.  Binding of a neurotrophin molecule to the ectodomain of the neurotrophin 
receptor induces its dimerization, resulting in phosphorylation of multiple tyrosine 
residues within its intracellular domain (Barbacid, 1995; Cunningham and Greene, 1998).  
As the subject of this dissertation is TrkB, these intracellular residues will be referred to 
with respect to their precise residue number within this receptor, though they are common 
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to all Trk receptors.  Phosphorylation of these residues is thought to occur in a lockstep 
fashion, beginning with tyrosine residues 705 and 706 (pY705/706), causing kinase 
activation.  This leads to autophosphorylation of residues 515 and 816 (pY515 and 
pY816), which in turn bind and activate alternate signal transduction cascades.  pY515 
recruits the Shc adaptor protein through phosphotyrosine binding domains, ultimately 
resulting in activation of the Ras-mitogen-activated protein kinase (MAPK) pathway.  
Through a complex set of protein interactions, this residue also signals 
phosphatidylinositol 3-kinase (PI3K), which results in activation of the protein kinase 
Akt (Minichiello, 2009).  These downstream signaling pathways of pY515 have been 
suggested to mediate actions of neurotrophin receptors related to survival signaling and 
suppression of apoptosis in neurons (Hetman and Xia, 2000).  pY816 recruits 
phospholipase-C γ1 (PLC-γ1) resulting in production of inositol-1,4,5-trisphosphate (IP3) 
and diacylglycerol (DAG) (Minichiello, 2009).  IP3 results in release of Ca2+ from 
intracellular stores, resulting in activation of Ca2+/calmodulin dependent kinases, whereas 
DAG activates protein kinase C (PKC).  Downstream signaling from pY816 is thought to 
mediate the actions of neurotrophins effecting synaptic plasticity, as will be described in 
more detail later in this section.  A basic schematic of TrkB signaling is illustrated in 
Figure 2.  
Neurotrophin receptors must be at the membrane in order to bind their 
extracellular ligands, are thought to be internalized into endosomes in response to  
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Figure 2: Schematic of TrkB, its important tyrosine signaling residues, and 
downstream signaling pathways. 
Figure adapted from (McNamara et al., 2006). 
activation, and once internalized may continue to signal from this locale (Howe and 
Mobley, 2005).  Retrograde transport of neurotrophin receptors in complex with their 
ligands have been described in axons, and may be a means by which signals are conveyed 
from synapse to nucleus (Bhattacharyya et al., 1997; Niewiadomska et al., 2011; Watson 
et al., 1999a).  Forms of TrkB and TrkC receptors have also been identified which lack 
their intracellular signaling domains, and thus are unable to activate any signaling 
cascades.  The role of these truncated receptors is not clear, however they have been 
hypothesized to act by competing for dimerization with full-length receptors, thus acting 
in a dominant negative fashion.  In support of this hypothesis, mice overexpressing a 
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truncated form of TrkC have similar neuronal losses as observed in TrkC knockout 
animals (Eide et al., 1996; Palko et al., 1999). 
1.4.2 Transactivation of Neurotrophin Receptors 
In addition to neurotrophin-mediated activation, neurotrophin receptors have been 
shown to undergo transactivation, a process by which a receptor is activated by a ligand 
without directly interacting with it (Carpenter, 1999).  Neurotrophin receptor 
transactivation was initially examined by Chao and colleagues, who demonstrated that 
adenosine, a neurotransmitter, could activate Trk receptors both in PC12 cells and 
hippocampal cultures through a neurotrophin-independent process (Lee et al., 2002a).    
Though the mechanism by which transactivation occurs is incompletely understood, use 
of specific adenosine receptor agonists and antagonists established that this effect was 
mediated through the adenosine-A2A receptor, which is a G-protein coupled receptor 
(GPCR).  Trk receptor transactivation was blocked by specific inhibitors of Src-family 
kinases (SFKs), suggesting that these signaling molecules may act downstream of the 
A2A receptor to mediate Trk receptor phosphorylation.  Pituitary adenylate cyclase-
activating polypeptide (PACAP), a neuropeptide which also activates a GPCR, 
transactivated Trk receptors through a similar SFK-dependent mechanism (Lee et al., 
2002b).  Transactivation of Trk receptors by adenosine and PACAP resulted in activation 
of downstream effectors, such as MAPK and PLC-γ1, showing that transactivated 
neurotrophin receptors also participated in downstream signaling (Lee et al., 2002a).  
Importantly, transactivation by adenosine and PACAP takes hours after exogenous 
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application to fully activate Trk receptors, whereas neurotrophin ligands robustly activate 
their receptors on a time scale of seconds to minutes.  Activation of Trk receptors by 
neurotrophins necessarily must occur at the cell membrane, but transactivation events by 
adenosine and PACAP may occur predominantly on receptors located at an intracellular 
locale, such as Golgi membranes (Rajagopal et al., 2004).  Trk transactivation has been 
suggested to have relevance in vivo, most notably supported by a study demonstrating 
that application of A2A-receptor agonists promoted survival of lesioned facial 
motoneurons in rodents through a process suggested to be dependent on TrkB 
transactivation (Wiese et al., 2007). 
Our laboratory discovered another means by which TrkB receptors can be 
transactivated, which stemmed from a finding involving activated TrkB within stratum 
lucidum during epileptogenesis.  In mice with a conditional deletion of BDNF, resulting 
in elimination of this neurotrophin from dentate granule cells and CA3 pyramidal neurons 
of stratum lucidum, TrkB activation was only partially diminished following seizures, 
and epileptogenesis was only modestly inhibited (He et al., 2004).  Subsequent work 
employing an NT-4 null mutant mouse demonstrated that absence of this neurotrophin 
likewise failed to diminish TrkB activation and epileptogenesis (He et al., 2006).  This 
prompted a search for other ligands which could activate this receptor.  Studies with 
epithelial growth factor receptor (EGFR), another tyrosine kinase, found that this 
molecule could be transactivated by the divalent cation, zinc (Wu et al., 2002).   
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Figure 3: Zinc activates TrkB signaling by a BDNF-independent mechanism. 
In the experiments above, cortical neurons cultured from E18 rat pups (A 
and C) or mouse P1 pups (B) were maintained in vitro for 12-14 days.  Cell lysates 
were subjected to immunoblotting with the indicated antibodies after the treatments 
described.  A) Both BDNF and zinc cause TrkB phosphorylation, resulting in 
phosphorylation of downstream Trk effectors Erk and PLC-γ1.  Addition of TrkB-
Ig (2 mg/mL), a BDNF scavenger, occludes BDNF but not zinc activation of Trk.  
Neurons were treated for 15 minutes with vehicle, BDNF (10 ng/ml) or zinc (100 
µM).  B) Zinc activates TrkB in cortical neurons of BDNF-/- mice.  Cortical neurons 
cultured from wild type and BDNF null mutant pups were incubated with vehicle, 
BDNF (10 ng/mL) or zinc (100 µM) for 15 minutes.  C) Activity facilitates 
endogenous zinc-induced TrkB activation.  High potassium induces Trk 
phosphorylation, which can be occluded by CaEDTA, a zinc chelator, but not TrkB-
Ig.  Cortical neurons were preincubated with CaEDTA (1 mM), a zinc chelator, or 
TrkB-Ig (2 µg/mL) for 30 minutes.  Each of these treatments was continued for an 
additional 30 minutes in the presence of high (50 mM) K+ buffer.  TrkB-Ig 
eliminated BDNF-mediated increases of pTrk in the presence of KCl, demonstrating 
the efficacy of TrkB-Ig under these experiments conditions.  Figure adapted from 
(Huang et al., 2008). 
Because of this finding, our lab hypothesized that zinc may similarly transactivate the 
TrkB receptor, and this was subsequently demonstrated in neuronal-glial cultures 
prepared from rodent cortex (Fig. 3A) (Huang et al., 2008).  TrkB transactivation after 
application of exogenous zinc could be observed within five minutes, peaked between 30 
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and 60 minutes, and declined by 120 minutes, following a kinetic time course more 
similar to activation of TrkB by BDNF than adenosine or PACAP transactivation.  
Exogenously applied zinc was found to mediate TrkB phosphorylation in neurons 
cultured from BDNF knockout mice, demonstrating this phenomenon to be BDNF 
independent (Fig. 3B) (Huang et al., 2008).  The mechanism by which zinc transactivates 
TrkB, as with adenosine or PACAP transactivation, was found to occur through SFK.  To 
this end, SFK was activated in a manner that paralleled transactivation of TrkB by zinc, 
and transactivation was blocked by SFK inhibitors.  The hypothesized mechanism by 
which TrkB is transactivated by SFK has to do with the ability of zinc to bind and inhibit 
another protein kinase, C-terminal Src kinase (Csk) (Sun and Budde, 1999).  When 
uninhibited, Csk will phosphorylate the C-terminal tyrosine residue, Y527, of SFK.  
pY527 causes intramolecular inhibition of SFK by preventing phosphorylation at its 
catalytic site, Y416 (Cole et al., 2003; Cooper and Howell, 1993).  Thus, the net effect of 
zinc inhibition of Csk is activation of SFK, and SFK itself can directly phosphorylate and 
thereby transactivate TrkB (Huang and McNamara, 2010; Huang et al., 2008). 
Our laboratory also found that endogenous zinc could activate TrkB in a BDNF 
independent fashion using the same in vitro neuronal preparations described above (Fig. 
3C) (Huang et al., 2008).  TrkB activation was induced in these experiments by neuronal 
activity, and chelation of extracellular zinc blocked this activation.  As zinc is found 
within presynaptic vesicles of many glutamatergic neurons throughout the CNS, and most 
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notably enriched in mossy fibers of stratum lucidum, we hypothesized that endogenous 
zinc may transactivate TrkB in vivo (Frederickson et al., 2005). 
1.4.3 The TrkB Receptor and Long Term Potentiation 
 Long term potentiation (LTP) is the phenomenon whereby brief high-frequency 
electrical stimulation of a synapse results in persistent augmentation of synaptic strength, 
usually measured by an increase in EPSPs following the stimulation (Minichiello, 2009).  
For many years, this phenomenon has been speculated to occur under physiological 
conditions, and may be a mechanism by which learning and memory take place.  LTP has 
been documented at various synapses within the nervous system, but is most commonly 
studied at the CA3-CA1 synapse within hippocampus, where Schaffer collaterals of CA3 
pyramidal neurons innervate the spines of CA1 pyramidal cells.  Induction of LTP at this 
synapse is NMDA receptor dependent, and expression can be divided into early LTP (E-
LTP), where cellular changes occur leading to potentiation, such as trafficking and 
phosphorylation of AMPA receptors, and late LTP (L-LTP), which involves changes in 
gene expression and protein synthesis (Minichiello, 2009).  At this synapse, considerable 
work has been performed showing that TrkB and BDNF are involved in E-LTP.  In mice 
that are genetic knockouts of BDNF, E-LTP is impaired at this synapse (Korte et al., 
1995), however reintroduction of BDNF through exogenous application or viral 
transduction successfully restored this defect (Korte et al., 1996; Patterson et al., 1996; 
Pozzo-Miller et al., 1999).  Further work suggested that BDNF may also be important for 
expression of L-LTP (Korte et al., 1998).  Mice with conditional deletions of TrkB from 
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both CA3 and CA1 pyramidal cells demonstrated impairment of LTP, showing the 
importance of signaling through this receptor for this phenomenon (Minichiello et al., 
1999; Xu et al., 2000).  In order to dissect the TrkB signaling pathways important for 
LTP, mice were generated with tyrosine to phenylalanine (YF) mutations of either the 
Y816 or Y515 residues of TrkB, preventing phosphorylation and downstream activation 
of signaling pathways from these sites.  Interestingly, studies revealed that it was pY816 
(Minichiello et al., 2002), which signals through PLC-γ1, and not pY515 (Korte et al., 
2000), which signals through Shc, which is important for LTP.  An important distinction 
is that though TrkB signaling may be necessary for development of LTP, TrkB activation 
alone induced by application of exogenous BDNF is not sufficient to cause LTP to 
develop in the absence of high frequency stimulation (Figurov et al., 1996; Lu et al., 
2008; Patterson et al., 1996). 
 A requirement of TrkB and BDNF for normal expression of LTP has also been 
found at the mossy fiber-CA3 (mf-CA3) synapse, where mossy fiber axons form 
synapses onto CA3 pyramidal neurons.  In contrast to LTP at the CA3-CA1 synapse, LTP 
at mf-CA3 synapses is induced and expressed by a mechanism intrinsic to the presynaptic 
dentate granule cell, and involves an increase in glutamate release (Nicoll and Schmitz, 
2005; Pan et al., 2011).  LTP is impaired at this synapse in mice that are genetic 
knockouts for TrkB (Huang et al., 2008).  Animals expressing a mutant form of TrkB, 
rendering it sensitive to inhibition by a small molecule, 1NMPP1, also had impaired LTP 
at this synapse in response to transient inhibition of this receptor by this small molecule 
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(Huang et al., 2008).  Interestingly, as with the CA3-CA1 synapse, it is the PLC-γ1 
signaling pathway through pY816 of TrkB that appears to be important for the effects of 
TrkB on LTP.  Y816F TrkB mutants showed impaired LTP at the mossy fiber-CA3 
synapse, whereas Y515F TrkB mutants displayed intact LTP (He et al., 2010). 
 In addition to LTP deficits, mice lacking the TrkB receptor have also been shown 
to have deficits in hippocampal-dependent learning, suggesting that neuronal excitability 
mediated by TrkB may also be critical for this process.  Mice with a conditional deletion 
of TrkB from cells of the hippocampus, as well as other regions of the forebrain, 
demonstrated deficits in the ability to learn the Morris water maze and other spatial 
learning tasks (Minichiello et al., 1999).  Interestingly, associative learning, also thought 
to be hippocampal-dependent, was shown to be disrupted in Y816F TrkB mutants, but 
not in Y515F mutant mice, suggesting that signaling through PLC-γ1 is critical to this 
process (Gruart et al., 2007).      
1.4.4 The TrkB Receptor and Epilepsy 
Given the importance of TrkB in regulating processes of synaptic plasticity and 
excitability, this receptor has been extensively investigated in terms of its ability to 
mediate the process of epileptogenesis.  Due to the pivotal role that this receptor plays in 
the pathogenesis of epilepsy, elucidating the cellular and molecular mechanisms by 
which TrkB mediates this phenomenon has become a primary topic of study by our 
laboratory.  It is our hope that through understanding the mechanisms by which this 
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receptor mediates the development of epilepsy, novel therapies may be developed which 
can prevent epileptogenesis through targeting TrkB. 
Early work noted increased expression levels of BDNF in models of epilepsy, 
suggesting that signaling through TrkB may be involved in this disease.  Using in situ 
hybridization, BDNF mRNA was increased in rodent hippocampus and other brain 
structures shortly after SE induced by kainic acid, or following kindling (Ernfors et al., 
1991; Isackson et al., 1991).  Striking increases in BDNF protein levels, particularly 
within stratum lucidum, were later observed within hippocampus following kainic acid 
induced seizures using immunohistochemical methods employing a BDNF-specific 
antibody (Conner et al., 1997).  Subsequently, immunohistochemical methods employing 
an antibody specific for phosphorylated Trk receptors also demonstrated increases in 
activated Trk within stratum lucidum (Binder et al., 1999a).  This finding was 
subsequently replicated by numerous studies in various models of epileptogenesis, all 
demonstrating what appeared to be a region-specific enrichment in activated Trk 
receptors within stratum lucidum of hippocampus during the development of limbic 
epilepsy (Danzer et al., 2004; He et al., 2004; He et al., 2002; He et al., 2010).  Notably, 
these increases within stratum lucidum did not occur in models of epileptogenesis in mice 
with Y515F mutations in TrkB using an antibody recognizing pY515 (He et al., 2002). 
Increased levels of Trk receptor activation in epilepsy models assayed using Western blot 
of hippocampus were also blocked in Y816F TrkB mutant mice using an antibody that 
recognized pY816 of the Trk receptor (He et al., 2010).  This demonstrated that the 
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striking increase observed in phosphorylated Trk receptors in models of epileptogenesis 
was due to pTrkB  
BDNF and TrkB have been demonstrated to be pivotal to the process of 
epileptogenesis, suggesting that this TrkB signaling within hippocampus and other CNS 
structures is likely to be integral to the pathogenesis of this disease.  Kindling was 
markedly impaired in mice heterozygous for the BDNF gene (Kokaia et al., 1995).  
Intraventricular infusion of TrkB-Fc, a BDNF scavenging protein, impaired 
epileptogenesis in this model (Binder et al., 1999b).  Interestingly, infusion of TrkA-Fc or 
TrkC-Fc, scavengers for NGF or NT-3, respectively, did not affect kindling development 
in the same study, suggesting that BDNF/TrkB signaling in particular is important for this 
phenomenon (Binder et al., 1999b).  Both transgenic overexpression of BDNF (Croll et 
al., 1999) and infusion of BDNF into hippocampus (Xu et al., 2004) of rodents enhances 
the process of limbic epileptogenesis, demonstrating that excess activation of TrkB 
promotes limbic epilepsy. 
All of these studies, while suggesting that BDNF facilitates epileptogenesis by 
signaling through TrkB, fail to directly show the involvement of this receptor in the 
development of limbic epilepsy.  Compelling evidence that TrkB is directly involved in 
this process, however, was provided in (He et al., 2004).  In this study, TrkB conditional 
knockout mice, which lack this receptor from regions of forebrain including cells 
populating stratum lucidum, failed to undergo kindling.  Importantly, these animals were 
still capable of experiencing acute seizures, demonstrating that this observation was not 
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due to a broader developmental defect in these animals which compromised their ability 
to experience behavioral seizures.  In order to dissect the TrkB signaling pathways 
important for epileptogenesis, animals with Y515F and Y816F mutations in TrkB were 
kindled.  Interestingly, mice with Y515F mutations kindled normally, whereas kindling 
was impaired in Y816F animals, demonstrating the importance TrkB signaling through 
the PLC-γ1 pathway in the development of epileptogenesis. This is notable given that 
pY816 signaling has also been demonstrated to be necessary for the development of some 
forms of LTP. 
  A recent, intriguing study has demonstrated that even transient inhibition of 
TrkB signaling can prevent epileptogenesis (Liu et al., submitted).  Mice with a mutant 
TrkB receptor, making it susceptible to reversible inhibition in the presence of a small 
molecule, 1NMPP1, were given SE through kainic acid microinfusion into the basolateral 
amygdala.  Following this episode, animals were treated with 1NMPP1 for a period of 
two weeks, after which treatment was discontinued.  Almost no SRSs in these animals 
were detected during 1NMPP1 treatment, whereas TrkB mutants not administered 
1NMPP1, or wild type mice given this small molecule, experienced numerous SRSs 
consistent with the development of epilepsy in these animals.  Most notably, even after 
discontinuation of 1NMPP1 following the two week treatment period, mice susceptible to 
inhibition of TrkB by this small molecule failed to demonstrate significant numbers of 
SRSs, even up to six weeks after the initial SE episode.  In contrast, animals treated with 
SE that never experienced TrkB inhibition by 1NMPP1 experienced many SRSs at this 
 31 
 
time point.  The fact that 1NMPP1 was administered directly after SE in this study is 
particularly important because TrkB inhibition during the episode could have 
anticonvulsant effects, confounding the ability to examine its antiepileptogenic effects.  
These findings demonstrate that transient inhibition of TrkB after an initial precipitating 
event, such as SE, is actually sufficient to permanently suppress plastic changes resulting 
in epileptogenesis.  Such results suggest that therapies even transiently inhibiting TrkB 
signaling during the process of epileptogenesis may permanently prevent this process.  
Development of such potential therapies will therefore be the subject of future studies. 
1.5 Zinc in the CNS 
The transition metal, zinc, is an essential micronutrient (Sandstead, 2000) which 
is a critical component of many enzymes and proteins (Berg, 1990).  Within the nervous 
system, zinc is thought to be an important neuromodulator, and is known to affect the 
activity of many neurotransmitter receptors and signaling proteins (Frederickson et al., 
2005).  It is shuttled by transporters between cellular compartments and organelles, 
sequestered within intracellular storage pools, and released in response to various stimuli.  
Despite its critical functions, however, its excess is thought to be neurotoxic (Choi and 
Koh, 1998), and its levels must therefore be tightly regulated.  Zinc has been implicated 
in playing a role in a variety of nervous system pathologies including Alzheimer’s 
disease (Sensi et al., 2009) and neurotoxicity following cerebral ischemia (Koh et al., 
1996).   
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Zinc has been found to be enriched in the presynaptic vesicles of certain 
glutamatergic neurons that populate both limbic and neocortical structures (Sindreu et al., 
2003), most notably within boutons of mossy fibers of dentate granule cells, and is co-
released with glutamate in response to neuronal activity (Frederickson and Danscher, 
1990; Frederickson et al., 2005).  This “free” (chelatable) zinc within mossy fibers was 
first detected by Maske using histochemical methods, who noted a bright red band within 
stratum lucidum of hippocampus that corresponded to large deposits of this transition 
metal within mossy fiber boutons (Maske, 1955).  Ever since this finding, the precise role 
of this vesicular zinc in modulating CNS function has been a matter of debate, its 
functions still incompletely understood.  The mechanism by which vesicular zinc 
becomes enriched at glutamatergic synapses is through a zinc transporter, ZnT3, and it is 
notable that a Timm’s stain, which detects free transition metals, is abolished in mice that 
are knockouts for this receptor (Cole et al., 1999).  Zinc release from mossy fiber boutons 
has been visualized using dyes that detect zinc (Qian and Noebels, 2005), and this release 
was not detected in ZnT3 knockout animals.  Concentrations of zinc in the synaptic cleft 
in response to neuronal activity have been estimated at around 10–30 µM (Li et al., 2001; 
Thompson et al., 2000; Ueno et al., 2002).  The potential contribution of this synaptically 
released zinc to TrkB transactivation and epileptogenesis, particularly given the 
concordance of this synaptically released zinc and pTrkB immunoreactivity within 
stratum lucidum in models of epilepsy, has been of great interest to our lab.  Notably, 
chelation of zinc has been found to impair LTP at the mf-CA3 synapse (Huang et al., 
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2008; Pan et al., 2011), suggesting that TrkB transactivation by vesicular zinc may be 
critical to development of LTP at this locale.  However, the observation that LTP was 
unimpaired in ZnT3 knockout mice failed to further substantiate this finding (Pan et al., 
2011).  
A widely studied example of how zinc functions as a neuromodulator is through 
its inhibition of NMDA receptors (Peters et al., 1987).  This is mediated by both a high-
affinity binding site on the NR2A subunit, with an IC50 of around 5 nM, as well as a low-
affinity, voltage-dependent site on the NR2A subunit with an IC50 which is in the low 
micromolar range, thought to be important during neuronal activity (Aslamkhan et al., 
2002; Coughenour and Barr, 2001; Low et al., 2000).  Given concentrations of zinc found 
under physiological concentrations, the expectation is that this high affinity binding site 
would be at least partially occupied by zinc, therefore providing tonic inhibition of 
NMDA receptors (Frederickson et al., 2005).  Evidence for this has been provided using 
zinc chelators, which have been demonstrated to potentiate NMDA currents (Martin et 
al., 1992; Paoletti et al., 1997; Vogt et al., 2000).  A recent study generated a mouse with 
a mutant high-affinity zinc binding site, rendering zinc unable to bind at this locale.  
Interestingly, these animals showed enhanced sensitivity to pain as well as allodynia, 
providing evidence that tonic inhibition of NMDA receptors by zinc has physiological 
importance (Nozaki et al., 2011).  Other examples of the numerous documented 
neuromodulatory effects of zinc are its ability to inhibit GABA receptors, its proposed 
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modulation of voltage-gated ion channels, as well as the inhibition of glutamate and 
dopamine reuptake transporters (Frederickson et al., 2005). 
1.5.1 Vesicular zinc and plasticity at the mf-CA3 synapse 
Generation of mice that are knockouts for the ZnT3 protein have provided the 
opportunity to examine the effects of ridding vesicular zinc from neurons that normally 
co-release this metal along with glutamate from presynaptic vesicles.  The ZnT3 
transporter is a member of a large family of zinc transporters which mediate zinc efflux 
from the cytosol, either to intracellular organelles or across the plasma membrane 
(Palmiter and Huang, 2004).  Importantly, the distribution of ZnT3 is restricted to the 
nervous system, where it is found only in neurons that contain zinc within their synaptic 
vesicles.  Therefore, this genetic knockout provides a clean and specific means of 
eliminating synaptic zinc (Cole et al., 1999).  Given the large amounts of synaptic 
vesicular zinc found within hippocampus, and the known neuromodulatory effects of this 
metal, examination of the ZnT3 knockout largely sought to find deficits in synaptic 
transmission and neuronal excitability at this locale, as well as deficits in hippocampal-
dependent behaviors such as learning. 
At first assessment, ZnT3-/- mice were grossly normal, with no differences in 
body weight, lifespan, or fertility compared to wild type littermates (Cole et al., 1999).  
Ultrastructural assessment of mossy fiber boutons revealed no abnormalities.  Zinc levels 
were reduced by approximately 20% in the hippocampi and neocortex of these mice, as a 
result of a lack of synaptic vesicular zinc.  Interestingly, mutant mice were shown to be 
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more sensitive to seizures induced by kainic acid, whereas they were less sensitive to 
those induced by biccuculine, a GABAA antagonist (Cole et al., 2000).  These effects 
could potentially reflect disinhibition of both NMDA receptors and GABAA receptors in 
the absence of synaptic zinc.  Early studies failed to find any deficits in learning when 
animals were tested in paradigms of hippocampal-dependent learning tasks (Cole et al., 
2001), such as the Morris water maze, and basal synaptic transmission as well as LTP 
was unimpaired at the mossy fiber-CA3 synapse (Lopantsev et al., 2003; Pan et al., 
2011).  All of this suggested that synaptic transmission and hippocampal function in the 
absence of synaptic zinc remained grossly normal. 
 However, further study of ZnT3 knockout animals revealed that some forms of 
hippocampal-dependent learning were impaired.  Studies conducting more in-depth 
examinations of hippocampal-mediated learning, such as reversal learning in the Morris 
water maze and working memory in the rewarded-alternation T-maze task, did find 
deficits (Martel et al., 2011; Sindreu et al., 2011).  Furthermore, ZnT3 knockouts were 
found to have deficits in contextual fear discrimination (Martel et al., 2011; Sindreu et al., 
2011), contradicting an earlier study (Lopantsev et al., 2003).  Interestingly, one of these 
studies also found that MAPK signaling was impaired in ZnT3 knockouts, though the 
mechanism was attributed to the enhanced activation of a phosphatase in the absence of 
synaptic zinc, not to any decrease in TrkB activation (Sindreu et al., 2011).  Furthermore, 
examination of learning tasks thought to be dependent on the amygdala, which also 
contains glutamatergic neurons possessing synaptic zinc, found deficits in associative 
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fear memory and extinction (Martel et al., 2010).  Finally, testing spatial memory in older 
mice (six months of age), as opposed to young mice examined in the previous study 
(Cole et al., 2001), demonstrated that ZnT3 mutant animals performed significantly 
worse in the Morris water maze compared to wild type controls (Adlard et al., 2010).  
Furthermore, the investigators noted decreased levels of proteins involved in synaptic 
transmission, such as NMDA receptors and TrkB.  The investigators hypothesized that 
vesicular zinc is critical to maintaining normal synaptic function during the aging 
process. 
 Despite the fact that LTP did not appear to be impaired in ZnT3 knockout mice at 
the mf-CA3 synapse, further study revealed qualitative differences in LTP in mutant 
compared to wild type  animals (Pan et al., 2011).  As previously discussed, expression of 
LTP at the mf-CA3 synapse occurs through a presynaptic mechanism of increased 
glutamate release from mossy fiber boutons (Nicoll and Schmitz, 2005).  A means of 
measuring this is through paired pulse facilitation (PPF), which is inversely related to 
neurotransmitter release from a synapse (Cowan et al., 2001).  Interestingly, LTP at the 
mf-CA3 synapse in slices from wild type animals is associated with decreased PPF, 
whereas it was found to be unchanged in ZnT3 knockout animals, or in the presence of a 
zinc chelator.  Furthermore, mice mutant for rim1α, a protein localized to the presynaptic 
active zone, do not express LTP at the mf-CA3 synapse, as enhanced glutamate release at 
this synapse in response to LTP-inducing stimuli does not occur (Castillo et al., 2002).  
Strikingly, however, LTP at this synapse in these mutant animals could be induced in the 
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presence of a zinc chelator.  This, as well as other data within (Pan et al., 2011), 
demonstrates that LTP at the mf-CA3 synapse in the ZnT3 knockout animal occurs 
through a novel postsynaptic mechanism, not the conventional presynaptic one.  This is 
particularly interesting in light of the fact that studies have suggested that TrkB is 
involved in LTP through a presynaptic mechanism, and that work from this dissertation 
localizes activated TrkB to mossy fiber boutons (Helgager et al., 2013; Xu et al., 2000).  
All of this evidence demonstrates that zinc plays a critical neuromodulatory role at the 
glutamatergic synapses where it is released, and that one such component of this role 
could be TrkB transactivation.  
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2. The Cellular and Synaptic Location of Activated TrkB 
in Mouse Hippocampus during Limbic Epileptogenesis 
This chapter has been adapted from (Helgager et al., 2013). 
2.1 Introduction 
Epilepsy is a serious common neurological disorder, afflicting an estimated 1% of 
the population worldwide (Shorvon, 1996).  Limbic epilepsy (synonymous with temporal 
lobe epilepsy [TLE]) is particularly problematic because it is both common and 
commonly resistant to optimal contemporary treatment (Arroyo et al., 2002).  Clinical 
observations led Sir William Gowers (1881) to propose that seizures themselves promote 
progression of epilepsy, a proposal supported by subsequent studies of animal models in 
which recurrent seizures alone are sufficient to destroy limbic neurons and induce 
lifelong severe epilepsy (Sayin et al., 2003).  An extension of Gowers’ hypothesis is that 
an episode of continuous seizure activity spanning 30 minutes to hours (status epilepticus, 
SE) is sufficient to induce TLE that persists for a lifetime.  Indeed SE alone is sufficient 
to induce TLE in models of both developing and adult rodents (Dunleavy et al., 2010; 
Loscher, 2002).  Circumstantial evidence supports the idea that SE contributes to the 
pathogenesis of TLE in humans (Annegers et al., 1979; Tsai et al., 2009; 
VanLandingham et al., 1998). 
Understanding how seizures promote induction and/or progression of epilepsy 
may reveal molecular targets for preventive therapy.  Experimental evidence suggests 
that the neurotrophin, brain-derived neurotrophic factor (BDNF), promotes limbic 
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epileptogenesis by activation of its cognate receptor, tropomyosin-related kinase B 
(TrkB).  Epileptogenesis was markedly impaired in the kindling model in mice 
heterozygous for the BDNF gene or in rats following intraventricular infusion of a BDNF 
scavenging protein (Binder et al., 1999b; Kokaia et al., 1995).  Conditional deletion of 
TrkB in mice abolished limbic epileptogenesis in an animal model induced by recurrent 
seizures (He et al., 2004), and transient inhibition of TrkB signaling following SE in a 
mouse model prevented subsequent development of spontaneous recurrent seizures (SRS) 
(Liu et al., submitted).  These findings demonstrate that TrkB is necessary for limbic 
epileptogenesis.  Transgenic overexpression of BDNF enhances limbic epileptogenesis 
(Croll et al., 1999), as does direct infusion of BDNF into hippocampus of adult rodents 
(Xu et al., 2004), suggesting that excess activation of TrkB by BDNF is sufficient to 
promote limbic epilepsy.  Importantly, diverse models of limbic epileptogenesis exhibit 
enhanced activation of TrkB (Binder et al., 1999a; Danzer et al., 2004; He et al., 2004; 
He et al., 2002; He et al., 2010) as evidenced by a surrogate measure, namely increased 
tyrosine phosphorylation (Segal et al., 1996).  Collectively, these findings underscore the 
importance of elucidating the cellular consequences of enhanced TrkB activation because 
these are likely to promote limbic epileptogenesis.   
Establishing the cellular and subcellular locale of the enhanced TrkB activation 
evident during limbic epileptogenesis is necessary to elucidate its cellular consequences.  
Using an antibody that recognizes the phosphorylated tyrosine 816 (pY816) of TrkB 
together with cellular markers and confocal microscopy, we examined the anatomic 
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locale of pY816 TrkB immunoreactivity in a model of limbic epileptogenesis involving 
SE induced by microinfusion of the chemoconvulsant kainic acid (KA) into the 
basolateral amygdala of adult mice (Araki et al., 2002; Li et al., 2008; Mouri et al., 2008).  
Advantages of this model include low mortality, as well as the reliable induction of 
spontaneous recurrent seizures and hippocampal pathology similar to humans with TLE 
(Mathern et al., 1997).  Notably, work employing mice with mutations in either of two 
key TrkB tyrosine signaling residues, Y816 and Y515, revealed that Y816, but not Y515, 
is critical for the development of epilepsy (He et al., 2002; He et al., 2010), underscoring 
the rationale for examining the phosphorylation of this particular tyrosine residue of TrkB 
during epileptogenesis.  The present study reveals evidence of enhanced TrkB activation 
in two populations of neurons within hippocampal circuitry—dentate granule cells and 
CA1 pyramidal cells.  The enhanced TrkB activation was localized in part to excitatory 
synapses in each of these neuronal populations.  Importantly, the model employed in this 
study is the same one used to demonstrate that transient TrkB inhibition following SE 
prevented the development of SRS (Liu et al., submitted), suggesting that TrkB signaling 
from these locales is likely to be critical for the development of limbic epilepsy. 
2.2 Materials and Methods 
2.2.1 Thy1-GFP Expressing Mice 
C57/BL6 mice which express a green fluorescent protein (GFP) transgene under 
control of the Thy1 promoter were a generous gift from Dr. Guoping Feng (Duke 
University School of Medicine, Durham, NC).  These mice were of either the M or O line, 
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as described previously (Feng et al., 2000).  Animals used for experiments were bred 
from mice hemizygous for the Thy1-GFP allele crossed to wild type C57/BL6 mice from 
a local colony, the founders of which were originally obtained from Charles River 
(Wilmington, MA).  Thy1-GFP animals were crossed to the local colony for at least five 
generations before use in experimentation.  Thy1 belongs to the Ig superfamily and is 
expressed in both neuronal as well as non-neuronal cells, and both lines express GFP in a 
subset of dentate granule cells, as well as CA3 and CA1 pyramidal cells.  Importantly for 
the purpose of this study, these cells represent typical granule and pyramidal cells in that 
their dendritic, axonal, and somatic morphologies reflect patterns observed using other 
techniques (Ramón y Cajal, 1911).  Dentate granule cell mossy fiber axons expressing 
GFP can be visualized, and their giant boutons are easily identifiable based on their 
location within stratum lucidum, their continuity with the axon, and their large size (8-
17µm2) (Amaral and Dent, 1981).  The dendritic processes and spines of GFP-expressing 
pyramidal neurons within hippocampus, though more sparse, are also readily observable.  
These mice have been used previously as a means of examining the cellular morphology 
of hippocampal neurons, as well as for colocalization analyses similar to those performed 
in this study (Copanaki et al., 2010; Danzer et al., 2008; Danzer and McNamara, 2004; 
Walter et al., 2007).   
2.2.2 Induction of SE 
All animal procedures described were approved for use by the Institutional 
Animal Care and Use Committee (IACUC) at Duke University, and conformed to 
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National Institutes of Health and Duke University institutional guidelines for the care and 
use of animals.  Animals were maintained on 12 hour light/dark cycles.  Littermate GFP-
expressing and non-expressing mice were included in experiments, and an effort was 
made to pair control and SE treated animals of the same GFP genotype whenever 
possible.  Mice that died during treatment or that did not develop SE were discarded from 
the experiment. 
2.2.2.1 SE Induced by Microinfusion of KA 
A model of limbic epileptogenesis whereby SE was induced by microinfusion of 
KA into the basolateral amygdala was adopted for the majority of experiments conducted 
in this study, and has been extensively characterized in C57/BL6 mice (Araki et al., 2002; 
Li et al., 2008; Mouri et al., 2008).  This model was selected for several reasons: a) 
animals usually develop SE; b) animals undergoing SE uniformly develop spontaneous 
recurrent seizures after a seizure free latent period of 3-6 days; c) mortality is low; d)  
unlike systemic administration of KA in C57/BL6 mice (Schauwecker and Steward, 
1997), hippocampal sclerosis similar to that of human TLE develops in the hippocampus 
ipsilateral to the amygdala into which KA is infused.  The unilaterality of the 
hippocampal damage also provides the advantage of an intra-animal control not present 
in other models.  
It should be noted, however, that prominent cell death is not found directly 
following SE induced by KA microinfusion into amygdala in C57/BL6 mice (Kasugai et 
al., 2007), such as at the time point examined in this study, but rather occurs over 
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subsequent days and weeks (Araki et al., 2002; Li et al., 2008; Mouri et al., 2008).  In the 
present study, pY816 immunoreactivity was examined under conditions where cell 
damage should be minimal, as the presence of significant amounts of dead tissue would 
have confounded the ability to accurately quantify pY816 immunoreactivity in the 
remaining viable neuropil.  This was exemplified in two KA treated animals in this study 
that were found to have disruption of the cytoarchitecture within stratum lucidum 
accompanied by a loss of pY816 staining, and were subsequently discarded from analysis 
(see below).  The paucity of cell death in this study is reinforced by the presence of GFP+ 
pyramidal cells and their processes in KA treated Thy1-GFP mice; no obvious 
differences in their numbers or morphology were evident in NS compared to KA infused 
animals.   
A total of 34 mice undergoing infusion of KA or NS into the right amygdala were 
used in this portion of the study.  Both male and female C57BL/6 mice aged 3-6 months 
old and weighing at least 20 g were anesthetized with 60 mg/kg pentobarbital (Lundbeck, 
Deerfield, IL) via intraperitoneal injection and placed in a stereotactic frame.  Animals 
were surgically implanted with a guide cannula (1.1 mm posterior, 2.9 mm lateral to 
Bregma; Plastics One, Roanoke, VA), following which a bipolar electrode was inserted 
into the contralateral dorsal hippocampus (2.0 mm posterior, 1.6 mm lateral to Bregma, 
depth of 1.5 mm below dura).  Mice were allowed to recover postoperatively for at least 
three days.  Before microinfusions, digital EEG recording commenced from the 
previously placed hippocampal electrode (Grass Technologies, West Warwick, RI).  An 
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injection cannula (Plastics One) was inserted through the guide cannula at a depth of 4.6 
mm below dura so as to target basolateral amygdala.  Through this cannula, a total of 21 
mice to be given SE received infusions of 0.3 µg of KA (Sigma, St. Louis, MO) in 0.5 µL 
of normal saline (NS) which was infused over a period of five minutes using a motorized 
infusion/withdrawal pump (Harvard Apparatus, Holliston, MA).  A total of 13 mice to be 
used as surgical controls were infused with an equivalent volume of vehicle, NS, in the 
same fashion.  The EEG was subsequently monitored for electrographic seizure activity, 
and mice were simultaneously observed for the development of behavioral SE.  SE was 
defined as in (Danzer and McNamara, 2004): partial or whole body clonus, myoclonic 
jerks, rearing and falling, shivering, and/or loss of posture that was uninterrupted by 
normal behavior.  Animals that developed SE were monitored until three hours after the 
first recorded electrographic seizure, at which time they were sacrificed, as described 
below, along with littermates that had been treated as surgical controls.  Of the 21 
animals infused with KA, four did not survive for the full three hours of SE, whereas 
another three failed to developed SE.    
2.2.2.2 SE Induced by Pilocarpine 
A total of 15 male and female C57/BL6 mice 2-3 months of age, generated as 
described above, were used in the portion of the study that examined pY816 
immunoreactivity within CA1 of hippocampus.  Mice received methylscopolomine 
nitrate (1 mg/kg by intraperitoneal injection) (Sigma), in order to block peripheral effects 
of the subsequent pilocarpine treatment.  Fifteen minutes later, animals to be given SE 
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were injected with pilocarpine (375 mg/kg, intraperitoneal) (Sigma), whereas those to be 
used as controls were injected with NS.  In total, 11 mice received pilocarpine treatment 
and four NS.  Pilocarpine treated mice were observed for the development of behavioral 
SE as described above.  An additional dose of pilocarpine (75 mg/kg, intraperitoneal) was 
administered to animals that failed to develop SE by 50 minutes following the initial 
pilocarpine injection.  Animals were allowed to remain in SE for three hours at which 
time diazepam (10 mg/kg, intraperitoneal) (Hospira, Lake Forest, IL) was given to 
terminate seizure activity.  Control animals also received diazepam.  Animals were 
sacrificed, along with NS treated controls, at six hours following onset of SE.  Of the 11 
animals injected with pilocarpine, four did not survive the full SE episode and two failed 
to develop SE.  In a separate experiment, a total of 12 animals (six pilocarpine and six 
NS) were treated in a similar fashion in order to quantify and examine the cellular 
distribution of pY816 immunoreactivity within stratum lucidum. 
2.2.3 Preparation of Brain Specimens for Immunohistochemistry 
Animals treated as above were anesthetized with 100 mg/kg pentobarbital by 
intraperitoneal injection and underwent transcardial perfusion through the left ventricle 
with a solution of ice-cold PBS, pH 7.4, containing 1 U/mL heparin (Sigma) and 2 mM 
sodium orthovanadate (Sigma), at a rate of 10 ml/min for one minute.  This was followed 
by a seven minute perfusion with ice-cold 4% paraformaldehyde (Sigma) and 2 mM 
sodium orthovanadate in PBS, pH 7.4.  Brains were removed and postfixed overnight at 
4°C in the same solution, after which they underwent cryoprotection for 36 hours in a 
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solution of 30% sucrose, 2 mM sodium orthovanadate in PBS at pH 7.4 and 4°C.  Brains 
were verified as being appropriately cryoprotected when they sank in this solution.  
Brains were then frozen by slow immersion in 2-methylbutane (J.T. Baker, Phillipsburg, 
NJ) cooled to -20°C with dry ice, and stored at -80°C until cryosectioning.  Sections were 
cut at a thickness of 40 µm, placed in cryoprotection solution, and stored at -80°C until 
immunostaining.  In animals that received KA microinfusions to induce SE, sections 
containing the cannula tract were examined to confirm that microinfusion had targeted 
the basolateral amygdala.   
Any brains with misplaced cannulas or that were found to contain blood in the 
hippocampi upon sectioning, indicating a suboptimal perfusion, were discarded from 
further processing.  Furthermore, sections from two animals treated with SE by KA 
microinfusion revealed disruption of the cytoarchitecture within stratum lucidum 
compared to control animals as determined by Nissl stain, probably a result of 
particularly severe SE (Fig. 5B; arrows).  For this reason, these animals were discarded 
from the final quantitative analysis.  The region of disrupted cytoarchitecture revealed 
striking paucity of pY816 staining compared to control mice (Fig. 5C; arrows), however 
it should be noted that inclusion of these animals would not have altered the statistical 
significance level of any results of this study. 
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2.2.4 Antibody Characterization 
Details of antibodies employed in this study are provided in Table 1 (Primary 
Antibodies) and Table 2 (Secondary Antibodies).  These antibodies were characterized in 
terms of their specificity as follows: 
       Table 1: Primary antibodies employed in study. 
Target Immunogen Source Working 
Dilution 
Phosphorylated 
tyrosine residue 816 
(pY816) of TrkB 
Receptor 
LQNLAKASPVpYLDI, 
corresponding to amino 
acids 806-819 of mouse 
TrkB. 
McNamara 
Laboratory; Rabbit 
Polyclonal. 
1:2000 
Green Fluorescent 
Protein (GFP) 
GFP-BSA Millipore; Mouse 
Monoclonal; 
MAB3580. 
1:1000 
MAP2 Rat brain microtubule-
associated proteins 
(MAPs). 
Sigma; Mouse 
Monoclonal; 
M4403. 
1:500 
Tau-1 Purified denatured 
bovine microtubule 
associated proteins. 
Millipore; Mouse 
Monoclonal; 
MAB3420. 
1:1000 
 
Table 2: Secondary Antibodies Employed in Study. 
Secondary Antibody Source Working Dilution 
Alexa Fluor 555 Goat Anti-
Rabbit IgG (H+L), highly 
cross-adsorbed 
Invitrogen; A-21429 1:1000 
Alexa Fluor 488 Goat Anti-
Mouse IgG (H+L), highly 
cross-adsorbed 
Invitrogen; A-11029 1:500 
Alexa Fluor 633 Goat Anti-
Mouse IgG (H+L), highly 
cross-adsorbed 
Invitrogen; A-21052 1:500 
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Rabbit polyclonal antibody which recognizes phosphorylated tyrosine residue 816 
of the TrkB receptor (pY816) was generated using the peptide LQNLAKASPVpYLDI, 
corresponding to amino acids 806-819 of mouse TrkB , and was used in all experiments 
at a 1:2000 dilution following IgG purification using protein-A beads.  Importantly, the 
specificity of this antibody was previously established for immunohistochemistry (He et 
al., 2010).  This was evidenced by demonstrating a significant reduction in 
immunoreactivity in stratum lucidum of genetically modified mice with a substitution of 
phenylalanine for tyrosine at the 816 residue (Y816F) of TrkB compared to wild type 
controls, as shown in Supplementary Figure 1 of (He et al., 2010).   
A mouse monoclonal antibody recognizing GFP (1:1000; Millipore, Temecula, 
CA) was found to augment GFP fluorescence.  This was tested by incubating GFP-
expressing mouse brain sections with this antibody, followed by an Alexa Fluor-555 
conjugated secondary antibody, which fluoresces red.  Augmented (red) and endogenous 
(green) GFP fluorescence could be seen to overlap when viewed using an epifluorescent 
microscope.  Mouse monoclonal MAP2 (1:500; Sigma) and tau (1:1000; Millipore) 
antibodies were employed as tissue markers of dendrites and axons, respectively (Binder 
et al., 1985; Huber and Matus, 1984).  MAP2 antibody was found to label what appeared 
to be dendrites throughout mouse brain, confirmed by the fact that dendritic shafts of 
GFP+ CA1 and CA3 pyramidal cells were found to colocalize with MAP2 
immunoreactivity within CA3 stratum lucidum and CA1 stratum radiatum when 
examined in Thy1-GFP mice.  Tau immunoreactivity was found to colocalize with GFP+ 
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mossy fiber axons in stratum lucidum, and was also excluded from GFP+ dendrites that 
could be identified within this structure. 
2.2.5 Immunohistochemistry 
NS and SE treated littermates were always incubated in parallel using the same 
solutions and conditions.  All incubations took place at 4°C in 5% normal goat serum 
(Invitrogen, Carlsbad, CA) in PBS, pH 7.4, with 2 mM sodium orthovanadate.  Floating 
sections were permeabilized for one hour in 0.5% Triton-X100 (GE Healthcare, Chalfont 
St. Giles, UK), and solutions of primary antibodies added for 36 hours.  Alexa Fluor 555 
conjugated goat anti-rabbit (1:1000; Invitrogen) and, for colocalization experiments, 
Alexa Fluor 488 or 633 conjugated goat anti-mouse secondary antibodies (1:500; 
Invitrogen) were then applied for six hours.  Adjacent sections not treated with primary 
antibody were also run in parallel for each animal as negative controls.  Sections were 
wet-mounted on Superfrost Plus slides (Erie Scientific, Portsmouth, NH) and stepped 
through serial dehydration solutions of two minutes each of 50%, 70%, 85%, 95%, 100%, 
and 100% ethanol, followed by 20 minutes incubation in xylene (VWR, Radnor, PA) 
before coverslipping.   
2.2.6 Confocal Microscopy and Data Analysis 
2.2.6.1 Imaging Parameters 
Imaging was performed with a Leica (Nussloch, Germany) DMIRE2 inverted 
microscope with a 10x (numerical aperture, 0.4) air or 63x (numerical aperture, 1.4) oil 
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immersion objective equipped with a Leica TCS SL confocal system.  All images were 
acquired with the pinhole set to 1.0 Airy units.  All images shown for visual comparison 
between treatment groups or used for quantitative analysis were acquired so as to prevent 
systematic differences in image intensities between mouse genotypes.  To this end, 
sections to be compared within an experiment were incubated together and imaged using 
the same laser intensity and detection settings during the same imaging session, thereby 
permitting relative densitometry measurements to be made between treatment groups.  
Because overall staining intensities necessarily varied between staining experiments, 
confocal settings were adjusted optimally for each experiment so that all image intensities 
fell within the dynamic range of detection of the device.   
Low power (10x objective, total of 100x magnification) images of hippocampus 
are average projections of z-series “stacks” taken through the entire thickness of the 
hippocampal section.  Unless otherwise stated, high power (63x objective, total of 630x 
magnification) images are average projections of z-series taken through a 1 µm depth of 
hippocampus where pY816 staining was of greatest intensity.  Average projections were 
used because they best reflect representative staining intensities in the z-plane for 
quantification of immunoreactivity.  Images depicting colocalizations were confirmed in 
the x, y, and z dimensions.  The focal plane thickness is a significant factor in the z-
dimension.  For the 63x objective used in this study, assuming ideal conditions and 488 
nm of light, z resolution is stated to be 235 nm (Leica).  The resolution in the x-y plane is 
stated to be 180 nm (Leica).  All image quantification described was performed on raw 
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images which were not adjusted for brightness or contrast.  However, brightness and/or 
contrast were optimized in all images shown within this chapter in order to best convey 
relevant features.  In images of pY816 immunoreactivity used for comparison, brightness 
and contrast were adjusted equally between images. 
2.2.6.2 Quantification of pY816 Immunoreactivity 
Analysis of imaging data was performed by an investigator blinded to treatment 
group.  The program ImageJ (Abramoff, 2004) was used for data analysis.  All 
quantitative data are presented as mean ± SEM, analyzed by 1-way ANOVA with 
significance values between individual groups determined by post-hoc Bonferroni’s test 
or Student’s t-test.   
For quantification of stratum lucidum immunoreactivity for animals in the KA 
model of SE, one hippocampal image including the CA3b regions of stratum lucidum and 
stratum radiatum, taken both ipsilateral and contralateral to the side of infusion, was used 
from each animal acquired at both low power (100x) and high power (630x).  If there was 
any discrepancy in stratum lucidum brightness between sections, that with the brightest 
stratum lucidum immunoreactivity was used.  Low power quantification of pY816 
immunoreactivity within stratum lucidum was performed by outlining a square region of 
interest (ROI) in the CA3b region, of uniform dimension for all images sampled, and 
taking the average intensity within this region.  The average intensity of an ROI of equal 
dimension was taken within stratum radiatum of CA3, reflective of background 
immunoreactivity, and subtracted from the stratum lucidum value so as to compensate for 
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differences in background staining intensity between animals.  Other hippocampal 
regions quantified at low power (100x) were analyzed in the same fashion.  
Quantification of stratum lucidum values in pilocarpine treated mice was done as in the 
KA model, except only one stratum lucidum was quantified per mouse.  In the rare 
instance where a notable discrepancy was observed in pY816 stratum lucidum 
immunoreactivity between hemispheres, the side with the brightest immunoreactivity was 
used.  Quantification at high power (630x) focused on specific areas within stratum 
lucidum that were enhanced in pY816 immunoreactivity and shown to correspond to 
axon tracts in colocalization experiments.  Representative regions enriched in pY816 
immunoreactivity were outlined as ROIs until 50,000 pixels in total area were reached or 
exceeded, and the average intensity of this area quantified.  The average intensity of 
stratum radiatum of CA3 that was included in the same micrograph was also taken, and 
subtracted from the value obtained from stratum lucidum in order to compensate for 
variations in background staining.  Signal within stratum radiatum was used for 
normalization for several reasons: a) signal within stratum radiatum immunoreactivity 
was always substantially lower than stratum lucidum; b) signal within stratum radiatum 
was found to be of the same average intensity when compared between control and SE 
treated animals at both low power (100x) and high power (630x) (data not shown); c) the 
CA3 pyramidal cell dendrites which populate this region were found not to contain 
significant amounts of pY816 immunoreactivity (Fig. 11E; CA3 SR; also observe CA3 
stratum radiatum in Fig. 5A).   
 53 
 
For quantification of other regions within hippocampus, the investigator counted 
the total numbers of individual neuronal processes discerned within a given region within 
an image.  In mice treated with the KA microinfusion model, two images were taken both 
ipsilateral and contralateral to the site of infusion in each of the following regions for 
every animal: CA1 stratum radiatum, CA1 stratum oriens, CA1 stratum lacunosum 
moleculare, CA3 stratum radiatum, CA3 stratum oriens, and the suprapyramidal and 
infrapyramidal molecular layers of dentate gyrus.  In mice treated with the pilocarpine 
model, two images from each side were taken from each of the regions above, and those 
that appeared to display the greatest number of neuronal processes were used for analysis.  
In order to quantify how far within apical dendritic shafts of CA1 pyramidal cells the 
pY816 immunoreactivity extended into stratum radiatum, individual GFP+ apical shafts 
that could be traced through the vertical extent of stratum radiatum were imaged in a KA 
infused animal in the hippocampus ipsilateral to microinfusion.  In those dendritic shafts 
that contained pY816 immunoreactivity, measurements were made of both the distance 
from the soma that this immunoreactivity was observed, and the total dendritic length 
within stratum radiatum of CA1.  From these measurements, the percent of the total 
length of the dendritic shaft containing pY816 immunoreactivity was calculated. 
Quantification of synaptic pY816 immunoreactivity employed just the subset of 
mice that expressed Thy1-GFP (5 KA and 5 NS out of 9 KA and 9 NS).  Sections from 
these animals treated in the KA microinfusion model were imaged within a given region 
both ipsilateral and contralateral to the side of infusion.  For quantification of pY816 
 54 
 
immunoreactivity within giant mossy fiber boutons of stratum lucidum, z-series were 
acquired at 200 nm intervals over a total depth of 1 µm.  For quantification of 
immunoreactivity within dendritic spines of stratum radiatum of CA1, stratum oriens of 
CA1, stratum lacunosum moleculare of CA1, stratum radiatum of CA3, and the outer two 
thirds of the suprapyramidal and infrapyramidal molecular layers, z-series were taken at 
250 nm intervals over a total depth of 2 µm.  Note that pY816 antibody generally 
penetrated sections only superficially, but this was particularly pronounced within 
stratum lucidum, limiting the depth in which immunoreactivity could be imaged in this 
region more than the others.  Individual spines and boutons from each of these regions 
were checked for pY816 immunoreactivity in the x, y, and z planes, and scored as being 
positive if they appeared to contain at least one discrete immunoreactive puncta, even if 
only in one z-section.  This immunoreactivity needed to occupy at least 20% of the area 
of a bouton, whereas for a spine the majority of its area needed to be filled. 
2.3 Results 
2.3.1 Enhanced pY816 Immunoreactivity within Stratum Lucidum 
Following Kainic Acid Status Epilepticus (KA-SE)  
Initial studies centered on characterization of the intensity of pY816 
immunoreactivity within stratum lucidum in the KA model.  As KA microinfusion 
directly activates limbic structures on the side in which it is infused (Araki et al., 2002), 
pY816 immunoreactivity was examined in stratum lucidum both ipsilateral and 
contralateral to the side of infusion.  Littermate mice were infused with either normal  
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Figure 4: Immunoreactivity labeling phosphorylated tyrosine 816 (pY816) of TrkB 
is enhanced within stratum lucidum (SL) following kainic acid (KA) induced status 
epilepticus (SE), observed preferentially in the hippocampus ipsilateral to KA 
microinfusion. 
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A) Representative images of hippocampi stained with pY816 from animals 
infused with normal saline (NS, top) or given SE (KA, bottom) through 
microinfusion of KA into right amygdala (KA-SE).  Hippocampi both ipsilateral 
(IPSI, right) and contralateral (CONTRA, left) to the side of infusion are shown.  A 
noticeable increase in SL immunoreactivity can be discerned in the KA animal 
compared to NS on the side of infusion (IPSI, arrows point to SL).  Other regions 
within hippocampus that are referred to within the text are labeled for reference in 
(A): stratum radiatum of CA3 (CA3 SR), stratum oriens of CA3 (CA3 SO), stratum 
radiatum of CA1 (CA1 SR), stratum oriens of CA1 (CA1 SO), stratum lacunosum 
moleculare of CA1 (CA1 SLM), the suprapyramidal molecular layer of dentate 
gyrus (SML), and the infrapyramidal molecular layer of dentate gyrus (IML).  Each 
image is a montage of two images taken at low magnification (100x).  Scale bar = 
300 µm.  B) Low power (100x) quantification of pY816 intensity in various regions 
from hippocampi both ipsilateral (IPSI) and contralateral (CONTRA) to 
microinfusion.  A 2.1-fold, highly significant increase (p<0.001, one-way ANOVA; 
p<0.001, post-hoc Bonferroni’s test) was observed in CA3b SL of KA treated 
animals (n=9) compared to NS (n=9) on the side ipsilateral to infusion, whereas on 
the contralateral side the increase was only 1.3-fold (p>0.05, post-hoc Bonferroni’s 
test).  Analysis of CA1 SO and CA1 SLM did not demonstrate any significant 
differences in pY816 intensity between NS and KA treated mice on either side.  C) 
Analysis of CA1 SR did not demonstrate differences in pY816 intensity between NS 
and KA treated animals either ipsilateral (IPSI) or contralateral (CONTRA) to 
infusion.  All quantification is presented as mean intensity values ± SEM; all data 
were analyzed by one-way ANOVA and post-hoc Bonferroni’s test; ***p<0.001.  
saline (NS) or KA, and those receiving the latter treatment allowed to seize for three 
hours following the first electrographic seizure, as recorded from a bipolar electrode in 
CA1 of the hippocampus contralateral to the side of infusion.  At this time mice were 
sacrificed along with their NS controls and coronal sections containing dorsal 
hippocampi were stained with pY816 antibody.  Visual inspection at low magnification 
(100x) revealed striking increases of pY816 immunoreactivity in stratum lucidum 
ipsilateral to KA microinfusion compared to contralateral stratum lucidum or to NS 
treated mice (Fig. 4A; compare KA IPSI to others, arrows point to stratum lucidum).  
Quantification of pY816 immunoreactivity within CA3b of stratum lucidum using low 
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power (100x) images revealed approximately a 2-fold increase ipsilateral to KA infusion  
(n=9) compared to NS littermates (n=9) (Fig. 4B; CA3 SL; p<0.001); by contrast, only a 
1.3-fold increase was observed contralateral to KA infusion (p>0.05).  Thus, pY816 
immunoreactivity was preferentially increased within stratum lucidum ipsilateral to the 
KA infused amygdala, a site at which immunoreactivity in all KA treated mice (n=9) 
exceeded that of either side in NS treated littermates.  Furthermore, in all but one KA 
treated animal (n=8), pY816 immunoreactivity was greater ipsilaterally than 
contralaterally.  Except for stratum radiatum of CA1 (see below), no overt changes in 
pY816 TrkB immunoreactivity were evident in other regions of hippocampus following 
KA-SE, consistent with past reports (Binder et al., 1999a; Danzer et al., 2004; He et al., 
2004; He et al., 2002; He et al., 2010); quantification within stratum oriens and stratum 
lacunosum moleculare of CA1 revealed no significant differences in immunoreactivity 
between NS (n=9) and KA (n=9) infused animals (Fig. 4B; CA1 SO and CA1 SLM). 
 Stratum lucidum was also visualized at high magnification (630x) in sections 
from the same NS (n=9) and KA (n=9) treated mice as above (Fig. 5A).  This revealed 
discrete patches of pY816 immunoreactivity within CA3b of stratum lucidum, which 
appeared noticeably brighter in hippocampi ipsilateral to infusion in KA treated animals 
(Fig. 5A; compare IPSI KA to others, arrows mark areas of enhanced immunoreactivity), 
confirming observations at low magnification (100x).  Importantly, the pattern of pY816 
immunoreactivity was similar in NS and KA treated animals, suggesting that the cellular 
locale was similar in experimental and control conditions. 
  
 
Figure 5:  High magnification (630x) images reveal discrete patches of pY816 immunoreactivity within SL, enhanced 
preferentially on the side ipsilateral to KA microinfusion. 
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A) Representative high magnification (630x) images of SL from CA3b in NS 
(top) and KA (bottom) treated mice, both ipsilateral (IPSI, right) and contralateral 
(CONTRA, left) to microinfusion.  Arrows point to discrete patches of pY816 
immunoreactivity that could be discerned within SL, and a noticeable increase in 
intensity of these immunoreactive areas can be seen in the KA treated animal 
ipsilateral to infusion compared to NS (IPSI, right).  Scale bar = 50 µm.  B) Nissl 
stain of the CA3 region from a KA treated mouse (KA) showing disruption of SL 
cytoarchitecture (arrows).  The SL damage observed is representative of that found 
in two animals discarded from analysis due to this issue.  Note the normal appearing 
SL in the NS treated littermate (NS).  Pyr is CA3 pyramidal cell layer.  Scale bar = 
100 µm.  C) pY816 staining from the same hippocampi as in (B) demonstrates a 
relative paucity of stain in the KA treated animal (KA, arrows) within SL compared 
to its NS infused littermate (NS).  Scale bar = 50 µm. 
2.3.2 Localization of Stratum Lucidum pY816 Immunoreactivity to 
Mossy Fiber Axons Following KA-SE 
To further explore the cellular and subcellular locations of the discrete patches of 
pY816 TrkB immunoreactivity in stratum lucidum observed at high magnification 
(630x), sections from NS and KA infused animals examined above were co-labeled with 
pY816 antibody and various markers of cellular structures, and confocal microscopy used 
to examine colocalization.  To survey pY816 immunoreactivity within mossy fiber axons 
and giant boutons, a transgenic mouse that expresses green fluorescent protein (GFP) 
under control of the Thy1 promoter was employed for a subset of the KA microinfusion 
experiments (Feng et al., 2000).  Subsets of dentate granule cells are labeled with GFP in 
these mice, and GFP fills the processes of these cells so that mossy fiber axons and their 
giant boutons can be directly visualized (Danzer et al., 2008; Danzer and McNamara, 
2004).   pY816 immunoreactivity prominently colocalized with GFP-labeled mossy fiber 
axons in CA3b of stratum lucidum in both NS (n=5) and KA (n=5) mice (Fig. 6A, B; 
arrows).  This immunoreactivity was finely granular but appeared relatively  
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Figure 6: pY816 TrkB immunoreactivity colocalizes with axons of dentate granule 
cells (DGCs) in SL of hippocampus under both NS conditions and following KA-SE. 
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A) Images of CA3 region of hippocampus from a KA treated animal 
demonstrates striking overlap of enhanced pY816 immunoreactivity (red; arrows) 
with GFP-labeled mossy fibers (green; arrows) that populate SL.  Merged pY816 
and GFP is shown in the rightmost panel.  Scale bar = 200 µm.  B) Images from 
CA3b of SL of sections stained with pY816 (red) that also contain GFP (green) 
under conditions of NS infusion (NS) and following KA-SE (KA).  A subset of mossy 
fiber axons of DGCs (green; arrows) are filled with GFP, and can be seen to 
colocalize with pY816 (red; arrows) under both NS and KA conditions.  In contrast, 
most mossy fiber boutons (green; arrows with asterisks) do not contain prominent 
pY816 immunoreactivity (red; arrows with asterisks) compared to axons.  Note that 
the distribution of immunoreactivity does not change between NS and KA treated 
animals.  Merged pY816 and GFP is shown in the rightmost panels.  Scale bar = 50 
µm.  C) Images from CA3b of SL from a control animal stained with pY816 (red) 
and tau (green), an axonal protein.  Tau stained mossy fiber axon tracts (green; 
arrows) prominently colocalize with pY816 (red; arrows).  Merged pY816 and Tau 
is shown in the rightmost panel.  Scale bar = 50 µm. 
homogeneous throughout the axons.  A subset of giant boutons of mossy fiber axons 
exhibited pY816 immunoreactivity in both NS and KA treated animals (see below), 
though most did not contain prominent immunoreactivity (Fig. 6B; arrows with 
asterisks). 
Though GFP-expressing mice permit visualization of fine structures of dentate 
granule cells, only a subset of mossy fiber axons are labeled with GFP, and therefore the 
full extent of pY816 overlap with mossy fiber axons could not be appreciated.  To 
circumvent this limitation, axons were visualized with an antibody to the protein tau, 
which selectively labels axons (Binder et al., 1985).  Striking overlap of tau and pY816 
immunoreactivity in the CA3b region of stratum lucidum was evident in a control mouse 
(Fig. 6C; arrows), further supporting axonal localization of pY816.  Difficulties in 
detecting tau immunoreactivity following SE precluded its study in KA treated animals. 
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Figure 7: pY816 TrkB immunoreactivity does not prominently colocalize with 
MAP2 stained dendrites of CA3 pyramids under either NS conditions or following 
KA-SE. 
Images from CA3b of SL of pY816 stained sections (red) co-stained with 
MAP2 (green), a marker of dendrites, under conditions of NS infusion (NS) and 
following KA-SE (KA).  Linear patches of pY816 immunoreactivity (red; arrows), 
demonstrated to colocalize with mossy fiber axons (Fig. 6), do not colocalize with 
MAP2 (green; arrows).  Furthermore, MAP2 labeled dendrites of CA3 pyramidal 
cells (green; arrows with asterisks) do not contain prominent pY816 
immunoreactivity (red; arrows with asterisks).  No apparent differences are 
observed in the cellular distributions of pY816 immunoreactivity between NS and 
KA treated animals.  Merged pY816 and MAP2 is shown in rightmost panels.  Scale 
bar = 20 µm. 
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To determine whether pY816 immunoreactivity is detectable within dendrites of 
CA3 pyramidal cells which populate stratum lucidum and onto which giant boutons of  
dentate granule cells form synapses, an antibody for MAP2 was employed.  The MAP2 
protein is selectively expressed in dendrites (Huber and Matus, 1984) which were 
oriented largely perpendicular in CA3b of stratum lucidum in coronal sections (Fig. 7; 
MAP2 panels, arrows with asterisks).  In sharp contrast to axonal markers, no prominent 
overlap of pY816 and MAP2 immunoreactivity was detected in either NS (n=3) or KA 
(n=3) treated animals (Fig. 7).  Collectively, these findings demonstrate that pY816 
immunoreactivity is largely confined to mossy fiber axons and boutons under both basal 
conditions and following KA-SE, not within dendrites of CA3 pyramids.  
In these same NS and SE treated mice, imaging was also performed within the 
CA3c region of stratum lucidum, located more proximally to hilus than the CA3b 
portion.  Not surprisingly, the cellular distribution of pY816 was the same as in the CA3b 
region.  However, CA3 pyramidal cell dendrites were found to run in parallel to the plane 
of section in this portion of stratum lucidum, whereas mossy fiber axons run obliquely to 
the section plane.  The different orientation of these structures provided an alternative 
perspective by which the cellular distribution of pY816 could be visualized, which also 
clearly illustrated pY816 exclusion from MAP2-labeled CA3 pyramidal cell dendrites.  
Representative confocal images obtained from this area are shown in Figure 8. 
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Figure 8: Colocalization of pY816 TrkB immunoreactivity with cellular markers 
within the CA3c region of SL. 
A) In the CA3c region of SL in a KA-treated mouse, mossy fiber axons 
(green; arrows) can be seen to run largely oblique to the plane of section in bundles 
that are strongly enriched in pY816 immunoreactivity (red; arrows).  Boutons 
(green; arrow with asterisk) are largely devoid of immunoreactivity (red; arrow 
with asterisk).  A similar result was obtained in NS treated animals (data not 
shown).  Merged pY816 and GFP is shown in the rightmost panel.  Scale bar = 50 
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µm.  B) pY816 (red) reveals striking overlap with Tau (green), a marker for axons.  
Arrows point to clear regions of colocalization.   Merged pY816 and Tau is shown in 
the rightmost panel.  Scale bar = 75 µm.  C) A MAP2 stain (green) labels dendrites 
of CA3 pyramidal cells (arrows with asterisks) running parallel to the plane of 
section.  These MAP2 stained dendrites surround patches of pY816 
immunoreactivity (red; arrows) presumably composed of mossy fiber axons, but 
themselves do not contain significant amounts of pY816 immunoreactivity (red; 
arrows with asterisks).  Merged pY816 and MAP2 is shown in the rightmost panel.  
Scale bar = 50 µm.  Pyr demarks the CA3 pyramidal cell layer.  
 
2.3.3 Quantification of pY816 Immunoreactivity Within Axons of 
Stratum Lucidum Following KA-SE  
Given the localization of pY816 immunoreactivity within stratum lucidum to 
axons of dentate granule cells, additional quantification of immunoreactivity within these  
structures was performed at high power (630x) in the same NS (n=9) and KA (n=9) 
treated mice used for the low power (100x) quantification (Fig. 5A shows representative 
630x images).  Unlike the low power (100x) quantification performed above, this high 
power (630x) quantification specifically measured immunoreactivity found within axon 
tracts of stratum lucidum (see Materials and Methods), thus focusing on the anatomical 
locale where pY816 immunoreactivity was most prominent.  Quantification revealed a 
significant increase of pY816 immunoreactivity on the side ipsilateral to KA infusion of 
approximately 2-fold (NS = 51.5 ± 8.4, KA = 105.1 ± 8.1, mean ± SEM, intensity units); 
by contrast, an increase of 1.5-fold was detected contralaterally (NS = 53.9 ± 8.1, KA = 
78.9 ± 7.9, mean ± SEM, intensity units).  As with the low power (100x) quantification, 
this difference was significant only on the side ipsilateral to KA infusion (p<0.001, one-
way ANOVA; p<0.001 ipsilateral NS vs. ipsilateral KA, p<0.001 contralateral NS vs. 
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ipsilateral KA, post-hoc Bonferroni’s test).  The high power (630x) quantification 
mirrored the low power (100x) in that immunoreactivity ipsilateral to infusion was 
greater than contralateral in KA infused mice in all but the one animal where this was not 
observed with low power (100x) quantification (n=8); in all KA infused animals (n=9), 
the pY816 immunoreactivity in stratum lucidum ipsilateral to KA infusion exceeded that 
on either side in NS infused littermates. 
2.3.4 Localization of Stratum Lucidum pY816 Immunoreactivity to 
Mossy Fiber Axons Following Pilocarpine SE 
To determine whether this cellular and subcellular location of pY816 TrkB was 
generalizable to other models of epileptogenesis, additional mice underwent three hours 
of SE induced by systemically administered pilocarpine (n=6), and were matched with 
NS injected littermate controls (n=6).  A subset of these animals contained a Thy1-GFP 
transgene.  Consistent with past reports (He et al., 2010), a significant increase in pY816 
immunoreactivity was observed within stratum lucidum of pilocarpine treated animals 
compared to controls when quantified at low power (100x) (Fig. 9A, B).  In contrast to 
the KA microinfusion model, however, this increase was observed to be bilateral in 
nature (data not shown).  As in the KA microinfusion model, pY816 immunoreactivity 
exhibited striking colocalization with GFP-labeled mossy fiber axons but not with 
dendrites labeled with MAP2 following pilocarpine SE (Fig. 9C, D).  A subset of giant 
boutons of mossy fiber axons also exhibited pY816 immunoreactivity in pilocarpine SE 
treated animals (Fig. 9C, arrow with asterisk).  Thus, pY816 immunoreactivity exhibits   
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Figure 9: pY816 immunoreactivity increases within SL following pilocarpine SE, 
and colocalizes with axons of DGCs. 
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A) Representative images of hippocampi stained with pY816 from a mouse 
that experienced three hours of SE induced by intraperitoneal (IP) injection of 
pilocarpine (Pilo) and its littermate control that received IP normal saline (NS).  A 
noticeable increase in pY816 immunoreactivity can be seen within SL of the 
pilocarpine treated animal (Pilo; arrows point to SL).  Each image is a montage of 
two confocal images acquired at low magnification (100x).  Scale bar = 300 µm.  B) 
Low power (100x) quantification of pY816 immunoreactivity within SL of NS (n=6) 
and pilocarpine (n=6) treated mice.  A 2-fold, significant increase (p<0.05, Student’s 
t-test) in immunoreactivity was observed in pilocarpine treated animals compared 
to controls.  As in KA versus NS infused mice, no significant differences in pY816 
intensity between NS and pilocarpine treated animals was apparent in other 
hippocampal regions by visual inspection at low power (100x).  C) In a pilocarpine 
treated animal (Pilo), pY816 (red; arrows) is enriched in GFP-labeled mossy fiber 
axons (green; arrows).  A minority of boutons (green; arrow with asterisk) also 
contained some pY816 immunoreactivity (red; arrow with asterisk), though the 
majority were devoid.  Similar distributions of pY816 immunoreactivity were 
observed in NS injected animals (data not shown).  Merged pY816 and GFP is 
shown in the rightmost panel.  Scale bar = 25 µm.  D) MAP2 labeled CA3 dendrites 
(green; arrows with asterisks) do not prominently colocalize with pY816 (red; 
arrows with asterisks) in a pilocarpine (Pilo) treated mouse.  Areas of enriched 
pY816 immunoreactivity (red; arrows) are largely devoid of MAP2 labeled 
dendrites (green; arrows).  A similar distribution of pY816 immunoreactivity was 
observed in NS injected animals.  Merged pY816 and MAP2 is shown in the 
rightmost panel.  Scale bar = 15 µm. 
similar patterns of cellular localization following SE in two distinct models of 
epileptogenesis. 
2.3.5 Enhanced pY816 Immunoreactivity Within Synaptic Mossy Fiber 
Boutons Following KA-SE 
A subset of GFP+ giant boutons of mossy fibers in stratum lucidum in Thy1-GFP 
mice exhibited pY816 immunoreactivity (Fig. 10A; arrow demarks a pY816+ bouton, 
arrow with asterisk demarks a bouton not prominently immunoreactive).  In contrast to 
the finely granular pattern of pY816 immunoreactivity within mossy fiber axons, the 
immunoreactivity within boutons was punctate in nature.  To determine whether  
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Figure 10: pY816 TrkB immunoreactivity is enhanced within synaptic mossy fiber 
boutons in SL following KA-SE, observed preferentially in the hippocampus 
ipsilateral to infusion. 
A) Confocal micrographs of two z-sections (top panels, z-section one; bottom 
panels, z-section two) taken at a 1 µm increment containing GFP+ mossy fiber 
boutons (green; arrow and arrow with asterisk) within SL ipsilateral to infusion in a 
KA treated animal.  One bouton contains obvious pY816 immunoreactivity (red; 
arrow), whereas an adjacent bouton does not contain prominent pY816 (red; arrow 
with asterisk).  Merged pY816 and GFP is shown in rightmost panels.  A pY816 
puncta within the bouton (top; arrow with dagger) disappears as the portion of the 
bouton containing it leaves the focal plane (bottom; arrow with dagger).  Scale bar = 
3.3 µm.  B) Quantification of percentages of GFP+ boutons in SL found to contain 
pY816 immunoreactivity in Thy1-GFP-expressing mice under NS (n=5) and KA 
(n=5) treated conditions, both ipsilateral (IPSI) and contralateral (CONTRA) to the 
side of infusion.  In boutons ipsilateral to KA infusion, a 3.8-fold (p<0.01, one-way 
ANOVA; p<0.05, post-hoc Bonferroni’s test) increase in the numbers of pY816+ 
boutons was observed compared to NS treated animals.  On the contralateral side, 
there was only a 1.9-fold (p>0.05) increase in the number of boutons containing 
immunoreactivity.  A total of 901 boutons were analyzed under NS conditions, 934 
under KA conditions.  Quantification is presented as mean % of neuronal processes 
± SEM; all data analyzed by one-way ANOVA and post-hoc Bonferroni’s test; 
*p<0.05. 
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immunoreactivity within giant boutons increased during epileptogenesis, GFP+ boutons 
were imaged in the subset of mice treated with NS (n=5) or KA-SE (n=5) that expressed  
Thy1-GFP.  A stack of z-sections were scored for pY816 immunoreactivity by a blinded 
investigator; a bouton was deemed positive if it contained a discrete pY816 puncta that 
filled at least 20% of the bouton in at least one z-section.  A total of over 1800 boutons 
were scored in this fashion. 
Under basal conditions, a small fraction (average of 6.5%) of GFP+ boutons in 
stratum lucidum exhibited pY816 immunoreactivity.  Strikingly, the fraction of GFP+ 
boutons exhibiting pY816 immunoreactivity increased approximately 4-fold in the 
stratum lucidum ipsilateral to the amygdala infused with KA (Fig. 10B; NS = 5.4 ± 2.0 
%, KA = 20.2 ± 2.9 %, mean ± SEM; p<0.05); a 1.9-fold increase was evident in stratum 
lucidum in the contralateral hippocampus (NS = 7.7 ± 1.9 %, KA = 14.7 ± 3.0 %, mean ± 
SEM; p>0.05).  The increased fraction of pY816 immunoreactive synaptic boutons 
paralleled the increase of mossy fiber axonal immunoreactivity in that it was most 
prominent in the hippocampus ipsilateral to the KA infused amygdala.  Towards this end, 
more boutons were labeled with pY816 in the stratum lucidum ipsilateral to KA infusion 
than on the contralateral side in all KA treated mice examined (n=5).  Furthermore, 
percentages of boutons labeled on the ipsilateral side in all KA treated mice (n=5) were 
always greater than the percentages labeled in NS infused littermates on either side 
relative to infusion. 
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2.3.6 Localization of pY816 Immunoreactivity within Apical Dendritic 
Shafts of CA1 Pyramidal Cells Following KA-SE 
Although no significant increases in pY816 TrkB immunoreactivity were detected 
in low power (100x) analyses of stratum radiatum of CA1 following SE induced by KA 
microinfusion (Fig. 4C), high power (630x) analyses of sections from these same mice 
revealed increases within neuronal processes populating this region in KA treated  
animals (n=9) compared to those infused with NS (n=9) (Fig. 11A; arrows point to 
pY816+ dendritic shafts).  The failure to detect an increased intensity of the CA1 stratum  
radiatum region in low-power analyses following SE is because only a subset of these 
processes exhibited increased immunoreactivity.  This increased pY816 
immunoreactivity was found to colocalize with a subset of GFP+ apical dendritic shafts 
of CA1 pyramidal cells (Fig. 12A; arrows), identified as such based on the fact that they 
emanated from cell bodies in the stratum pyramidale in the direction of stratum 
lacunosum moleculare (Ramón y Cajal, 1911).  Like the pY816 immunoreactivity within 
stratum lucidum, pY816 immunoreactive apical dendritic shafts of CA1 pyramidal cells 
were most prominent in the hippocampus ipsilateral to the KA-infused amygdala (Fig. 
11A; compare bottom right panel to others).  Counting the number of pY816-
immunoreactive processes detected in a total of two high power (630x) fields taken from 
stratum radiatum of CA1 (Fig. 11B; CA1 SR) revealed a 3.6-fold increase on the side 
ipsilateral to KA microinfusion compared to NS controls (NS = 19.3 ± 2.6, KA = 70.2 ± 
13.2, mean ± SEM, number of pY816+ neuronal processes; p<0.01); contralaterally, a  
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Figure 11: pY816 TrkB immunoreactivity is enhanced within apical dendrites of SR 
of CA1 following KA-SE, observed preferentially in the hippocampus ipsilateral to 
infusion. 
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A) Representative high power (630x) images of CA1 SR (region marked top 
left) from sections stained with pY816.  Animals were infused with either NS (top) 
or KA (bottom), and images taken from hippocampi both ipsilateral (IPSI, right) 
and contralateral (CONTRA, left) to the side of infusion.  Apical dendrites of CA1 
pyramidal cells labeled with pY816 immunoreactivity can be observed under SE 
conditions, most prominently on the side ipsilateral to KA infusion (bottom right; 
arrows).  Note that dendrites appear most immunoreactive in the region of SR more 
proximal to CA1 pyramidale (Pyr, marked top left).  Scale bar = 50 µm.  B) 
Quantification of total numbers of neuronal processes observed in two high 
magnification (630x) images taken from NS (n=9) and KA (n=9) treated animals, 
both ipsilateral and contralateral to the side of infusion.  In CA1 SR ipsilateral to 
KA infusion, a 3.6-fold (p<0.01, one-way ANOVA; p<0.01, post-hoc Bonferroni’s 
test) increase in the numbers of discerned neuronal processes was observed 
compared to NS treated animals.  On the contralateral side, there was only a 1.8-
fold (p>0.05) increase in the number of pY816 apical dendrites stained.  
Quantification in the same fashion of CA1 SO, CA1 SLM, CA3 SR, CA3 SO, SML, 
and IML in hippocampi taken both ipsilateral and contralateral to infusion also 
demonstrated no significant differences in the numbers of discerned neuronal 
processes between NS and KA conditions on either side (CA1 SO p=0.342, CA1 
SLM p=0.885, CA3 SR p=0.462, CA3 SO p=0.449, SML p=0.758, IML p=0.557 by 
one-way ANOVA).  Quantification is presented as mean number of neuronal 
processes ± SEM; all data analyzed by one-way ANOVA and post-hoc Bonferroni’s 
test; **p<0.01. 
1.8-fold increase in number of pY816-immunoreactive processes was detected (NS = 
20.0 ± 5.3, KA = 36.2 ± 12.5, mean ± SEM, number of pY816+ neuronal processes, 
p>0.05).  In all but one KA-SE treated animal (n=8), more immunoreactive processes 
were observed on the side ipsilateral to infusion than on the contralateral side, or on 
either side in NS infused littermates.  In the one KA infused animal where these 
observations did not hold, no dendritic processes were detected in stratum radiatum of 
CA1 on either side, despite a clear lateralized increase in pY816 immunoreactivity within 
stratum lucidum compared to NS infused littermates.   
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Localization of pY816 immunoreactivity to apical dendritic shafts of CA1 
pyramidal cells in KA treated animals exhibited striking anatomic specificity.  That is, 
basal dendritic shafts of CA1 pyramidal cells did not exhibit prominent pY816 
immunoreactivity (Fig. 12A; arrows with asterisks) nor were significant differences 
detected in stratum oriens of CA1 between NS (n=9) and KA (n=9) treated animals in the 
hippocampus either ipsilateral or contralateral to the infused amygdala (Fig. 11B; CA1 
SO; ipsilateral: NS = 12.7 ± 3.4, KA = 7.8 ± 1.5, contralateral: NS = 7.3 ± 2.3, KA = 7.7 
± 1.8, mean ± SEM, number of pY816+ neuronal processes).  Likewise, stratum 
lacunosum moleculare contains the distal apical dendritic arbors of CA1 pyramidal cells, 
and this region exhibited few pY816+ neuronal processes (data not shown).  No 
significant differences in the numbers of pY816+ neuronal processes were detected in 
this region between NS (n=9) and KA (n=9) treated animals (Fig. 11B; CA1 SLM; 
ipsilateral: NS = 4.1 ± 1.0, KA = 4.8 ± 1.3, contralateral: NS = 4.1 ± 0.8, KA = 5.2 ± 1.5, 
mean ± SEM, number of pY816+ neuronal processes).  Finally, little pY816 
immunoreactivity was detected in either apical or basal dendritic shafts of CA3 pyramids 
(in CA3 stratum radiatum and stratum oriens respectively) nor in apical dendritic shafts 
of dentate granule cells in either the suprapyramidal or infrapyramidal molecular layers 
of dentate gyrus (data not shown); no significant differences in the numbers of discerned 
neuronal processes between NS (n=9) and KA (n=9) infused animals were found in any 
of these regions (Fig. 11B; CA3 SR, CA3 SO, SML, and IML).  Importantly, in each of 
the above regions, abundant GFP-labeled dendritic shafts were evident in Thy1-GFP 
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animals (data not shown).  Thus, apical but not basal dendritic shafts of CA1 pyramidal 
cells exhibited pY816 immunoreactivity under basal conditions, and this 
immunoreactivity increased following KA-SE; the immunoreactivity was detected within 
the proximal dendritic tree within stratum radiatum but not in the most distal portion 
within stratum lacunosum moleculare.  Likewise, minimal pY816 immunoreactivity was 
detectable within the dendritic arbors of CA3 pyramids and dentate granule cells, nor 
were differences detected in NS compared to KA treated animals. 
2.3.7 Localization of pY816 Immunoreactivity Within Apical Dendritic 
Shafts of CA1 Pyramidal Cells Following Pilocarpine SE 
Similar increases of pY816 labeling of apical dendritic shafts of CA1 pyramidal 
cells were evident in mice after three hours of SE induced by intraperitoneal injection of 
pilocarpine.  That is, a 6.2-fold increase in the number of pY816-immunoreactive apical 
shafts of CA1 pyramidal cells was evident in pilocarpine treated animals (n=5) compared 
to NS (n=4) (NS = 12.3 ± 3.3, Pilocarpine = 76.4 ± 12.0, mean ± SEM, number of 
pY816+ neuronal processes; p<0.01 by Student’s t-test).  In contrast to the KA-SE 
model, apical shaft staining increased bilaterally within both hippocampi in all 
pilocarpine treated mice (n=5) when compared to NS injected littermates (data not 
shown).  As in the KA-SE model, examination of other regions within hippocampus 
revealed no detectable differences in the total number of pY816+ basal dendrites 
observed in stratum oriens of CA1 following SE, nor in any of the other hippocampal 
regions quantified in the KA-SE model (data not shown).  
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Figure 12: pY816 TrkB immunoreactivity is intracellular and punctate within the 
dendritic shaft of proximal apical dendrites of CA1 pyramidal cells. 
A) The primary apical dendrite of a GFP+ CA1 pyramidal neuron (green; 
arrows) contains clear pY816 immunoreactivity (red; arrows) within its aspinous 
proximal shaft, whereas a secondary dendritic branch (green; arrow with dagger) 
does not contain prominent immunoreactivity within its shaft (red; arrow with 
dagger).  Basal dendritic processes (green; arrows with asterisks) clearly do not 
contain pY816 immunoreactivity (red; arrows with asterisks).  Merged pY816 and 
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GFP is shown in the rightmost panel.  Image is a maximum projection (displaying 
the region of highest intensity) of multiple confocal scans taken at 0.4 µm 
increments in the z-plane.  Scale bar = 50 µm.  B) Close-up of a proximal, aspinous 
portion of a GFP+ apical dendritic process (green; arrows) with intracellular, 
punctate pY816 immunoreactivity (red; arrows) within the shaft.  Merged pY816 
and GFP is shown in the rightmost panel.  Scale bar = 10 µm.  C) A spiny portion of 
a GFP+ apical dendrite (green; arrows) also displaying intracellular, punctate 
pY816 immunoreactivity (red; arrows) within the shaft.  Merged pY816 and GFP is 
shown in the rightmost panel.  Scale bar = 10 µm. 
2.3.8 Characterization of pY816 Immunoreactivity Within Apical 
Dendritic Shafts of Pyramidal Cells in CA1 Following KA-SE 
The finding of increased pY816 immunoreactivity within apical dendritic shafts 
of CA1 pyramidal cells warranted further analysis of its location within these structures.  
Colocalization analysis with GFP+ shafts in hippocampi of KA-SE treated mice (n=5) 
revealed immunoreactivity that appeared intracellular and punctate (Fig. 12A-C; arrows).  
Further inspection of the distribution of pY816 immunoreactivity within apical dendritic 
shafts of CA1 pyramidal cells in SE treated animals in the KA microinfusion model 
revealed that this punctate immunoreactivity appeared most prominently within the 
portion proximal to the soma, becoming sparser and more difficult to identify with 
increased distance from stratum pyramidale (Fig. 11A; KA).  Sections stained with 
MAP2 from KA-SE treated mice (n=3) revealed apical shafts of CA1 pyramidal cells 
projecting throughout the entire stratum radiatum, and continuing into stratum lacunosum 
moleculare (Fig. 13A; arrows).  Thus, this finding was not a result of large differences in 
the numbers of apical dendritic shafts populating proximal versus distal stratum radiatum, 
or because these shafts were not running parallel to the plane of section.  As stated 
previously, few pY816+ neuronal processes were counted in stratum lacunosum 
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moleculare and no increase was detected following SE (Fig. 11B; CA1 SLM), 
demonstrating that pY816 immunoreactivity was also not prominent within the most 
distal dendritic shafts of CA1 pyramidal cells that populate this region of hippocampus.  
pY816 immunoreactivity was generally most prominent within the primary apical shaft, 
with immunoreactivity much less noticeable within secondary branches (Fig. 12A; arrow 
with dagger).  Interestingly, the most proximal segments of primary apical dendrites of 
CA1 pyramidal cells are generally aspinous (Papp et al., 2001), and immunoreactivity 
was found within the shafts of these aspinous portions (Fig. 12B; arrows), demonstrating 
that this immunoreactivity existed even when glutamatergic synapses were not in 
immediate proximity.  However, dendritic immunoreactivity was also readily discernible 
on some spiny portions of dendritic shaft (Fig. 12C; arrows). 
To quantify the distance that pY816 immunoreactivity within the apical dendritic 
shaft was most prominent within stratum radiatum, GFP+ dendritic shafts containing 
pY816 immunoreactivity that could be traced throughout the entire vertical span of 
stratum radiatum were imaged, and the distance that this immunoreactivity was 
detectable within stratum radiatum was measured (Fig. 13B).  In six such apical shafts 
taken from the ipsilateral hippocampus of a KA infused animal, pY816 immunoreactivity 
was detected an average of 78.7 µm from the soma.  In contrast, mean total dendritic 
shaft length within stratum radiatum was found to be 235.8 µm.  Thus, pY816 
immunoreactivity was readily detectable throughout only about 32% of the total apical 
shaft length within stratum radiatum (Fig. 13C).  All of these findings demonstrate that  
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Figure 13: pY816 TrkB immunoreactivity is enriched preferentially within the 
portion of the apical dendritic shaft of CA1 pyramidal cells more proximal to soma. 
A) Image of the entire longitudinal span of CA1 SR, from pyramidale (Pyr) 
to CA1 SLM, stained with MAP2.  Prominent dendritic shaft labeling by MAP2 can 
be seen within the entire vertical span of CA1 SR (arrows), showing that apical 
dendrites remain within the focal plane throughout.  Scale bar = 50 µm.  B) 
Quantification of the total distance that pY816 immunoreactivity in GFP+ apical 
dendritic shafts was found to extend distally into CA1 SR in a KA treated animal, 
measured from soma (n=6 dendritic shafts).  Only GFP+ dendritic shafts that were 
also found to be pY816+ were used in this analysis.  The entire lengths of these 
GFP+ dendrites were imaged until their intersection with SLM, and total dendritic 
length from soma to SLM was also quantified.  pY816 immunoreactivity was found 
to extend an average of 78.7 ± 19.4 µm into the shaft, whereas average dendritic 
length was found to be 235.8 ± 11.7 µm.  C) Quantification of the percent of total 
dendritic length that pY816 immunoreactivity was found to occupy (n=6), using 
measurements made from the same dendritic shafts as in (B). Immunoreactivity was 
found, on average, within 38 ± 7 % of the most proximal portion of pY816+ apical 
dendritic shafts within CA1 SR.  Error bars represent SEM. 
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pY816 TrkB immunoreactivity is enhanced within proximal shafts of apical dendrites of 
CA1 pyramidal cells following SE, and appears intracellular and punctate within these 
structures. 
2.3.9 Enhanced pY816 Immunoreactivity Within Dendritic Spines of 
Pyramidal Cells in CA1 Stratum Radiatum Following KA-SE 
The localization of pY816 immunoreactive puncta to presynaptic boutons of 
mossy fiber axons within stratum lucidum raised the question as to whether pY816 
immunoreactivity within CA1 might be localized to synaptic specializations of the apical 
dendrites of CA1 pyramidal cells.  Small specializations of apical dendrites of CA1 
pyramidal cells indicative of spines were evident in Thy1-GFP mice in both NS and KA 
infused animals.  Moreover, analysis of pY816 immunoreactivity within stratum radiatum 
of CA1 revealed that, in addition to signal corresponding to apical dendritic shafts, the 
entire region was also filled with many small puncta.  Inspection of GFP+ spines of 
apical dendrites in Thy1-GFP mice revealed that a subset colocalized with pY816 puncta 
(Fig. 14A; arrows).  To quantify colocalization of pY816 immunoreactivity with GFP+ 
dendritic spines in CA1 stratum radiatum, z-stacks were acquired and spines scored as 
positive or negative for pY816 by a blinded observer; a spine was scored as positive if 
filled with a pY816 immunoreactive puncta in at least one z-section.  Over 1800 spines 
were examined in the same NS (n=5) and SE (n=5) Thy1-GFP animals used previously in 
this study.  The percentages of pY816+ spines in CA1 stratum radiatum in NS and KA 
treated mice both ipsilateral and contralateral to infusion was then determined (Fig. 14B;  
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Figure 14: pY816 TrkB immunoreactivity is enhanced within dendritic spines in 
CA1 SR following KA-SE, observed preferentially in the hippocampus ipsilateral to 
infusion. 
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A) Confocal micrographs from CA1 SR from a Thy1-GFP mouse treated 
with KA.  Three z-sections are shown taken at 750 nm increments above (top 
panels), within (middle panels), and below (bottom panels) two GFP+ spines 
(middle, green panel; arrows) of an apical dendrite that contain small pY816 puncta 
(middle, red panel; arrows).  Other spines (middle, green panel; arrow with 
asterisk) do not appear to contain pY816 (middle, red panel; arrow with asterisk).  
Note colocalization of pY816 with spines in the z-plane (observe panels from top to 
bottom and note arrows), such that these pY816 puncta are observable within the 
spine but not above or below it.  Merged pY816 and GFP images are shown in the 
rightmost panels.  Scale bar = 2.5 µm.  J) Quantification of percentages of GFP+ 
spines found to contain pY816 immunoreactivity in Thy1 GFP-expressing mice in 
CA1 SR, CA1 SO, CA1 SLM, CA3 SR, the outer two-thirds of SML, and the outer 
two-thirds of IML.  This was quantified under both NS (n=5) and KA (n=5) 
conditions, both ipsilateral (IPSI) and contralateral (CONTRA) to the side of 
infusion.  In spines of CA1 SR ipsilateral to KA infusion, a 2.0-fold increase in the 
numbers of pY816+ spines was observed compared to NS treated animals (p<0.01, 
one-way ANOVA; p<0.01, post-hoc Bonferroni’s test).  The contralateral side 
demonstrated a more modest, 1.6-fold increase which was not significant.  Data are 
from 994 spines analyzed under NS conditions, 1020 spines analyzed under KA 
conditions.  No significant differences in the numbers of pY816+ spines were found 
in any of the other regions analyzed (CA1 SO p=0.993, 2097 spines; CA1 SLM 
p=0.272, 2428 spines; CA3 SR p=0.899, 2263 spines; SML p=0.604, 1940 spines; 
IML p=0.128, 1958 spines, one-way ANOVA). Quantification is presented as mean 
% of neuronal processes ± SEM; all data analyzed by one-way ANOVA and post-
hoc Bonferroni’s test; **p<0.01. 
CA1 SR).  Importantly, no overt differences in spines were noticeable between conditions 
(data not shown).   
Under basal conditions, a small fraction (approximately 10%) of spines of 
proximal apical dendrites of CA1 pyramidal cells exhibited pY816 immunoreactivity.  
The fraction of GFP+ spines exhibiting pY816 immunoreactivity approximately doubled 
in the apical dendrites of CA1 pyramidal cells in the hippocampus ipsilateral to the 
amygdala infused with KA (NS = 10.7 ± 1.4%, SE = 21.0 ± 2.7%, mean ± SEM; p<0.01); 
a 1.6-fold increase was detected in the hippocampus contralateral to the infused amygdala 
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(NS = 10.4 ± 1.1%, SE = 16.9 ± 1.9%, mean ± SEM, p>0.05).  The percentage of pY816 
colocalization with spines in stratum radiatum of CA1 in KA infused animals was always 
greater in hippocampus ipsilateral to the infused amygdala compared to contralateral and 
this value always exceeded that found in either hippocampus of NS infused littermates  
 (n=5).  Thus, similar to giant boutons of the mossy fiber-CA3 synapse, pY816 
immunoreactivity was found to increase in spines of the CA3-CA1 synapse following SE 
induced by KA microinfusion, and this effect was lateralized to the side ipsilateral to 
infusion.   
As GFP+ spines could also be visualized in stratum oriens of CA1 and stratum 
lacunosum moleculare in these same mice (data not shown), similar analyses were 
conducted in these regions (Fig. 14B; CA1 SO and CA1 SLM).  Similar to stratum 
radiatum of CA1, pY816 puncta could be discerned within these regions and colocalized 
with a subset (approximately 10%) of GFP+ spines (data not shown).  However, unlike 
stratum radiatum of CA1, no significant differences in the numbers of pY816 
immunoreactive spines on basal dendrites within stratum oriens of CA1 were detected 
between NS (n=5) and KA animals (n=5), either ipsilateral or contralateral to infusion 
(ipsilateral: NS = 10.3 ± 1.0%, KA = 10.0 ± 0.7%, contralateral: NS = 10.0 ± 1.4%, KA = 
10.4 ± 0.5%, mean ± SEM; p>0.05).  Similar results were obtained with quantification of 
spines of apical dendrites of CA1 pyramidal neurons within stratum lacunosum 
moleculare (ipsilateral: NS = 11.7 ± 1.7%, KA = 12.9 ± 2.7%, contralateral: NS = 10.6 ± 
0.9%, KA = 15.9 ± 1.9%, mean ± SEM; p>0.05; n=5 mice per treatment group).   Thus, 
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pY816 activation within spines of CA1 pyramidal neurons following SE appeared to be 
confined to the proximal apical dendrites within stratum radiatum, just as increased 
pY816+ immunoreactivity was also only found within this portion of the dendritic tree of 
CA1 pyramidal neurons. 
Finally, GFP+ spines of CA3 pyramids were readily discerned within stratum 
radiatum of CA3, and spines of dentate granule cells could be imaged in the dentate gyrus 
(data not shown).  This afforded the opportunity to quantify pY816 immunoreactivity in 
spines within these other important neuronal populations of hippocampus.  Quantification 
of spines in CA3 stratum radiatum demonstrated that about 10% of spines were found to 
contain significant pY816 immunoreactivity, but no differences were found between NS 
(n=5) and KA (n=5) conditions on either side relative to infusion (Fig. 14B; CA3 SR; 
p>0.05).  For spines of the molecular layer of dentate gyrus, the outer two-thirds of this 
region was quantified, as this is the portion that receives perforant path innervation from 
entorhinal cortex and is robustly activated during limbic seizures.  Quantification of both 
suprapyramidal and infrapyramidal molecular layers demonstrated that approximately 9% 
of imaged spines contained pY816 immunoreactivity in NS treated mice (n=5), and there 
was no significant increase in this percentage in KA-SE treated animals (n=5) (Fig. 14B; 
SML and IML; p>0.05).  Thus, enhanced pY816 immunoreactivity within synaptic 
spines appeared to be confined only to stratum radiatum in hippocampus following KA-
SE, the only region where increases in pY816 immunoreactivity were found in dendritic 
shafts after SE.  Furthermore, the only regions where increases in immunoreactivity 
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within synaptic boutons or spines was detected were also the only regions where 
increases in pY816 immunoreactivity within axons or dendritic shafts was detected, 
namely stratum lucidum and stratum radiatum of CA1.    
2.4 Discussion 
This study tested the hypothesis that enhanced pTrkB immunoreactivity evident in 
the hippocampus in multiple animal models was localized to the mossy fibers of dentate 
granule cells.  To test this hypothesis, confocal microscopy was employed to examine 
colocalization of pY816 immunoreactivity with axonal and dendritic markers, and with 
GFP expressed in hippocampal neurons of Thy1 GFP mice following SE.  Four principal 
findings emerged:  (1) pY816 immunoreactivity in stratum lucidum was found within 
mossy fiber axons and giant presynaptic boutons of dentate granule cells of control adult 
mice.  (2) A robust increase of pY816 immunoreactivity was detected within both of 
these structures following SE.  (3) Unexpectedly, pY816 immunoreactivity was also 
found within the shafts and spines of apical dendrites of CA1 pyramidal cells of control 
adult mice.  (4) pY816 immunoreactivity was also robustly enhanced within these 
structures following SE.  Collectively, these findings provide evidence that SE induces 
enhanced activation of TrkB at two distinct excitatory synapses within hippocampal 
circuitry.  This enhanced TrkB activation is well positioned to regulate the plasticity of 
these synapses, an attractive cellular mechanism underlying epileptogenesis. 
The results reveal that activated TrkB within hippocampus is most prominent 
within stratum lucidum, and robustly increases within this region following KA-SE.  The 
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activated TrkB within stratum lucidum was localized to the axons and giant boutons of 
the mossy fibers of dentate granule cells by colocalization of pY816 immunoreactivity 
with GFP expressed in these neurites, and confirmed by colocalization with the axonal 
marker, tau.  Whereas all mossy fiber axons appeared to contain activated TrkB, only a 
small minority (5%) of mossy fiber boutons contained activated TrkB under basal 
conditions.  Notably, a striking 4-fold increase was found in the percentage of mossy 
fiber boutons containing activated TrkB in the hippocampus ipsilateral to KA infusion.  
These results confirm earlier work that reported increased pTrkB immunoreactivity in 
stratum lucidum during epileptogenesis, yet was unable to identify the cellular structures 
containing this immunoreactivity (Binder et al., 1999a; Danzer et al., 2004; He et al., 
2004; He et al., 2002; He et al., 2010).  The present results are also consistent with recent 
ultrastructural evidence localizing pY816 immunoreactivity to mossy fiber axons and a 
minority (5%) of boutons within SL under basal conditions (Spencer-Segal et al., 2011); 
pY816 immunoreactivity within boutons was most often affiliated with small synaptic 
vesicles opposite the synaptic contact. 
The abundance of activated TrkB found in stratum lucidum correlates with high 
levels of expression of ligands known to activate it.  The highest levels in forebrain of the 
canonical TrkB ligand, BDNF, are found within stratum lucidum, where its expression is 
increased during epileptogenesis (Conner et al., 1997; He et al., 2004; Yan et al., 1997).  
Unexpectedly, increases of activated TrkB within stratum lucidum were identified during 
epileptogenesis despite conditional deletion of BDNF (He et al., 2004), a finding leading 
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to the discovery that the divalent cation, zinc, can transactivate TrkB in the absence of 
BDNF (Huang and McNamara, 2010; Huang et al., 2008).  Synaptic vesicles of mossy 
fiber boutons contain copious stores of zinc, presumably released during neuronal 
activity, suggesting a role for this metal in contributing to TrkB activation at this locale 
(Cole et al., 1999; Qian and Noebels, 2005).  pTrkB within mossy fiber boutons is likely 
to have been activated at the synaptic membrane by one of these ligands.  The pTrkB 
within axons may be in transit back to the soma; transport of pTrk-ligand complexes have 
been previously described in axons and may promote communication of TrkB signaling 
from synapse to cell body (Bhattacharyya et al., 1997; Watson et al., 1999a) in a manner 
similar to NGF-TrkA signaling (Niewiadomska et al., 2011).  
The discovery of activated TrkB within shafts of apical dendrites and spines of 
CA1 pyramidal cells following epileptogenesis was unexpected based upon previous 
work (Binder et al., 1999a; Danzer et al., 2004; He et al., 2004; He et al., 2002; He et al., 
2010).  Use of less sensitive antibodies together with quantitative analyses conducted 
solely at low magnification (100x) accounts for this finding previously escaping 
detection.  Indeed, quantification at low power (100x) in stratum radiatum of CA1 in the 
present study revealed no significant differences between NS and KA treated animals, 
despite robust increases following KA when pY816+ dendritic shafts and spines were 
quantified at high power (630x).  These results are consistent with ultrastructural 
evidence localizing pY816 immunoreactivity to dendritic shafts of CA1 pyramidal cells 
and a minority (5%) of spines within stratum radiatum of CA1 under basal conditions 
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(Spencer-Segal et al., 2011); notably, activated TrkB was clustered next to the 
postsynaptic density.  Light microscopic studies have also colocalized pTrkB 
immunoreactivity with a subset of PSD-95 (5%) in stratum radiatum of CA1, and the 
fraction of pTrkB colocalizing with PSD-95 increased approximately 2-fold following an 
unsupervised learning paradigm (Chen et al., 2010a; Chen et al., 2010b).  These values 
are similar to those detected under basal conditions in the present study.  Notably, BDNF 
and synaptic zinc are readily detectable within stratum radiatum of CA1, but are present 
in lower amounts than in stratum lucidum, correlating with the less robust pY816 
immunoreactivity detected in this region (Conner et al., 1997; Yan et al., 1997).  Like in 
mossy fiber boutons, TrkB at the spine is likely to be activated by one of these ligands, 
and pTrkB within dendritic shafts may be undergoing retrograde transport to the soma.   
The restricted localization of activated TrkB induced by SE raises multiple 
questions.  Why is the activation not more widespread?  And what accounts for its 
activation within synapses at these two sites?  With respect to the first question, we 
suspect that enhanced TrkB activation does indeed occur at sites outside the hippocampus 
and perhaps even at additional sites within hippocampus.  The present study examined 
TrkB activation at a single point in time, following 3 hours of SE; study at additional 
times following SE might reveal additional sites of TrkB activation.  Moreover, an 
antibody with greater sensitivity may have revealed additional sites of TrkB activation 
even at 3 hours.  With respect to the second question, we favor the explanation that 
enhanced release of BDNF and/or zinc from presynaptic terminals of axons of the dentate 
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granule cells and CA3 pyramidal cells is responsible for TrkB activation in mossy fiber 
boutons and CA1 pyramidal cell spines respectively.  That is, SE, the inducing stimulus, 
is characterized by enhanced firing of populations of neurons which would be expected to 
trigger release of BDNF and zinc which are packaged in synaptic vesicles.  The 
localization of activated TrkB to synapses is consistent with this idea. The bilateral tonic 
and clonic motor activity of the induced seizures notwithstanding, the lateralization of 
activated TrkB preferentially to the hippocampus ipsilateral to the infused amygdala is 
consistent with enhanced neuronal activity within these circuits, a proposal consistent 
with direct projection ipsilaterally—but not contralaterally—from the basal nucleus of 
amygdala to CA3 and CA1 of hippocampus (Pikkarainen et al., 1999).  
This idea may also account for the localization of pY816 immunoreactivity to the 
spines and shafts of proximal apical dendrites, while sparing the spines and shafts of 
basilar dendrites and of the distal portion of apical dendrites within stratum lacunosum-
moleculare.  The observed distribution of TrkB activation implies that afferents 
innervating the apical dendrites of CA1 pyramidal cells were activated during KA-SE to 
a greater extent than those innervating the basilar dendrites.  Interestingly, axons of CA3 
pyramidal neurons positioned closer to dentate gyrus (CA3c) project preferentially to 
superficial layers of stratum radiatum of CA1 (located closer to stratum lacunosum 
moleculare) (Ishizuka et al., 1990).  In contrast, axons of CA3 pyramidal cells located 
closer to CA1 (in CA3a) project preferentially to proximal apical dendrites of CA1 
pyramidal cells and to basilar dendrites in stratum oriens.  These differential patterns of 
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anatomic projections support the possibility that preferential firing of subpopulations of 
CA3 pyramidal cells during KA-SE may promote release of TrkB ligands from 
subpopulations of synapses formed by CA3 axons on spines of proximal apical dendrites 
of CA1 pyramidal cells, thereby accounting for the observed pattern of pY816 
immunoreactivity.     
Activation of TrkB within these hippocampal neuronal populations likely 
promotes epileptogenesis, though study of this process in mutant mice carrying cell type 
specific deletions of TrkB will be required to provide definitive answers.  Lesion studies 
implicate hippocampal circuitry in epileptogenesis triggered by stimulation of amygdala 
in the kindling model as evidenced by striking inhibition following knife cuts of 
entorhinal cortex or selective destruction of the dentate granule cells (Dasheiff and 
McNamara, 1982; Savage et al., 1985).  With respect to how TrkB activation at these 
locales may contribute to the development of epilepsy, one cellular consequence of 
activated TrkB in mossy fibers that might promote epileptogenesis is long term 
potentiation (LTP).  Both ex vivo and in vivo studies of animal models support the idea 
that LTP of excitatory synapses between principal cells contributes to limbic 
epileptogenesis (Sutula and Steward, 1987), the hypothesis being that potentiation of 
these synapses may facilitate propagation of seizure activity via synaptically coupled 
neuronal populations throughout the limbic system and beyond. 
The excitatory synapse formed by mossy fiber boutons with spines of CA3 
pyramids undergoes LTP which is notable in that mechanisms underlying its induction 
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and expression reside presynaptically (reviewed by Nicoll and Schmitz, 2005; Pan et al. 
2011; but see Yeckel et al. 1999).  Mossy fiber-CA3 LTP is eliminated by inhibition of 
TrkB kinase (Huang et al., 2008) and by inhibition of TrkB-mediated activation of 
phospholipase C gamma-1 (PLCγ1) signaling through pY816 (He et al., 2010), the same 
residue critical for epileptogenesis.  Interestingly, study of hippocampal slices isolated 
from animals following KA induced seizures in vivo revealed that LTP of the mossy 
fiber-CA3 synapse was occluded, suggesting that  this synapse had undergone LTP in 
vivo (Goussakov et al., 2000).  Collectively, it seems plausible that enhanced activation 
of TrkB in mossy fibers may contribute to LTP of this synapse in vivo during 
epileptogenesis.  The axonal localization of pY816 immunoreactivity within stratum 
lucidum is also consistent with the possibility that TrkB-PLCγ1 signaling within these 
structures, through evoking rises in cytosolic calcium, is positioned to promote LTP by 
activating type 2 ryanodine receptors.  These ER-bound channels mediate calcium-
induced calcium release (CICR) from internal stores, and themselves open in response to 
rises in calcium (Verkhratsky, 2005).  These receptors have been localized to mossy fiber 
axons (Shimizu et al., 2008) in a distribution similar to pY816 found in this study.  
Mossy fiber-CA3 LTP is inhibited by ryanodine (Bortolotto et al., 2003), consistent with 
the idea that type 2 ryanodine receptor activation may be a consequence of pY816 
signaling.  Interestingly, epileptic seizures are one manifestation of mice genetically 
engineered to express leaky type 2 ryanodine receptors (Lehnart et al., 2008). 
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Like activated TrkB within mossy fiber boutons, one cellular consequence of the 
enhanced TrkB activation within spines of CA1 pyramidal cells may be LTP of synapses 
formed by Schaffer collateral axon terminals onto these structures (Huang et al., 2008; 
Minichiello et al., 1999).  TrkB activation at these synapses has been implicated in both 
LTP and hippocampal-dependent associative learning (Gruart et al., 2007).  Like the 
mossy fiber-CA3 synapse, mutation of Y816, but not Y515, inhibited induction of LTP of 
the Schaffer collateral-CA1 synapse (He et al., 2010; Korte et al., 2000; Minichiello et 
al., 2002), the same residue implicated in promoting epileptogenesis.  Furthermore, in 
immunohistochemical studies examining pTrkB using brain slices treated with LTP-
inducing stimuli at the Schaffer collateral-CA1 synapse, increases in numbers of pTrkB-
immunoreactive puncta were observed in CA1 stratum radiatum (Lu et al., 2011), and 
enhanced colocalization of pTrkB puncta with PSD-95 was found in brain slices after 
such a stimuli (Chen et al., 2010b).  The location of activated TrkB within spines of CA1 
pyramidal neurons is optimally positioned to promote a postsynaptic LTP of this synapse.  
Whereas the pTrkB found within dendritic spines in the present study is well positioned 
to regulate synaptic function (Lu, 2003), the function of pTrkB within shafts is less 
obvious.  If pTrkB within dendritic shafts is in transit back to the soma, it may ultimately 
affect key transcriptional regulators, such as CREB, implicated in the expression of the 
late phase of LTP, which is protein synthesis dependent and also mediated by TrkB 
(Minichiello, 2009).  
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In summary, the present work demonstrates that epileptogenesis is associated with 
a highly specific pattern of enhanced activation of TrkB within hippocampus.  Among the 
diverse populations of neurons within hippocampus, enhanced activation of TrkB was 
identified only within dentate granule cells and CA1 pyramidal neurons, suggesting that 
the functional consequences of its activation are multifocal yet discrete within limbic 
circuitry.  The localization within these populations was highly specific, involving the 
axons of the granule cells and apical, but not basal, dendritic shafts of CA1 pyramidal 
neurons.  While localization to synapses was common to each population of neurons, the 
localization was to presynaptic boutons of the granule cell axons and to postsynaptic 
spines of the CA1 pyramidal cells.  One plausible cellular consequence of enhanced TrkB 
activation is increased efficacy of excitatory synapses between principal neurons, a 
cellular event likely pivotal to the pathogenesis of limbic epilepsy. 
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3. The Contribution of Vesicular Zinc to Transactivation 
of TrkB in Stratum Lucidum of Mouse Hippocampus 
3.1 Introduction 
TrkB is a tyrosine kinase receptor in the tropomyosin-related kinase (Trk) family 
of neurotrophin receptors which is critical to neuronal processes including survival, 
differentiation, and synaptic plasticity (Chao et al., 2006; Huang and Reichardt, 2001; 
McAllister et al., 1999; Poo, 2001).  The importance of this receptor in diverse neuronal 
processes, as well as its involvement in several diseases of the nervous system (Barbacid, 
1995; Chao et al., 2006; McNamara et al., 2006), underscores the importance of 
understanding the ligands which mediate its activation.  The canonical neurotrophin 
ligand that activates TrkB is brain derived neurotrophic factor (BDNF) (Barbacid, 1995).  
Binding of BDNF to the ectodomain of TrkB induces phosphorylation at intracellular 
tyrosine residues, resulting in receptor activation and downstream signal transduction 
(Barbacid, 1995; Cunningham and Greene, 1998).  Antibodies that recognize specific 
epitopes of phosphorylated tyrosine residues on TrkB (pTrkB) therefore can be used as 
surrogate measures of receptor activation (Segal et al., 1996).  BDNF is highly enriched 
in stratum lucidum of hippocampus, an area where dentate granule cells synapse on CA3 
pyramidal neurons (Yan et al., 1997).  BDNF is thought to be released following 
neuronal activity, and striking increases in BDNF protein expression have been observed 
following seizures (Danzer and McNamara, 2004; He et al., 2004; Lessmann and 
Brigadski, 2009; Yan et al., 1997).  In rodent models of epilepsy, antibodies recognizing 
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pTrkB reveal enriched immunoreactivity in stratum lucidum using immunohistochemical 
methods (IHC) (Binder et al., 1999a; He et al., 2004; He et al., 2002; He et al., 2010).  
This temporal and spatial concordance of increased BDNF expression and pTrkB 
immunoreactivity led to the hypothesis that BDNF was activating this receptor under 
these conditions.  Unexpectedly, however, in mice with a conditional deletion of BDNF 
from cells of stratum lucidum, this enhanced pTrkB immunoreactivity persisted (He et al., 
2004).  These findings suggested that another ligand may be contributing to TrkB 
activation under these conditions, and prompted a search for another such molecule.   
Transactivation is a process by which a ligand activates its receptor without 
interacting directly with it (Carpenter, 1999).  The divalent cation, zinc, has been found to 
transactivate another tyrosine kinase receptor, epidermal growth factor receptor (EGFR), 
which led to the hypothesis that zinc may also be capable of TrkB transactivation (Wu et 
al., 2002).  To this end, our laboratory found that exogenous zinc can activate the TrkB 
receptor in neuronal-glial cultures prepared from rodent cortex through a mechanism 
independent of BDNF (Huang et al., 2008).  Endogenous zinc, under conditions of 
increased neuronal activity, was also found to promote TrkB transactivation in vitro 
(Huang et al., 2008).  Zinc is present in glutamate-containing synaptic vesicles of axon 
terminals throughout hippocampus and neocortex, and is incorporated into these vesicles 
by zinc transporter protein-3 (ZnT3), expressed only on the membranes of presynaptic 
vesicles of glutamatergic neurons that concentrate this metal (Palmiter and Huang, 2004).  
Vesicular zinc is particularly enriched in boutons of dentate granule cells in vivo, where it 
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is found in the highest quantities in the nervous system, and is co-released with glutamate 
in an activity dependent fashion (Choi and Koh, 1998; Frederickson and Danscher, 1990; 
Frederickson et al., 2005).  TrkB activation is necessary for LTP at the mossy fiber-CA3 
synapse, and chelation of extracellular zinc prevents development of this LTP (Huang et 
al., 2008).  All of these findings suggest that both vesicular zinc and BDNF may 
contribute to activation of TrkB within stratum lucidum.  Whether this synaptic pool of 
zinc activates TrkB in vivo, however, remains to be tested. 
The objective of this study was to examine the contribution of vesicular zinc to 
TrkB transactivation within stratum lucidum of hippocampus under physiological 
conditions, and to compare this contribution to that of the canonical TrkB ligand, BDNF.  
In order to do this, two strains of genetically modified mice were utilized :  (1) a 
conditional knockout of BDNF which eliminates this molecule from stratum lucidum (He 
et al., 2004), allowing examination of TrkB activation in the absence of BDNF, and (2) a 
complete genetic knockout of ZnT3 (Cole et al., 1999), which completely eliminates 
vesicular zinc from mossy fibers and other CNS neurons, allowing for the study of TrkB 
activation in the absence of synaptic zinc stores.  Breeding these lines together resulted in 
generation of mice which were deficient in both BDNF and vesicular zinc within stratum 
lucidum, and thus allowed for the study of TrkB activation in the absence of both BDNF 
and synaptic zinc.  As presented in Chapter 2 of this dissertation and (Helgager et al., 
2013), an antibody detecting an activated form of TrkB, that which is phosphorylated on 
tyrosine residue 816 (pY816) of the receptor, found it to be enriched within important 
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cellular and synaptic structures within stratum lucidum.  As immunoreactivity was 
readily detectable within these structures under physiological conditions, use of this 
antibody offered an ideal means by which to assay levels of activated TrkB at these 
cellular locales in the absence of synaptic zinc and/or BDNF. 
3.2 Materials and Methods 
3.2.1 Generation of BDNF Mutant, ZnT3 Mutant, and ZnT3/BDNF 
Double Mutant Mice 
BDNF mutant mice were generated as described (Monteggia et al., 2004; Zhu et 
al., 2001), a gift from the lab of Luis Parada (University of Texas Southwestern Dallas, 
TX).  Cre/loxP technology (Gu et al., 1994) was utilized in these animals, and to this end 
exon five of the BDNF gene was flanked by two loxP sites (“floxed”) so that it would be 
deleted in the presence of Cre recombinase.  These animals were backcrossed for at least 
seven generations into a C57/BL6 background at which time they were bred to transgenic 
mice, also backcrossed in the same fashion, expressing Cre recombinase under the 
control of a synapsin-1 promoter (Syn-Cre).  Mice homozygous for BDNF floxed alleles 
which also contain Syn-Cre (Syn-Cre+/BDNFflox/flox) will have BDNF protein eliminated 
from a subset of CNS neurons.  In the hippocampus this results in elimination of BDNF 
gene expression in virtually all dentate granule cells and CA3 pyramidal neurons and in a 
subset of CA1 pyramidal cells (see Figure 1 of He et al., 2004).  These conditional 
knockout animals will henceforth be referred to as BDNF-/- mice.  BDNF-/- animals were 
generated for experiments as outlined in Fig. 15A, yielding litters in which approximately 
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50% of animals do not contain Syn-Cre (Syn-Cre-/BDNFflox/wt or Syn-Cre-/BDNFflox/flox) 
and therefore express BDNF at wild type levels, henceforth referred to as BDNF+/+ mice,  
25% are BDNF+/-, and 25% BDNF-/-  (He et al., 2004). 
ZnT3 mutant mice, generated as described in (Cole et al., 1999), were obtained 
from the Jackson Laboratory (Bar Harbor, ME) and backcrossed for seven generations 
into a C57/BL6 background, the founders of which were originally obtained from Charles 
River (Wilmington, MA).  These animals contain a targeted deletion in which exons 1-4 
of the ZnT3 gene have been replaced with a cassette containing nlacZ and neor
. 
 Mice 
homozygous for this mutant allele (ZnT3-/-) express no ZnT3 protein.  By breeding those 
heterozygous for the mutant allele (ZnT3+/-) together, litters can be generated that are 
approximately 25% wild type (ZnT3+/+), 50% heterozygotes (ZnT3+/-), and 25% ZnT3-/- 
(Fig. 15B).  
ZnT3/BDNF double mutant animals (ZnT3 -/-/Syn-Cre+/BDNFflox/flox) were 
generated using a similar breeding strategy as for generation of BDNF-/- mice.  
Specifically, ZnT3-/-/Syn-Cre-/BDNFflox/flox animals were mated with ZnT3-/-
/SynCre+/BDNFflox/wt mice (Figure 15C).  As with generation of BDNF mutant animals, 
this breeding resulted in litters in which approximately 50% of mice do not express Syn-
Cre and therefore express BDNF protein at normal levels, though are knockouts of ZnT3 
(ZnT3 -/-/Syn-Cre-/BDNFflox/wt or ZnT3 -/-/Syn-Cre-/BDNFflox/flox), 25% are heterozygous 
for the BDNF allele (ZnT3 -/-/Syn-Cre+/BDNFflox/wt), whereas 25% are ZnT3/BDNF 
double knockouts, henceforth referred to as ZnT3-/- BDNF-/- mice.  Double mutant  
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Figure 15:  Breeding strategies for generating BDNF, ZnT3, and ZnT3/BDNF 
mutant and double mutant mice. 
Animals were crossed as described in A, B, and C above.  Red denotes the 
genotype of the mutant (A, devoid of BDNF; B, devoid of synaptic zinc) or double 
mutant (C, devoid of both BDNF and synaptic zinc), whereas green denotes the 
genotype(s) of the littermate controls.  Note that in (A) and (B), the control animals 
express normal levels of BDNF and synaptic zinc, whereas in (C) the control mice 
express normal levels of BDNF but are devoid of synaptic zinc.  wt = wild type allele, 
flox = floxed BDNF allele, Syn-Cre+ = Cre recombinase positive, Syn-Cre- = Cre 
recombinase negative. 
animals were always compared to mice that are single knockouts for either BDNF or 
ZnT3, referred to in this context as ZnT3+/+ BDNF-/- (ZnT3+/+/Syn-Cre+/BDNFflox/flox)  
or ZnT3-/- BDNF+/+ (ZnT3 -/-/Syn-Cre-/BDNFflox/wt or ZnT3 -/-/Syn-Cre-/BDNFflox/flox) 
animals. 
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All mice used in experiments were 3-6 months of age and genotyped for ZnT3, 
BDNF floxed alleles, and Syn-Cre at least twice to confirm their genotypes.  
Comparisons between BDNF+/+ vs. BDNF-/- and between ZnT3-/- BDNF+/+ vs. ZnT3-/- 
BDNF-/- were performed using littermates, as the breeding strategy enabled this.  In the 
case of ZnT3+/+ vs. ZnT3-/- single knockout comparisons, littermate controls were used in  
some experiments and mice age-matched within 1.5 months of age of one another were 
used in others; similar results were obtained using both strategies.  For ZnT3 +/+ BDNF -/- 
vs. ZnT3 -/- BDNF -/- comparisons, the breeding strategy necessitated that age-matched 
mice within 1.5 months of age of one another were used. 
3.2.2 Preparation of Brain Specimens for Immunohistochemistry 
Animals generated as described above were anesthetized with 100 mg/kg 
pentobarbital (Lundbeck, Deerfield, IL) by intraperitoneal injection and underwent 
transcardial perfusion through the left ventricle with a solution of ice-cold PBS, pH 7.4, 
containing 1 U/mL heparin (Sigma, St. Louis, MO) and 2 mM sodium orthovanadate 
(Sigma), at a rate of 10 ml/min for one minute.  This was followed by a seven minute 
perfusion with ice-cold 4% paraformaldehyde (Sigma) and 2 mM sodium orthovanadate 
in PBS, pH 7.4.  Brains were removed and postfixed overnight at 4°C in the same 
solution, after which they underwent cryoprotection for 36 hours in a solution of 30% 
sucrose, 2 mM sodium orthovanadate in PBS at pH 7.4 and 4°C.  Brains were verified as 
being appropriately cryoprotected when they sank in this solution.  Brains were then 
frozen by slow immersion in 2-methylbutane (J.T. Baker, Phillipsburg, NJ) cooled to at 
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least -20°C with dry ice, and stored at -80°C until cryosectioning.  Sections were cut at a 
thickness of 40 µm, placed in cryoprotection solution, and stored at -80°C until 
immunostaining. 
3.2.3 Immunohistochemistry 
Rabbit polyclonal antibody which recognizes phosphorylated tyrosine residue 816 
of the TrkB receptor (pY816) was generated using the peptide LQNLAKASPVpYLDI, 
corresponding to amino acids 806-819 of mouse TrkB, and was used in all experiments at 
a 1:2000 dilution following IgG purification using protein-A beads.  Importantly, the 
specificity of this antibody was previously established by demonstrating a significant 
reduction in immunoreactivity in stratum lucidum of genetically modified mice with a 
substitution of phenylalanine for tyrosine at the 816 residue (Y816F) of TrkB compared 
to wild type controls, as shown in Supplementary Figure 1 of (He et al. 2010).   
Mouse monoclonal antibodies recognizing synapsin-1 (1:500; Synaptic Systems, 
Goettingen, Germany) and tau (1:1000; Millipore, Temecula, CA) were employed for 
colocalization experiments.  Mice of the genotypes to be compared in a given experiment 
were always incubated in parallel using the same solutions and conditions.  All 
incubations took place at 4°C in 5% normal goat serum (Invitrogen, Carlsbad, CA) in 
PBS, pH 7.4, with 2 mM sodium orthovanadate.  Floating sections were permeabilized 
for one hour in 0.5% Triton-X100 (GE Healthcare, Chalfont St. Giles, UK), and solutions 
of primary antibodies added for 36 hours.  Alexa Fluor 555 goat anti-rabbit (1:1000; 
Invitrogen) and, for colocalization experiments, Alexa Fluor 488 or 633 goat-anti-mouse 
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secondary antibodies (1:500; Invitrogen) were then applied for six hours.  Adjacent 
sections not treated with primary antibody were also run in parallel for each animal as 
negative controls.  Sections were wet-mounted on Superfrost Plus slides (Erie Scientific, 
Portsmouth, NH) and stepped through serial dehydration solutions of two minutes each of 
50%, 70%, 85%, 95%, 100%, and 100% ethanol, followed by 20 minutes incubation in 
xylene (VWR, Radnor, PA) before coverslipping. 
3.2.4 Confocal Microscopy and Data Analysis 
3.2.4.1 Imaging Parameters 
Imaging was performed with a Leica (Nussloch, Germany) DMIRE2 inverted 
microscope with a 10x (numerical aperture, 0.4) air or 63x (numerical aperture, 1.4) oil 
immersion objective equipped with a Leica TCS SL confocal system.  All images were 
acquired with the pinhole set to 1.0 Airy units.  All images used for quantitative analysis 
or shown for visual comparison between genotypes were acquired so as to prevent 
systematic differences in image intensities.  To this end, sections from mice which were 
incubated together within a given staining experiment were imaged using the same laser 
intensity and detection settings during the same imaging session, allowing relative 
densitometry measurements to be made between animals of different groups.  Because 
overall staining intensities varied among experiments, confocal settings were adjusted 
optimally for each experiment so that all image intensities fell within the dynamic range 
of detection of the device.   
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Low power (10x objective, total of 100x magnification) images of hippocampus 
are average projections of z-series “stacks” taken through the entire thickness of the 
hippocampal section.  Unless otherwise stated, high power (63x objective, total of 630x 
magnification) images are average projections of z-series taken through a 1 µm depth of 
hippocampus where pY816 staining was of greatest intensity.  Average projections were 
used because they best reflect representative staining intensities in the z-plane for 
quantification of immunoreactivity.  Images depicting colocalizations were confirmed in 
the x, y, and z dimensions.  The focal plane thickness is a significant factor in the z-
dimension.  For the 63x objective used in this study, assuming ideal conditions and 488 
nm of light, z resolution is stated to be 235 nm (Leica).  The resolution in the x-y plane is 
stated to be 180 nm (Leica).  All image quantification described was performed on raw 
images which were not adjusted for brightness or contrast.  However, brightness and/or 
contrast were optimized in all images shown within this chapter in order to best convey 
relevant features.  In images of pY816 immunoreactivity used for comparison, brightness 
and contrast were adjusted equally between images. 
3.2.4.2 Quantification of pY816 Immunoreactivity within Stratum Lucidum of 
Hippocampus 
Analysis of imaging data was performed by an investigator blinded to treatment 
group.  The program ImageJ (Abramoff, 2004) was used for data analysis.  All 
quantitative data are presented as mean ± SEM, analyzed by Student’s t-test.   
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Quantification of pY816 immunoreactivity within stratum lucidum was performed 
using images acquired at high power (630x).  Hippocampal images including the CA3b 
regions of stratum lucidum and stratum radiatum were acquired bilaterally, for a total of 
two images per animal.  Quantification focused on specific areas within stratum lucidum 
that were enhanced in pY816 immunoreactivity and shown to correspond to axon tracts 
in colocalization experiments (Helgager et al., 2013).  Representative regions enriched in 
pY816 immunoreactivity were outlined as regions of interest (ROIs) until 40,000 pixels 
in total area were reached or exceeded in a given image, and the average intensity of this 
area quantified.  The average intensity of stratum radiatum of CA3 that was included in 
the same micrograph was also analyzed, and subtracted from the value obtained from 
stratum lucidum in order to compensate for variations in background staining.  This 
procedure was performed for both images acquired from each hippocampus in a given 
animal, and the results averaged to yield one value per mouse.  Signal within stratum 
radiatum was used to normalize for overall staining intensity because signal within 
stratum radiatum was always substantially lower than stratum lucidum, was found to be 
of the same average intensity when compared between animals of different genotypes 
(data not shown), and the CA3 pyramidal cell dendrites which populate this region were 
found not to contain significant amounts of pY816 immunoreactivity.   
Quantification of synaptic pY816 immunoreactivity within stratum lucidum 
utilized a synapsin-1 antibody, a specific marker of synapses (De Camilli et al., 1983; 
Fletcher et al., 1991; Moore and Bernstein, 1989), as described above.  Z-series were 
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acquired at 200 nm intervals over a total depth of 1 µm at 1.7x digital zoom, with three 
images taken per hippocampus, yielding a total of six images per animal.  Individual 
synapsin-1 puncta were checked for pY816 immunoreactivity in the x, y, and z planes, 
and scored as being positive if they appeared to contain at least one discrete 
immunoreactive puncta, even if only in one z-section.  This immunoreactivity needed to 
occupy at least 20% of the area of a bouton.  50 puncta were quantified per image, with a 
total of 300 synapsin-1 puncta per animal, and the percent of synapsin-1 puncta found to 
colocalize with pY816 computed.  
3.2.5 Preparation of Brain Specimens for Western Blot and ELISA 
Mice were anesthetized with 100 mg/kg pentobarbital by intraperitoneal injection 
and decapitated.  Mouse heads were swiftly dipped into liquid nitrogen three times in 
order to cool the brain during the dissection process, and placed on a cold ice pack.  Both 
hippocampi were dissected and placed into ice cold lysis buffer (137 mM NaCl [Sigma], 
20 mM Tris [pH 7.6; Merck, Whitehouse Station, NJ], 1% NP40 [Sigma], 10% glycerol 
[Merck], 1 mM PMSF [Sigma], 2 mM sodium orthovanadate, and a Complete Mini 
protease inhibitor tablet [Roche, New Mannheim, Germany]).  The hippocampi were then 
homogenized using a motorized tissue homogenizer and centrifuged at 4°C at 14,000 
RPM.  The amount of total protein in the supernatant was quantified using a Micro 
BCATM Protein Assay Kit (Pierce, Rockford, IL).  For Western blot, samples were diluted 
while on ice to a final concentration of 1 mg/mL using lysis buffer and 6x SDS-PAGE 
sample buffer (350 mM Tris [pH 6.8], 30% glycerol, 1% SDS [Crystalgen, Plainview, 
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NY], 6% β-mercaptoethanol [Sigma], and 0.2 mg/mL bromophenol blue [Sigma]), the 
latter mixed into the sample so that it was at 1x concentration.  For ELISA, samples were 
diluted with PBS-V to a final concentration of 5 mg/mL.  As acid treatment will increase 
yield of BDNF (Okragly and Haak-Frendscho, 1997), the pH of the sample was adjusted 
to <3.0 with 1N HCl for 20 minutes at room temperature, after which it was placed on ice 
and brought to a pH of approximately 7.0 using 1N NaOH.  Samples were then diluted to 
a concentration of 2.5 mg/mL using the Block & Sample buffer provided with the BDNF 
Emax® ImmunoAssay System (Promega, Madison, WI) used to assay BDNF levels (see 
below). 
3.2.6 Western Blot 
10 µg of samples previously prepared for Western blot were loaded onto SDS-
PAGE gels containing 8% polyacrylamide (Bio-Rad, Hercules, CA).  The gels were 
electrophoresed at 90 Volts until the loading dye reached the bottom of the gel, and 
transferred onto nitrocellulose membranes (Whatman, Dassel, Germany) for 1.5 hours at 
90 Volts.  Membranes were then blocked with 5% bovine serum albumin (Sigma) in Tris 
buffered saline (TBS) for half an hour.  Membranes were incubated with primary 
antibodies probing for one of the following proteins: TrkB (rabbit polyclonal, 1:2000; 
Chemicon, Temecula, CA), pY816 of the TrkB receptor (rabbit monoclonal, 1:1000; 
AbCam, Cambridge, MA), or β-actin (rabbit polyclonal, 1:5000; Sigma).  Membranes 
were washed five times with TBS containing 0.05% Tween-20 (TBS-T; Amresco, Solon, 
Ohio), following which they were incubated with peroxidase conjugated goat anti-rabbit 
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IgG secondary antibody (1:5000; The Jackson Laboratory) for one hour.  Following five 
additional washes with TBS-T, membranes were probed using ECL™ Western Blotting 
Analysis System (GE Healthcare, Pittsburgh, PA), imaged in the dark on Biomax MR 
film (Kodak, Rochester, NY), and developed. 
3.2.7 BDNF ELISA 
 The BDNF Emax® ImmunoAssay System (Promega), a sandwich ELISA assay, 
was used to measure hippocampal BDNF levels.  In brief, a 96-well plate was coated 
with monoclonal mouse antibody (1:1000) overnight at 4°C, after which it was blocked at 
room temperature using the Block & Sample Buffer provided.  Samples prepared as 
described above were incubated in triplicate along with serial titrations (7.8-500 pg/mL) 
of the BDNF standard provided for two hours at room temperature.  The wells were then 
evacuated and washed with TBS-T, and incubated with a chicken polyclonal antibody 
recognizing BDNF (1:500) for two hours at room temperature.  Following evacuation and 
wash with TBS-T, the wells were incubated with a peroxidase conjugated, anti-IgY 
secondary antibody (1:200) for one hour at room temperature.  The wells were again 
evacuated and washed with TBS-T, following which the TMB One Solution provided 
was added and allowed to incubate at room temperature for 10 minutes.  Following this 
incubation, an equal volume of 1N HCl was added to the wells to stop color development, 
and a SpectraMax 190 Absorbance Microplate Reader (Molecular Devices, Sunnyvale, 
CA) used to record absorbance of the wells at 450 nm.  The average BDNF concentration 
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(pg/mL) was calculated for each sample based on this absorbance reading, which was 
then converted to ng of BDNF per gram of total protein (ng/g). 
3.3 Results 
3.3.1 Decreased Axonal and Synaptic pY816 Immunoreactivity within 
Stratum Lucidum in BDNF-/- Mice 
Initial studies examined the contribution of the canonical TrkB ligand, BDNF, to 
activation of TrkB within stratum lucidum of hippocampus.   To this end, pY816 
immunoreactivity was assayed within stratum lucidum in BDNF wild type (BDNF+/+) 
and knockout (BDNF-/-) mice using confocal microscopy.  Analysis concentrated on the 
cellular and synaptic structures within stratum lucidum known to be enriched in pY816—
axons and synapses of mossy fibers (Chapter 2 of this dissertation; Helgager et al. 2013).   
Survey of the hippocampus at low power (100x) in wild type animals 
demonstrated that pY816 immunoreactivity was particularly abundant within stratum 
lucidum (Fig. 16A), confirming previous results (Helgager et al. 2013).  High power 
(630x) images revealed discrete pY816 immunoreactive patches which colocalized with 
tau protein (Fig. 16B), a marker of axons, showing that this pY816 immunoreactivity 
corresponded anatomically to mossy fibers (Binder et al., 1985).  Notably, reductions of 
stratum lucidum immunoreactivity were evident in BDNF-/- compared to BDNF+/+ mice 
at low power (Fig. 17A), a pattern due to decreased axonal pY816 immunoreactivity 
within mossy fibers of BDNF-/- animals as detected in high magnification images (Fig. 
17B).   To quantify this reduction, high power images of stratum lucidum were acquired  
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Figure 16: pY816 TrkB immunoreactivity is enriched in mossy fiber axons and 
synapses within stratum lucidum (SL) of mouse hippocampus. 
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A) Image of an entire mouse hippocampus in a wild type animal, stained with 
pY816.  The SL region (arrows) appears particularly enriched in pY816 
immunoreactivity.  Image is a montage of two images taken at low magnification 
(100x).  Scale bar = 300 µm.  B) High power (630x) images of SL of hippocampus 
stained for pY816 (red) and tau (green), an axonal marker.  Discrete patches of 
pY816 immunoreactivity (red; arrows) overlap with tau labeled axons (green; 
arrows), demonstrating mossy fiber axons of dentate granule cells are particularly 
enriched in pY816 immunoreactivity.  Merged pY816 and tau is shown in the 
rightmost panel.  SR = stratum radiatum of CA3, Pyr = CA3 pyramidal cell layer.  
Scale bar = 50 µm.  C) Confocal micrographs showing SL stained with pY816 (red) 
and synapsin-1 (green), a marker of synapses.  The majority of synapsin-1 puncta 
(green; arrows) do not appear to contain substantial pY816 (red; arrows).  Merged 
pY816 and synapsin-1 are shown in the rightmost panel.  Scale bar = 30 µm.  D)  
Digitally zoomed images consisting of one z-section from images in panel (C) 
demonstrate synapsin-1 puncta (green; arrows) that contain pY816 
immunoreactivity (red; arrows).  A nearby synapsin-1 puncta (green; arrow with 
asterisk) does not contain pY816 immunoreactivity (red; arrow with asterisk), the 
situation for the majority of synapsin-1 puncta assessed.  Merged pY816 and 
synapsin-1 is shown in the rightmost panel.  Scale bar = 7 µm. 
from both hippocampi in BDNF+/+ (n=14) and BDNF-/- (n=10) animals, and axons 
measured for the intensity of their immunoreactivity.  This axonal quantification of  
pY816 immunoreactivity revealed an approximately 30% reduction in BDNF-/- compared 
to BDNF+/+ animals which was statistically significant (Fig. 17C; p<0.05, Student’s t-
test).  In order to examine synaptic immunoreactivity, an antibody labeling the synaptic 
marker synapsin-1 was employed and assessed for colocalization with pY816 (De 
Camilli et al., 1983; Fletcher et al., 1991; Moore and Bernstein, 1989).  As expected, in 
wild type animals a minority of synapsin-1 puncta contained pY816 immunoreactivity, 
also punctate in nature (Fig. 16C, D).  In order to quantify synaptic immunoreactivity in 
BDNF+/+ (n=9) and BDNF-/- (n=6) mice, synapsin-1 puncta were identified in z-section 
stacks and scored for pY816 immunoreactivity by a blinded investigator.  Such a  
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Figure 17: pY816 TrkB immunoreactivity in mossy fiber axons and synapses within 
SL is decreased in BDNF-/- compared to BDNF+/+ mice. 
A) Representative low power micrographs taken of hippocampi from 
BDNF+/+ (top) and BDNF-/- (bottom) mice stained with pY816, revealing that 
immunoreactivity within SL of the BDNF-/- animal (arrows, bottom) is reduced 
compared to its BDNF+/+ littermate (arrows, top).  Scale bar = 300 µm.  B) Images of 
SL taken at high power from pY816 stained sections from the same BDNF+/+ (top) 
and BDNF-/- (bottom) mice as in (A) demonstrates that this observed reduction is 
due to decreased pY816 immunoreactivity within mossy fiber axons of the BDNF-/- 
mouse (arrows point to pY816 enriched regions shown in Fig. 16 to correspond 
anatomically to mossy fiber axons; compare top and bottom images).  Scale bar = 50 
µm.  C) Quantification of axonal pY816 immunoreactivity in BDNF+/+ (n=14) and 
BDNF-/- (n=10) mice demonstrates a significant decrease in immunoreactivity in the 
BDNF-/- animal compared to BDNF+/+ (p<0.05, Student’s t-test).  Quantification is 
presented as mean pY816 axonal immunoreactivity ± SEM.  D) Quantification of 
percentages of synapsin-1 puncta within SL found to contain pY816 
immunoreactivity in BDNF+/+ (n=9) and BDNF-/- (n=6) mice.  A 30.8% reduction in 
synaptic pY816 immunoreactivity was found in BDNF-/- mice compared to their 
BDNF+/+ littermates (p<0.05, Student’s t-test).  A total of 2700 synapsin-1 puncta 
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were analyzed in BDNF+/+ mice, and 1800 in BDNF-/- animals.  Quantification is 
presented as mean % ± SEM.  All data were analyzed by Student’s t-test; *p<0.05.  
structure was scored as pY816+ if it contained a discrete pY816 puncta that filled at least 
20% of its area in at least one z-section, and at least 300 synapsin-1 puncta were 
examined in each animal in order to compute a percentage of synapsin-1 puncta that 
contained pY816 immunoreactivity for each mouse (4500 synapsin-1 puncta total).  In 
BDNF+/+ animals, an average of 17.4 ± 1.1% of synapsin-1 puncta were found to contain 
pY816 immunoreactivity, whereas only 13.3 ± 1.0% contained pY816 in the BDNF-/- 
mouse, a statistically significant reduction (Fig. 17D; mean ± SEM, p<0.05 by Student’s 
t-test).  The reductions of pY816 immunoreactivity within both axons and boutons of 
mossy fibers support the conclusion that BDNF contributes to TrkB activation under 
these conditions.   
3.3.2 Enhanced Axonal and Unchanged Synaptic pY816 TrkB 
Immunoreactivity within Stratum Lucidum of ZnT3-/- Mice  
 To assess the contribution of vesicular zinc to activation of TrkB within stratum 
lucidum of hippocampus, pY816 immunoreactivity was examined in hippocampal 
sections from mice in which the transporter required for concentrating zinc within 
synaptic vesicles (ZnT3) had been eliminated.  Timm’s staining labeling vesicular zinc in 
mossy fibers was abolished in these animals, demonstrating that knocking out ZnT3 
eliminated vesicular zinc (Cole et al., 1999).  Experimental evidence that zinc can 
transactivate TrkB (Huang et al., 2008) led us to hypothesize that pY816 
immunoreactivity would be reduced in mossy fiber boutons and axons, as observed in  
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Figure 18:  Axonal pY816 TrkB immunoreactivity increases in axons but remains 
unchanged at synapses within SL in ZnT3-/- compared to ZnT3+/+ mice. 
A) Representative low power images of hippocampi stained with pY816, 
taken from ZnT3+/+ (top) and ZnT3-/- (bottom) mice showing increased 
immunoreactivity within SL in the ZnT3-/- mouse (arrows, bottom) compared to its 
ZnT3+/+ littermate (arrows, top).  Scale bar = 300 µm.  B) High power micrographs 
of SL taken from pY816 stained sections from the same ZnT3+/+ (top) and ZnT3-/- 
(bottom) animals as in (A), demonstrating that the increased intensity within SL is 
due to enriched pY816 immunoreactivity within mossy fiber axons (arrows point to 
pY816 enriched regions shown in Fig. 16 to correspond anatomically to mossy fiber 
axons; compare top and bottom images).  Scale bar = 50 µm.  C) Quantification of 
axonal pY816 immunoreactivity in ZnT3+/+ (n=19) and ZnT3-/- (n=19) mice 
demonstrating an increase in the ZnT3-/- mouse compared to ZnT3+/+ (p<0.01, 
Student’s t-test).  Quantification is presented as mean pY816 axonal 
immunoreactivity ± SEM.  D) Percentages of synapsin-1 puncta within SL found to 
be pY816+ in ZnT3+/+ (n=19) and ZnT3-/- (n=19) animals.  No significant differences 
in synaptic pY816 immunoreactivity was found in ZnT3-/- compared to ZnT3+/+ mice 
(p=0.77, Student’s t-test).  A total of 5760 synapsin-1 puncta were analyzed in 
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ZnT3+/+ animals, and 5758 in ZnT3-/- mice.  Quantification is presented as mean % ± 
SEM.  All data were analyzed by Student’s t-test; **p<0.01.  
BDNF-/- mice.  Synaptic immunoreactivity was assayed in the same fashion as was 
performed in the BDNF knockout animals above, with over 11,500 synapsin-1 puncta  
examined in ZnT3+/+ (n=19) and ZnT3-/- (n=19) animals.  Contrary to our hypothesis, no 
significant differences in the percentages of pY816+ synapses were detected between the 
two genotypes (Fig. 18D; ZnT3+/+ = 17.5 ± 0.9%, ZnT3-/- = 17.1 ± 0.9%, mean % ± SEM, 
p=0.77 by Student’s t-test).  Unexpectedly, low power inspection of stratum lucidum 
from ZnT3-/- mice  revealed increased pY816 immunoreactivity within this region 
compared to the ZnT3+/+ animal (Fig. 18A).  High power micrographs demonstrated that, 
as in the wild type animal, pY816 immunoreactivity in the ZnT3 mutant colocalized with 
tau and was therefore located within axons of mossy fibers (data not shown). 
Quantification of axonal immunoreactivity in ZnT3+/+ (n=19) and ZnT3-/- (n=19) 
animals confirmed this observation, demonstrating that pY816 immunoreactivity was 
increased by approximately 24% in the ZnT3 knockout mouse compared to wild type 
(Fig. 18B, C; p<0.01 by Student’s t-test).  Finding an increase, rather than the 
hypothesized reduction, of axonal pY816 immunoreactivity raised the possibility of a 
homeostatic response to the absence of  vesicular zinc, perhaps involving either BDNF 
and/or TrkB expression.   
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3.3.3 Total TrkB Levels Are Unchanged in the Hippocampi of ZnT3-/- 
Mice 
The increases observed in pY816 immunoreactivity within mossy fiber axons in 
the ZnT3 knockout animal could be due to increased numbers of TrkB molecules in 
ZnT3-/- compared to ZnT3+/+ controls, a similar proportion of which are phosphorylated.  
Such a finding would reflect one potential compensatory response that could be 
responsible for increased pY816 in the absence of vesicular zinc.  Alternatively, the 
numbers of TrkB molecules could be equivalent in ZnT3-/- compared to ZnT3+/+ controls, 
but a greater proportion could be phosphorylated in the mutant compared to wild type.  
To begin to assess these possibilities, Western blots were performed on whole 
hippocampal lysates from ZnT3+/+ and ZnT3-/- animals, probing for TrkB receptor (Fig. 
19A).  Quantification of wild type (n=13) and knockout (n=11) animals revealed no overt 
differences in TrkB receptor levels between these two genotypes (Fig. 19B; p=0.64 by 
Student’s t-test).   
3.3.4 BDNF Levels Increase within Hippocampi of ZnT3-/- Mice 
The unexpected increase of axonal pY816 immunoreactivity together with the 
lack of change in TrkB protein levels raised the possibility of a homeostatic increase in 
expression of the canonical TrkB ligand, BDNF, in the ZnT3 mutant mouse.  To examine 
this possibility, BDNF content was measured in hippocampal lysates isolated from 
ZnT3+/+ (n=10) and ZnT3-/- (n=8) animals using an ELISA.  This revealed a 51% increase 
in BDNF content (ZnT3+/+ = 81.1 ± 9.1 pg/g, ZnT3-/- = 123.0  ± 10.0 pg/g, mean pg  
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Figure 19: Total TrkB and BDNF levels in whole hippocampal homogenates 
comparing ZnT3-/- and ZnT3+/+ animals. 
A) Representative Western blot demonstrating TrkB levels in ZnT3+/+ and 
ZnT3-/- mice assayed in whole hippocampal lysates.  FL TrkB = full length TrkB.  
Trunc. TrkB = truncated TrkB.  B) Quantification of full-length TrkB levels 
demonstrates no significant difference between wild type (n=13) and knockout 
(n=11) animals.  Data are represented as mean percent of average TrkB levels found 
in the ZnT3+/+ animal ± SEM, and was normalized to β-actin as a loading control.  C) 
Total BDNF levels in whole hippocampal lysates assayed by ELISA demonstrates an 
approximately 52% increase in the ZnT3-/- (n=10) compared to the ZnT3+/+ (n=8) 
mouse.  Data are represented as ng BDNF levels per gram of total protein ± SEM.  
All data were analyzed by Student’s t-test; **p<0.01. 
BDNF/g total protein ± SEM, p<0.01 by Student’s t-test) in ZnT3-/- compared to ZnT3+/+ 
mice (Fig. 19C).  It seems plausible that this homeostatic increase of BDNF content 
contributes to the similar levels of synaptic pY816 and increased levels of axonal pY816 
in ZnT3 mutant compared to wild type mice. 
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3.3.5 Axonal and Synaptic pY816 TrkB Immunoreactivity within 
Stratum Lucidum Is Reduced in ZnT3-/- BDNF-/- Compared to ZnT3-/- 
BDNF+/+ Mice 
 The increased BDNF content in ZnT3 mutant mice led us to hypothesize that this 
homeostatic response is required for the increased mossy fiber axonal pY816 detected in 
these animals.  To test this hypothesis, the effects of eliminating BDNF from ZnT3 
mutant mice on pY816 immunoreactivity were examined by breeding BDNF mutant mice 
on to a ZnT3 null mutant background (see Materials and Methods).  Importantly, ZnT3 
and BDNF double mutant animals (ZnT3-/- BDNF-/-) were behaviorally indistinguishable 
from wild type mice by casual observation, were born in normal Mendelian ratios, and 
did not show any differences in weight compared to their ZnT3-/- single knockout 
littermates (data not shown).   
 Consistent with our hypothesis, elimination of BDNF protein reduced pY816 
immunoreactivity in mossy fiber axons in  ZnT3-/- BDNF-/- compared to ZnT3-/- BDNF+/+ 
littermate controls  (Fig. 20A, B).  Quantification of axonal immunoreactivity revealed a 
significant 36% reduction in ZnT3-/- BDNF-/- (n=10) compared to ZnT3-/- BDNF+/+ (n=11) 
littermate controls (Fig. 20C; p<0.001 by Student’s t-test).  Similar results were evident 
with measures of pY816 immunoreactivity in mossy fiber boutons.  That is, 
quantification of over 4800 synapsin-1 puncta revealed significant reductions of pY816 
positive synapsin puncta in ZnT3-/- BDNF-/- (n=8) animals compared to ZnT3-/- BDNF+/+ 
(n=8) control mice (Fig. 20D; ZnT3-/- BDNF+/+ = 17.5 ± 1.4%, ZnT3-/- BDNF-/- = 11.8 ± 
1.6%, mean % ± SEM, p<0.05 by Student’s t-test).   In sum, these findings support the  
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Figure 20: pY816 TrkB immunoreactivity in mossy fiber axons and synapses within 
SL is decreased in ZnT3-/- BDNF-/- double knockouts compared to ZnT3 -/- BDNF+/+ 
single knockout mice. 
A) Representative low power micrographs of hippocampal sections from 
ZnT3-/- BDNF+/+ (top) and ZnT3-/- BDNF-/- (bottom) mice stained with pY816, 
demonstrating that immunoreactivity within SL of the ZnT3-/- BDNF-/- mouse 
(arrows, bottom) is diminished compared to its ZnT3-/- BDNF+/+ littermate (arrows, 
top).  Scale bar = 300 µm.  B) Images of SL taken at high power from hippocampal 
sections stained with pY816 from the same ZnT3-/- BDNF+/+ (top) and ZnT3-/- BDNF-
/-
 (bottom) mice as in (A) demonstrates that this observed reduction is due to 
decreased pY816 immunoreactivity within mossy fiber axons of the ZnT3-/- BDNF-/- 
double knockout (arrows point to pY816 enriched regions shown in Fig. 16 to 
correspond anatomically to mossy fiber axons; compare top and bottom images).  
Scale bar = 50 µm.  C) Quantification of axonal pY816 immunoreactivity shows a 
significant decrease in immunoreactivity in ZnT3-/- BDNF-/- (n=11) compared to 
ZnT3-/- BDNF+/+ (n=10) mice (p<0.001, Student’s t-test).  Quantification is presented 
as mean pY816 axonal immunoreactivity ± SEM.  D) Quantification of percentages 
of synapsin-1 puncta within SL found to contain pY816 immunoreactivity in ZnT3-/- 
BDNF+/+ (n=8) and ZnT3-/- BDNF-/- (n=8) mice demonstrates a 32.6% reduction in 
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synaptic pY816 immunoreactivity in the double knockout (p<0.05, Student’s t-test).  
A total of 2400 synapsin-1 puncta were analyzed in ZnT3-/- BDNF+/+ animals and 
2401 in ZnT3-/- BDNF-/- mice.  Quantification is presented as mean % ± SEM.  All 
data were analyzed by Student’s t-test; ***p<0.001, *p<0.05.  
hypothesis that BDNF contributed to both synaptic and axonal pY816 content in the 
ZnT3 null mutant mice. 
3.3.6 Axonal and Synaptic pY816 TrkB Immunoreactivity in Stratum 
Lucidum Is Not Further Reduced in ZnT3-/- BDNF-/- Compared to 
ZnT3+/+ BDNF-/- Mice 
If the homeostatic increase of BDNF is responsible for the increased pY816 
immunoreactivity in the ZnT3 mutant mice, then eliminating ZnT3 from mice mutant for 
BDNF would not be expected to increase pY816 immunoreactivity.  To test this idea, we 
compared pY816 immunoreactivity within mossy fiber axons and boutons of BDNF 
mutant mice in those wild type (ZnT3+/+ BDNF-/- single knockout) and null (ZnT3-/- 
BDNF-/- double knockout) for ZnT3.  As predicted, no significant increases of pY816 
immunoreactivity within mossy fiber axons were detected in the double compared to 
single knockout animals (Fig. 21A, B, C; p=0.25 by Student’s t-test).  Likewise, no 
significant change in the percent of pY816 immunoreactive synapses was detected in the 
double knockout (n=8) compared to BDNF single knockout (n=6) mice (Fig. 21D; 
ZnT3+/+ BDNF-/- = 13.3 ± 1.0%, ZnT3-/- BDNF-/- = 11.8 ± 1.6%, mean % ± SEM, p=0.49 
by Student’s t-test).  In sum, these findings support the idea that BDNF contributes to 
both synaptic and axonal pY816 immunoreactivity detected in the ZnT3 mutant mice.   
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Figure 21: Axonal and synaptic pY816 TrkB immunoreactivity is not further 
reduced within SL in ZnT3-/- BDNF-/- double knockouts compared to ZnT3+/+ 
BDNF-/- single knockout mice. 
A) Representative low power images of hippocampi stained with pY816, 
taken from ZnT3+/+ BDNF-/- (top) and ZnT3-/- BDNF-/- (bottom) mice.  
Immunoreactivity does not appear further changed in the double knockout (arrows, 
bottom) compared to the ZnT3+/+ BDNF-/- animal (arrows, top).  Scale bar = 300 µm.  
B) High power micrographs of SL taken from pY816 stained sections from the same 
ZnT3+/+ BDNF-/- (top) and ZnT3-/- BDNF-/- (bottom) animals as in (A), 
demonstrating that pY816 immunoreactivity within mossy fiber axons (arrows point 
to pY816 enriched regions shown in Fig. 16 to correspond anatomically to mossy 
fiber axons; compare top and bottom images), already weak in the absence of BDNF, 
is not further changed in the absence of both ZnT3 and BDNF.  Scale bar = 50 µm.  
C) Quantification of axonal pY816 immunoreactivity in ZnT3+/+ BDNF-/- (n=12) and 
ZnT3-/- BDNF-/- (n=12) mice reveals no change in the double compared to single 
knockout (p=0.25, Student’s t-test).  Quantification is presented as mean pY816 
axonal immunoreactivity ± SEM.  D) Percentages of synapsin-1 puncta within SL 
found to be pY816+ in ZnT3+/+ BDNF-/- (n=6) and ZnT3-/- BDNF-/- (n=8) mice.  No 
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significant difference in synaptic pY816 immunoreactivity was found between the 
two genotypes (p=0.48, Student’s t-test).  A total of 1800 synapsin-1 puncta were 
analyzed in ZnT3+/+ BDNF-/- mice, and 2401 in ZnT3-/- BDNF-/- animals.  
Quantification is presented as mean % ± SEM.  All data were analyzed by Student’s 
t-test.  
3.4 Discussion 
This study tested the hypothesis that synaptic vesicular zinc transactivates TrkB 
within the axons and presynaptic boutons of hippocampal dentate granule cells of adult 
mice.  We conducted immunohistochemical experiments with high resolution confocal 
microscopy using an antibody that probes for pY816 of TrkB in sections isolated from 
genetically modified mice devoid of BDNF and/or synaptic zinc within mossy fiber 
axons.  Four principal findings emerged:  (1) pY816 immunoreactivity is reduced in both 
axons and synaptic boutons of mossy fibers in mice lacking BDNF.  (2) Unexpectedly, 
axonal pY816 immunoreactivity is increased in mice deficient in synaptic vesicular zinc 
in dentate granule cells, whereas immunoreactivity within presynaptic boutons is 
unchanged.  (3) Marked increases of BDNF content were evident within the hippocampus 
in mice devoid of synaptic vesicular zinc.  (4) In mice null for BDNF, elimination of 
synaptic vesicular zinc failed to produce significant increases of pY816 in either axons or 
synaptic boutons.  These findings support the conclusion that both BDNF and synaptic 
vesicular zinc regulate TrkB activation within mossy fiber axons and boutons of adult 
mice. 
The reduction of pY816 immunoreactivity within axons and boutons of mossy 
fibers in BDNF mutants implicates BDNF in activation of TrkB under physiological 
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conditions in adult mice.  Using antibodies to phosphorylated TrkB as surrogate measures 
of TrkB activation (Segal et al., 1996), Western blot analyses have revealed altered TrkB 
activation in adult rodent brains following exposure to cocaine (Crooks et al., 2010) and 
treatment with antidepressant drugs (Saarelainen et al., 2003).  Immunohistochemical 
studies have confirmed and extended these biochemical results, revealing regulation of 
TrkB activation with distinct stages of estrous cycle (Spencer-Segal et al., 2011), and 
with learning paradigms (Chen et al., 2010a; Chen et al., 2010b).  While the favored 
molecular mechanism mediating TrkB activation in these diverse studies has been its 
canonical ligand, BDNF, few studies have directly tested this idea.  The present evidence 
implicating endogenous BDNF in TrkB activation under physiological conditions in the 
adult brain is consistent with behavioral observations of impaired learning and memory 
(Heldt et al., 2007; Linnarsson et al., 1997; Mizuno et al., 2000; Monteggia et al., 2004), 
as well as impaired synaptic plasticity caused by genetic or pharmacological 
perturbations of BDNF (Figurov et al., 1996; Korte et al., 1995; Korte et al., 1996; 
Patterson et al., 1996; Zakharenko et al., 2003).  In contrast to the present results, our 
earlier studies found no reduction of pTrkB immunoreactivity under physiological 
conditions in adult mice; this discrepancy is likely due to the insensitivity of the pTrkB 
antibody in the earlier study which precluded resolution at a cellular or subcellular level 
and assessed immunoreactivity within stratum lucidum averaging cellular and 
extracellular locales.  Assessing pTrkB immunoreactivity specifically within axons in the 
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present study was critical to establishing significant differences between wild type and 
BDNF knockout mice under physiological conditions (data not shown).         
The present findings are consistent with a model in which endogenous BDNF is 
released from mossy fiber boutons under physiological conditions, binds to the 
ectodomain of TrkB in the synaptic membrane of the same or nearby terminals, and is 
subsequently endocytosed.  We favor the mossy fiber axons as the cellular source 
because of the predominant immunohistochemical evidence of high levels of BDNF 
protein in giant boutons of the mossy fibers (Danzer and McNamara, 2004; Yan et al., 
1997), and within these boutons to dense core vesicles in particular (Dieni et al., 2012).   
By contrast, immunohistochemical studies failed to detect BDNF protein in dendrites of 
CA3 pyramidal cells (Danzer and McNamara, 2004; Dieni et al., 2012; Yan et al., 1997).  
It should be noted, however, that a small fraction of dendritic spines of CA3 pyramidal 
cells within stratum lucidum were found to be immunoreactive for BDNF (Danzer and 
McNamara, 2004), a localization consistent with putative dendritic translation of BDNF 
(Baj et al., 2011; Chiaruttini et al., 2009; Tongiorgi et al., 2004).  The idea that pTrkB 
immunoreactivity detected within boutons in this study may be localized to small 
organelles is consistent with its undergoing endocytosis following its activation at the 
membrane of the presynaptic terminal.  The established model of retrograde transport of 
NGF-activated TrkA based upon studies of the peripheral nervous system suggests that 
the pTrkB within mossy fiber axons may be en route from the presynaptic terminals to 
the granule cell bodies (Bhattacharyya et al., 1997; Niewiadomska et al., 2011; Watson et 
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al., 1999a).  Alternatively, the pTrkB in mossy fiber axons may reflect locally processed 
TrkB following its activation; the absence of detectable pY816 immunoreactivity in 
granule cell bodies favors this latter possibility (data not shown).  Electrophysiological 
studies reveal that one biological consequence of BDNF-mediated TrkB activation 
locally within mossy fiber boutons may be a form of LTP of the mossy fiber-CA3 
synapse that is presynaptic in both its induction and expression (Huang et al., 2008; Pan 
et al., 2011).   
The hypothesis that synaptic vesicular zinc contributed to TrkB activation under 
physiologic conditions in adult mice predicted reductions of synaptic and axonal pTrkB 
in ZnT3 knockouts similar to that observed in the BDNF knockouts.  The absence of a 
reduction of synaptic pTrkB and the paradoxical increase of axonal pTrkB in the ZnT3 
knockouts suggested the presence of a homeostatic response to the absence of vesicular 
zinc, leading to discovery of increased BDNF content in the ZnT3 null mutants.  
Importantly, reducing BDNF expression in the ZnT3 null mutants in turn reduced both 
synaptic and axonal pTrkB, implying that BDNF contributes to residual TrkB activation 
in the absence of vesicular zinc.  The homeostatic increase of BDNF and axonal pTrkB in 
the ZnT3 null mutants implicates vesicular zinc in regulation of BDNF and TrkB 
signaling under physiological conditions in adult mice.  One potential trigger of the 
homeostatic increase of BDNF expression is a reduction of transactivation of TrkB by 
vesicular zinc under physiological conditions.  Whether vesicular zinc contributes to the 
seizure-induced increases of TrkB activation detected in the same BDNF knockout mice 
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(He et al., 2004) used in this study, however, remains unclear.  Finally, whether disrupted 
BDNF content and TrkB signaling contributes to the defective hippocampal-dependent 
memory observed in the ZnT3 null mutant mice is presently uncertain (Adlard et al., 
2010; Martel et al., 2011; Sindreu et al., 2011).      
In summary, the present study demonstrates that BDNF and synaptic zinc are both 
important for TrkB activation within stratum lucidum of hippocampus under 
physiological conditions.  BDNF was directly implicated in TrkB activation within both 
mossy fiber axons and boutons.  Though the present study failed to provide direct 
evidence that synaptic zinc transactivates TrkB at these same locales, the presence of a 
compensatory increase in BDNF in the absence of vesicular zinc and consequential 
enhanced TrkB activation within mossy fiber axons shows that this ligand is important 
for regulating BDNF/TrkB signaling.  The precise mechanisms by which the absence of 
vesicular zinc leads to increased BDNF levels, as well as the contribution of vesicular 
zinc to transactivation of TrkB under epileptic conditions, may be topics of future study.   
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4. Concluding Remarks and Future Directions 
The objectives of this dissertation were (1) to study the cellular and synaptic 
locales within hippocampus at which TrkB is activated in hippocampus during 
epileptogenesis, and (2) to test the relative contributions of BDNF and synaptic vesicular 
zinc to activation of this receptor within this structure.  Understanding the cellular and 
subcellular locations whereby TrkB signaling occurs during epileptogenesis, given the 
pinnacle role of this receptor in the development of epilepsy and neuronal excitability, 
will elucidate specific locales where processes contributing to the pathogenesis of this 
disease likely occur.  Defining such locales will greatly simplify future studies of 
epileptogenesis as such lines of inquiry can specifically focus on these critical locations 
in examining potential epileptogenic processes.  Furthermore, understanding the specific 
ligands involved in activating TrkB at these cellular locales may help to elucidate 
molecules that contribute to neuronal excitability through this receptor.  Such molecules 
can also be the topics of future lines of study into epilepsy, as well as targets of potential 
therapies. 
The first part of this dissertation revealed that TrkB activation was enhanced in a 
model of epileptogenesis within two important cell populations of hippocampus—dentate 
granule cells and CA1 pyramidal neurons.  Within these cell populations, TrkB was 
activated within mossy fiber boutons and axons of dentate granule cells which populate 
stratum lucidum, whereas within CA1 pyramidal neurons it was localized to the spines 
and shafts of proximal apical dendrites within CA1 stratum radiatum.  Both the mf-CA3 
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and CA3-CA1 synapses have been extensively studied in terms of their ability to undergo 
LTP (Minichiello, 2009; Nicoll and Schmitz, 2005), synaptic plasticity at these locales 
has been hypothesized to contribute to learning and memory formation, and it seems 
likely that their contribution to neuronal excitability within the limbic system also 
promotes the process of epileptogenesis.  Mossy fiber axons and boutons form the 
presynaptic innervation of the mf-CA3 synapse, whereas spines and dendrites of CA1 
pyramidal neurons comprise the postsynaptic component of the CA3-CA1 synapse.  
Interestingly, TrkB has been implicated in LTP at both of these synapses (Huang et al., 
2008; Minichiello et al., 1999), making it likely that TrkB signaling from both of these 
locales may contribute to the development of neural excitability, likely facilitating the 
process of epileptogenesis.  The second part of this dissertation found that BDNF plays 
an important role in activation of TrkB within mossy fiber boutons and axons within 
stratum lucidum of hippocampus.  Furthermore, the presence of an increase in BDNF 
protein and concomitant increased activation of TrkB within mossy fiber axons found in 
the ZnT3 mutant animal suggests that synaptic zinc also has a role in regulating TrkB 
signaling through a mechanism dependent on BDNF. 
4.1 Examples of How the Findings of This Dissertation May 
Guide Epilepsy Research 
How might understanding the cellular and synaptic locales of TrkB activation 
within hippocampus guide future research into epilepsy?  The findings of this dissertation 
demonstrate activated TrkB to be prominent within mossy fibers of dentate granule cells, 
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an interesting observation given that LTP is induced and expressed at a presynaptic locale 
at the mf-CA3 synapse (Nicoll and Schmitz, 2005; Pan et al., 2011).  Such findings 
implicate the plasticity of dentate granule cells as likely being integral to the process of 
epileptogenesis.  Such findings would inform future lines of study by suggesting that they 
specifically examine processes intrinsic to dentate granule cells that could contribute to 
the development of epilepsy.  For example, one may want to test the role of TrkB 
signaling within dentate granule cells in epileptogenesis by generating a conditional 
knockout mouse deficient in this receptor only within this cell population, and examining 
its ability to develop epilepsy.  One may also hypothesize that LTP, expressed through 
increased glutamate release from the mossy fiber itself, is necessary for the process of 
epileptogenesis.  In this case, do mice with genetic or pharmacologic perturbations 
preventing enhanced glutamate release from the mf-CA3 synapse, impairing LTP, also 
show impairments in their ability to undergo epileptogenesis?  If so, such findings may 
even suggest that targeting molecules involved in LTP induction and/or expression at this 
synapse, such as rim1α, could be viable ways to interfere with epileptogenesis.  
Furthermore, given that TrkB signaling within the dentate granule cell is pinnacle to the 
process of epileptogenesis, understanding the ligands involved in activating it at this 
locale would further inform studies seeking to block its activation and prevent this 
process.  For example, the results of this dissertation suggest that synaptic vesicular zinc 
could contribute to TrkB transactivation.  If this is the case, could finding a drug that 
blocks the zinc transporter, ZnT3, be a potential therapy preventing epileptogenesis?  
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Beginning to answer these questions will require significant further study, but the 
findings presented within this dissertation lay the groundwork for such further 
investigations. 
4.2 Better Elucidating the Cellular and Synaptic Locales of 
Activated TrkB within Mouse Hippocampus 
A major future direction which is a logical extension from the present work would 
be to more accurately identify the subcellular and synaptic structures where TrkB is 
activated within mossy fibers and dendrites of CA1 pyramidal neurons.  Ultrastructural 
analyses of synapses, as well as many subcellular structures, requires a level of resolution 
that is simply unobtainable using conventional light imaging techniques, including the 
confocal microscopy methods used in the present study (Dani et al., 2010).  Resolution of 
confocal microscopy is particularly limited in the z-plane, which in practice is rarely 
better than 700 nm, and even in the x-y-plane is generally on the order of around 250 nm 
(Pawley, 1995).  For comparison, a synaptic cleft is about 20 nm (Kandel, 2013), and 
electron microscopy can routinely achieve resolution higher than this (Slayter and Slayter, 
1992).  To this end, the use of electron microscopy and immunogold labeling, such as 
what was used in a study which localized pTrkB under physiological conditions within 
mouse hippocampus (Spencer-Segal et al., 2011), would be an invaluable tool.  Questions 
that could be elucidated using this method include whether activated TrkB within mossy 
fiber axons resides within a signaling endosome, likely undergoing retrograde axonal 
transport, or at the plasma membrane.  Is activated TrkB in mossy fiber boutons located 
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at the cell membrane, and if so what is its proximity to the active zone?  Alternatively, 
does it reside within the bouton in association with an organelle, such as endosomes or 
synaptic vesicles?  Similar questions could be asked for activated TrkB within spines and 
dendrites of CA1 pyramidal neurons.  Is activated TrkB located at the plasma membrane 
of spines, and if so what is its proximity to the postsynaptic density?  Alternatively, might 
it be located intracellularly, possibly in association with signaling endosomes or secretory 
vesicles?  Electron microscopy would be a particularly powerful tool for answering these 
questions as there is intrinsic contrast of membranes, allowing easy identification of 
structures such as organelles and the synaptic cleft (Dani et al., 2010).   
In addition to electron microscopy, new light microscopy techniques have 
recently been developed that allow fluorescent localization of cellular and synaptic 
markers at a resolution that could better answer questions about subcellular locale.  One 
is array tomography, which relies on immunofluorescent markers and confocal imaging, 
but utilizes numerous sequential, ultrathin sections of around 200 nm each which are 
assembled digitally into 3D reconstructions following image acquisition (Micheva and 
Smith, 2007).  Instead of digital z-sections, this method creates physical z-sections, 
thereby largely circumventing the resolution limitations encountered with confocal 
microscopy in the z-plane.  Given the ultrathin nature of the sections, it also eliminates 
the problem of incomplete antibody penetration.  This is of added value given that the 
sections utilized in our studies were 40 µm in thickness, yet we frequently found 
penetration to be at best several micrometers.  Notably, this method is able to discern pre 
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and postsynaptic markers, which normally appear to overlap using confocal imaging 
techniques.  Superresolution fluorescence microscopy, including stochastic optical 
reconstruction microscopy (STORM), is a recent advance which allows for imaging 
fluorescent immunohistochemical markers with sub-diffraction limit resolution (Dani et 
al., 2010).  One study reported a resolution of 14 nm in the x-y-plane and 35 nm in the z-
plane, far superior to what could ever be achieved with confocal microscopy.  This 
method was able to discern synaptic markers located directly on the membrane of the 
synaptic cleft from those located intracellularly, thus showing incredible precision in its 
ability to localize protein markers to subcellular locales (Dani et al., 2010).  Use of such 
techniques could prove invaluable tools for better elucidating the precise subcellular and 
synaptic locales whereby TrkB is activated, particularly if one wanted to examine the 
relationship of this receptor to other subcellular proteins, as double labeling is not 
possible with electron microscopy techniques. 
Another interesting potential line of investigation for future studies involves better 
understanding of the cellular location of different forms of activated TrkB receptor. 
Interestingly, preliminary work examining the cellular distribution of an entirely different 
antibody, probing for pY515 of TrkB, demonstrated a very different localization pattern 
within stratum lucidum than that found with the pY816 antibody.  The specificity of this 
antibody was demonstrated in preliminary studies by showing that increased 
immunoreactivity within stratum lucidum following SE was blocked in a Y515F mutant 
mouse.  Use of this antibody found pY515 to be highly enriched within mossy fiber 
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boutons following SE, demonstrated by using both Thy1-GFP expressing mice and a 
synapsin-1 marker, whereas it was noticeably devoid from mossy fiber axons.  This was 
in striking contrast to the pY816 antibody, which demonstrated enrichment most 
prominently in mossy fiber axons of stratum lucidum, and labeled only a minority of 
boutons even after SE.   
We speculated that these contrasting cellular distributions were likely to be 
explained by one of two possibilities: (1) The cellular locales of pY515 and pY816 are 
largely non-overlapping, implying that individual activated TrkB molecules may only be 
phosphorylated at one, and not both, tyrosines.  This implies that the conventional model 
of TrkB being activated in a lockstep fashion by a ligand (Barbacid, 1995; Cunningham 
and Greene, 1998), involving phosphorylation of all of its tyrosine residues at once, may 
not be entirely correct.  Such an idea is supported by work showing that activation of 
TrkB by zinc versus BDNF may lead to preferential phosphorylation of different 
signaling residues (Huang and McNamara, 2010), and also raises the possibility that the 
ligands activating TrkB at these different cellular locales may be different.  (2) The 
different cellular distributions detected by these antibodies may be because each antibody 
is only recognizing a subset of activated TrkB, though both subsets are equally 
phosphorylated at both Y515 and Y816 residues.  The reason why these antibodies 
recognize different subsets may have to do with a conformational difference on the 
receptor which fundamentally alters the epitope that these antibodies recognize, rendering 
them only capable of detecting a particular conformation of pTrkB that resides at a 
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particular cellular locale.  For example, Trk receptors are glycosylated at a variety of 
sites, their glycosylation status appears to change as they mature through the secretory 
pathway, and this may even regulate membrane delivery (Watson et al., 1999b).  Such 
posttranslational modifications could fundamentally alter the ability of an antibody to 
detect a particular form of activated TrkB if it changes the epitope that the antibody 
recognizes.  It may be possible, therefore, that one antibody is preferentially detecting an 
intracellular form of TrkB (probably the pY816 antibody), whereas another is 
preferentially detecting a form that is located on the synaptic membrane (probably the 
pY515 antibody).  Examining the reasons for why these different cellular distributions of 
pTrkB were detected using these two different antibodies would undoubtedly make an 
exciting line of future investigation. 
4.3 Further Assessing the Contribution of Vesicular Zinc to 
Transactivation of TrkB in Stratum Lucidum of Mouse 
Hippocampus 
   Given the finding of increased BDNF levels in the ZnT3 knockout, it would be 
interesting to see if levels of other neurotrophins also increase, such as NT-3 and NT-4.  
Furthermore, given changes in BDNF levels in the ZnT3-/- mouse, it would be interesting 
to see if levels of ZnT3 protein may change in BDNF mutants.  Such a finding, 
particularly if ZnT3 levels were found to increase in a manner that was consistent with a 
homeostatic response to elimination of BDNF, would further suggest that vesicular zinc 
is likely to have an important role in contributing to TrkB signaling.  Furthermore, the 
presence of increased BDNF levels in the ZnT3-/- animal makes it possible that, if 
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synaptic vesicular zinc contributes a fundamental role to transactivation of TrkB which 
could not be directly detected in these studies, other homeostatic compensations also 
occur in the ZnT3 mutant.  Such compensations would block our ability to detect further 
decreased TrkB activation in the ZnT3/BDNF double knockout compared to the BDNF 
knockout alone, a finding that would directly implicate vesicular zinc in TrkB 
transactivation under physiological conditions.  In this regard, it is notable that ZnT3-/- 
animals are complete knockouts for the ZnT3 protein (Cole et al., 1999), unlike in the 
BDNF animal which is a conditional knockout (He et al., 2004).  Such complete 
knockouts may be particularly prone to compensatory responses if the gene they lack is 
important for normal function.  For this reason, future work may focus on generation of 
ZnT3 conditional knockouts, employing Cre-loxP technology (Gu et al., 1994) in a 
similar fashion as was utilized for BDNF conditional knockouts.  Examination of such 
animals using similar studies as performed in Chapter 3 of this dissertation may more 
directly reveal a role for synaptic zinc in transactivation of TrkB. 
 Examination of the contribution of synaptic vesicular zinc to TrkB transactivation 
during epileptogenesis, as well as the development of epileptogenesis itself, is an 
important future direction for this work.  Due to increased BDNF and the possibility of 
other homeostatic responses in the ZnT3 knockout mouse, however, this would have to be 
done in an animal in which such compensatory mechanisms did not occur, such as could 
hopefully be achieved with a conditional knockout for ZnT3.  An alternative would be to 
compare BDNF and ZnT3/BDNF knockout animals, as performed in Chapter 3 of this 
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dissertation, in models of epileptogenesis.  This would eliminate changes in BDNF 
protein levels between genotypes, though one could not exclude other compensatory 
effects.  Such studies could involve examining kindling development in these animals to 
see if mice lacking ZnT3 protein exhibited impaired kindling, and examination of pTrkB 
levels in fully kindled animals would reveal the contribution of vesicular zinc to 
activation of this receptor in the epileptic state.  It is possible, given the low probability of 
release at the mf-CA3 synapse (Nicoll and Schmitz, 2005), that synaptic vesicular zinc 
plays a much more profound role in TrkB transactivation under conditions of enhanced 
neuronal activity than under physiological conditions.   
 In conclusion, the findings presented within this dissertation reveal cellular and 
synaptic locales within hippocampus where TrkB signaling is likely to be important for 
the development of neuronal excitability culminating in the development of limbic 
epilepsy.  Furthermore, they suggest the importance of a novel endogenous ligand, 
synaptic vesicular zinc, in regulation of TrkB signaling within mossy fibers of stratum 
lucidum.  Future studies may use higher resolution microscopy techniques to further 
define the specific subcellular locales whereby TrkB is activated during epileptogenesis.  
They may also seek to further elucidate the specific contribution of vesicular zinc to 
transactivation of TrkB under both physiological conditions and following the 
development of epilepsy, as well as its contribution to the process of epileptogenesis 
itself.  Altogether, the findings contained within this dissertation contribute new and 
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important knowledge to the field of neurotrophin signaling, and will hopefully help to 
inform future lines of inquiry on this topic. 
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